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Abstract
MALDI Imaging has gained huge interest in the past few years with an ever 
increasing population of specialists choosing to investigate samples using MALDI 
imaging, including growing interest and financial backing from pharma and contract 
research organisations.
Presented within this thesis is the development and application of MALDI imaging 
techniques for a variety of analytical problems. The use of various software 
packages have been employed in the interpretation of the data acquired from MALDI 
experiments including, the use of statistical analysis for the identification of ion of 
interest from 6 distinct brain regions and also for the identification of ions of interest 
associated with small molecule tumour markers.
The advantages of MALDI-IMS-MSI as a further separation stage within MALDI-MSI 
have been shown. Demonstrated is a method for M ALDI-IMS-MS imaging of 
endogenous lipids in healthy tissue and tumours, also demonstrated is the 
application of MALDI-IMS-MS to xenobiotic distribution studies, it has been clearly 
shown that ion mobility separation within MALDI-MSI experiments can improve the 
analysis of xenobiotics by removing any interfering ions.
With instrumentation development for MALDI a high repetition rate N d :Y V 04 laser 
has been assessed as a possible method for decreasing acquisition time
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CHAPTER 1
Introduction
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1.0 Introduction
1.1 Drug Discovery
1.1.1 Target Identification.
The initial stage in the drug discovery process is the identification of a medical 
i for the development of a drug compound based on the lack of current 
methodology in the treatment or a lack of existing effective drugs. Once a 
medical need has been identified the drug development process starts. 
Figure 1.1 shows a schematic of the common steps involved with the drug 
discovery and development process from the identification of possible targets 
until a completed drug can be distributed into the market. This entire process 
takes several years to complete and only a few of the initial compounds make 
it to market. Typically <10% are finally marketed (Ashburn and Thor 2004).
De novo drug discovery and development
• 10-17 year process
• <10% overall probability of success
Target discovery Discovery & screening
n
Lead optimization ADMET ^Development |
f  •  Must start clinical Ttesting at Phase I
Registration
Discovery ■ Expression analysis / ■ Traditional 
> In vitro function .  Combinatorial• In vivo validation; 
for example, 
knockouts
• Bioinformatics
chemistry
• Structure-based 
drug designScreening
• In vitro
• Ex vivo and in vivo• High throughput
• Traditional 
medicinal chemistry
• Rational drug design
> Brcavai lability and systemic exposure 
(absorption, 
clearance anddistribution)
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v L
> United States
> Europe (EMEA 
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• Rest of world
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Figure 1.1 Schematic representation of the drug discovery process and approximate 
times involved at each stage. (Ashburn and Thor 2004).
The first stage, once a medical need has been identified, is to find disease 
modifying targets (Lindsay 2003). Possible drug targets are usually a single 
gene, gene product or molecular mechanism (Sams-Dodd 2005). Once a 
possible target has been identified it needs to be validated. Target validation
involves the determination of the theraputic value of the target within a 
specified patient population. If the target is deemed a viable target then a 
high throughput screening assay is developed. The use of high throughput 
screening allows for rapid analysis of possible target specific compounds from 
compound libraries and the identification of possible lead compounds.
1.1.2 Lead Optimisation
If a lead compound is identified this compound then needs to be optimised. 
Lead optimisation may involve the manipulation of the lead compound 
structure, or assessment of any structural isomers, using high throughput 
screening, until a compound that has the optimum specificty towards the 
target is found. Lead optimisation can involve the lead compound/s 
undergoing modification or synthesis. In order to improve target interaction, 
specificity, efficacy, reduce toxicity and improve pharmacokinetics and 
pharmacodynamics.
There is currently a requirement to use in vivo studies within certain areas of 
the drug discovery process, including toxicity and distribution studies. More 
and more, pharma are trying to use alternative in vitro studies to reduce the 
number of animal experiments. Repeat dose toxicity studies currently have to 
be carried out in vivo for both rodent and non rodent (commonly initially rabbit) 
species for a period of time consistant with the planned duration of clinical 
studies (Ng 2004). Possible metabolites of new chemical entities (NCE) are 
commonly characterised using several techniques including: LC/MS, 
HPLC/MS, GC/MS, UV/Vis spectroscopy etc (Zhang et a/., 2009). There is
scope within this field for the application of imaging technologies, and 
specifically MALDI imaging for the identification and analysis of the spatial 
distribution of NCEs and their metabolites. This could add additional spatial 
information within the metabolite identification experiments (Sugiura and 
Setou 2009).
When a lead compound has been shown to be a sucessful compound in the 
in vitro and in vivo animal studies it is required to enter clinical trials.
The final lead compound needs to be placed into a drug design. The drug 
design markedly differs depending on the possible market for the drug and 
more importantly the absorption, distribution, metabolism and excretion 
(ADME) properties of the compound. These can all be altered depending on 
the drugs formulation and route of administration. Factors that need to be 
considered are possible routes of administration, and initial dose formulation 
(Ricaurte ef a/., 1988).
1.1.3 Phase I clinical trials.
Phase I clinical trials are primarily designed to assess the safety of the drug 
within healthy human volunteers. A  small group of healthy human volunteers 
receive a single dose or a dosing regime of the drug. The pharmacokinetics 
and pharmacodynamics of the test compound are assessed and any 
physiological or behavioural effects are assessed.
1.1.4 Phase II clinical trials
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Phase I! Clinical trials involves either open label, blind or double blind trials, 
on the relevent disease group. Part of the group will receive the new test 
compound possibly with different dosing regimes and the other members of 
the group will receive a placebo or the current standard treatment depending 
on the patient risk if they receive only the placebo. The data obtained in 
phase II aids in the development of the most effective dosing regimes and the 
effectiveness of the treatment.
1.1.5 Phase III clincal trials.
Phase III is an extension of phase II and involves a much wider group 
compared to phase II. Normally over several locations. This allows more 
extensive assessment of the safety and efficacy and allows extensive 
statistical analysis of the obtained data. And a comparison of effecacy with 
current treatments can be made.
At this stage if the drug benefits and efficacy far outweigh any safety or side 
effects, the full data is presented to the regulatory authorities for assessment 
and approval. Once approved the drug can be marketed.
1.2 Drug distribution studies.
Current drug distribution studies are primarily carried out using quantitative 
whole body autoradiography (QWBA), and organ homogenate analysis using 
liquid scintillation counting (LSC). QWBA has taken over from more 
conventional animal dissection and determination of tissue homogenate 
composition (Solon and Kraus 2002). The pharmacokinetic data obtained
using QWBA are utilised in the prediction of the exposure of human 
volunteers to isotope labelled compounds during radioisotope mass balance 
studies. These studies are a requirement for new compounds (Solon and Lee 
2002)
1.2.1 Quantitative Whole Body Autoradiography (QWBA)
This is the most common way for determining the distribution of xenobiotics 
within whole body animal studies, and is utilised routinely within preclinical 
drug development studies (Coe 2000).
QWBA involves the synthesis of a drug compound which contains a radiolabel 
predominantly carbon 14 or tritium. Tritium labelled new drug entities (NDE) 
are easier and quicker to obtain (Potchoiba and Nocerini 2004). One problem 
with using tritium is that a percentage of the radiolabel may be lost during the 
freeze drying process as tritiated water. Radio labelling developmental drug 
compounds can be an expensive process (Ulberg 1954)
An animal is dosed with the labelled compound and sacrificed after a set time 
period, the animal is then frozen within a block of carboxymethyl cellulose 
(CMC) (QW BA methodology is covered further in Chapter 4 of this thesis). 
The animal is then sectioned using a whole body cryotome. The sections are 
placed onto a radiation sensitive plate and stored for a desired amount of time 
after they have been freeze dried. The radio sensitive plates are then 
automatically read using a plate reader. Using software the concentration of 
the known standards can be entered and the quantification of the radiolabel
and hence compound concentration can be calculated (Potchoiba et al 1997, 
Potchoiba et al 2004).
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Figure 1.2 QWBA image showing radiolabel distribution within three rat whole body 
tissue section, also shown are a series of spiked blood samples for calibration. 
(www. biosoacelab. com)
Maas et al., 2000 presented work recommending the standardisation of 
QWBA methodology. Within this work they assessed several parameters that 
are variable within QWBA analysis. They proposed that the optimum 
thickness for QWBA analysis was between 25-50pm. This was 
recommended due to the pg equivalents/g calculations from the detected 
radioactivity. The quantification was carried out using spiked blood standards 
included into the CMC block prior to sectioning to create a standard curve. 
One of the reasons for recommending this tissue section thickness is due to 
tissue self absorption of the radioactivity. This is highest within bone tissue, 
which is expected due to its density. They also recommend the orientation of 
the samples to be vertical to the scanning direction to reduce flaring from 
areas of high concentration, this can mask areas of lower intensity. 
Temperature should be maintained constant preferably at a low temperature
and the sample should be stored in a shielded box to reduce the background 
signal. Also scanning acquisition should be performed as soon as possible 
due to non linear fading of intensity over time.
The main limitations with the use of QWBA is the fact that only the radiolabel 
can be imaged, hence, this technique is unable to differentiate between 
parent compound and metabolites. Therefore in combination with this 
technique another animal receives a cold dose of the drug compound from 
which the organs of interest can be harvested and analysed to obtain the 
compound or metabolite identification and further quantification through 
various techniques, mainly a form of LC-MS, is used.
MALDI-MSI is a relatively new method which potentially addresses some of 
the issues arising from QWBA.
1.3 Mass spectrometry Instrumentation
Mass Spectrometry (MS) is an invaluable tool in biomedical research. It is 
used in the characterisation and structural elucidation of molecules and 
elements, as well as in qualitative and quantitative sample composition 
studies.
Mass spectrometers have at least three regions, an ionisation source to 
produce ions from a sample. Mass analysers or selectors to separate the 
ions based on their mass-to-charge, and finally a detector to measure the ions 
abundance and record the data.
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Figure 1.3 Simplified schematic of a mass spectrometer.
1.3.1 Ionisation sources
There are several ionisation sources used with in mass spectrometry. 
Different ion sources are used for different techniques. Each ion source has 
different characteristics including but not limited to mass range, fragmentation, 
sample depth penetration, sample destruction and spatial resolution (if 
required for an imaging technique). Another consideration when choosing an 
ionisation source is the type of sample that requires analysis e.g. Solid, liquid 
or gas.
Some of the ion sources used within mass spectrometry include radioactive 
ionisation, corona discharge ionisation (Ross and Bell 2002), photoionisation 
(Cooper et al., 2002), electrospray ionisation (ESI) (Postle et al., 2007), 
secondary electrospray ionisation, laser desorption ionisation (LDI) (Benazouz 
et al., 1999), Surface enhanced - LDI (Hinshelwood et al., 1999) and matrix 
assisted laser desorption ionisation (MALDI). Within Biological mass 
spectrometry the most common ionisation source used is ESI (which is 
usually coupled to a separation technique e.g. HPLC).
1.3.1.1 E lectrospray ionisation (ESI)
ESI is one of the most common ion sources used within biological mass 
spectrometry, and is often coupled to HPLC systems (high performance liquid 
chromatography). Figure 1.4 shows a schematic of an ESI source. In one 
embodiment the source has a capillary which carries the sample solution into 
it at range of flow rates from several pL/min down to a few nL/min.
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Figure 1.4 schematic of an electrospray ionisation source. (www. chm. bris. ac. uk)
A high voltage is applied to the capillary typically in the range of 2-5kV. This 
applied potential voltage causes the positively charged ions in the solution to 
accumulate at the tip forming a cone called a Taylor cone (Figure 1.5). This 
then starts budding and forms a spray/mist of multiply charged droplets. 
These droplets undergo solvent evaporation and hence size reduction. There 
is a critical point at which the droplet undergoes fission due to the charge 
repulsion overcoming the surface tension of the droplet this is known as the 
Rayleigh limit. This process can occur numerous times until the resulting ions 
are fully desolvated this occurs at atmospheric pressures. This process is
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depicted in figure 1.5. ESI often results in multiply charged ions compared 
with MALDI which predominantly results in singly charged ions. For further 
information on ESI, Gaskell 1997 has presented an excellent review.
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Figure 1.5 Schematic of the droplet desolvation during ESI. (vzww. chm. bris. ac. uk)
1.3.1.2 Desorption E lectroSpray ionisation Source (DESI).
ESI has recently been adapted into DESI (Desorption Electrospray Ionisation) 
(Takats et al., 2004) this involves desorbing ions from a sample surface with 
an ESI source. A schematic of the instrument arrangement is shown in figure
1.6
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Figure 1.6 DESI instrumentation schematic showing the electrospray source directed at 
the sample and not directly into the mass spectrometer as in ESI. (Takats et al 2004)
The sample is impacted by charged droplets and ions from the solvent in the 
electrospray. The impact of these results in the production of gaseous ions of 
the sample originally on the sample surface. The resulting mass spectra are 
similar to ESI mass spectra with singly and multiply charged ions. DESI can 
be used for the detection of small molecules and proteins and peptides. By 
varying the solvent composition from the ESI source within DESI, analytes 
can be selectively analysed, or with varying sensitivity.
Takats et al., 2005 have adapted this ionisation source for spatial analysis 
and imaging, although only the theory with no images has been presented. 
They also demonstrate the use of this technique for the detection of 
explosives for forensics. The authors present evidence for both charge 
transfer and droplet pick up mechanisms for the ionisation process in DESI. 
Imaging DESI has now been shown by many groups. Wiseman et al., 2006
have demonstrated rat brain tissue lipid imaging using DESI. DESI imaging 
involves acquiring a DESI mass spectrum at a location which is then stored as 
a pixel within the image. The sample is then moved left or right relative to the 
source depending on the instrument configuration, and another mass 
spectrum is recorded. This process is repeated across the sample area. 
Once one line is completed the sample is moved towards the MS inlet, this 
reduces the possibility of analysing material redistributed in the direction of 
the electrospray flow (Figure 1.7).
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Figure 1.7 Schematic of the pattern from an imaging DESI experiment, showing the 
possible spread of analytes due to the electrospray.
DESI has recently been used for whole body imaging by Kertesz et al., 2008 
and has been compared to whole body autoradiography which is the standard 
for whole body tissue imaging for drug distribution studies, as previously 
described.
1.3.1.3 Matrix assisted laser desorption ionisation (MALDI)
Matrix Assisted Laser Desorption Ionisation (MALDI) was introduced in the 
late 1980’s (Karas et al., 1985, Tanaka et al., 1988) as a soft ionisation 
technique intended for extending MS analysis to large biomolecules. The 
conventional MALDI-MS technique has since been developed into an imaging 
technology. MALDI-MS imaging (MALDI-MSI) has been used in a wide 
variety of applications since the first full paper (Caprioli et al., 1997).
MALDI is a relatively soft ionisation technique producing predominantly singly 
charged ions (Karas et al., 2000). MALDI is a two stage process involving the 
desorption/ablation event followed by ionisation of the analytes. These two 
events will be discussed further later in this introduction. Usually a sample is 
coated with a matrix (predominantly an organic acid) which absorbs radiation 
within the wavelength of the laser used within the experiment, commonly UV  
lasers. The desorption and ionisation within MALDI is predominantly done 
under vacuum conditions compared to ESI which is at atmospheric pressure. 
The sample once coated with the matrix is then placed in the instrument 
where the sample is irradiated by a laser.
There are two modes of operation for MALDI MSI, these are microprobe and 
microscope mode (Luxembourg et al., 2004 and Klerk et al., 2009).
1.3.1.3.1 Microprobe MALDI.
Microprobe mode MALDI involves irradiating a small area/pixel with a laser 
and recording the resulting mass spectra for each position defined by the 
user. After image acquisition is complete ions are selected and an image is
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reconstructed as a 2D ion density map based on the ion intensity at each 
location. This is the mode all experiments within this thesis have been carried 
out using. Figure 1.8 shows a representation of microprobe mode MALDI 
imaging experiment.
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Figure 1.8 Schematic representation of a microprobe MALDI setup. (Klerk et al., 2009)
1.3.1.3.2 M icroscope MALDI.
Microscope MALDI involves irradiating the entire area that is to be imaged. 
This results in the generation of ions from the sample which retain their spatial 
distribution and are detected using a 2D position sensitive detector. Figure 
1.9 shows a representation of a microscope mode MALDI experiment.
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Figure 1.9 Schematic representation o f a microscope MALDI setup. (Klerk et al., 2009)
1.3.1.4 SIM S (Secondary Ion M ass Spectrom etry).
SIMS imaging is a complimentary technique to MALDI MSI. SIMS imaging 
currently has a much higher spatial resolution compared to MALDI however 
the effective mass range is much smaller than achievable using MALDI 
(Heeren et al 2008, Monroe et al 2008).
SIMS involves the generation of ions from a sample by bombarding the 
sample with a primary ion beam generated by an ion gun. The primary ion 
beam is focused onto the sample and penetrates the surface. This causes 
the ionisation and sputtering of some of the sample surface into the surround. 
These ions then pass through various ion optics and into a mass analyser 
commonly a TOF MS (Zheng et al., 2008). A schematic of ion formation in 
SIMS is shown in figure 1.10.
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Figure 1.10 Schematic representation of the generation o f secondary ions within SIMS. 
(Castner 2003)
SIMS and MALDI data sets have been combined from the same tissue 
section by Eijkel et al., 2009. The possible benefits from the correlation of 
both imaging techniques was demonstrated, including the high spatial 
resolution obtainable by SIMS. They used principle component analysis 
(PCA) and canonical correlation analysis (CCA) to extract information on the 
spatial distributions of different ions of interest and combine the two data sets.
1.3.2 M ass analysers
There are several possible analysers that can be used within mass 
spectrometry including ion traps (Beaudry et al., 2009), Fourier transform ion 
cyclotron (Irungu et al., 2008) and magnetic sector (Bereman et al., 2008). 
These analysers will not be covered in the scope of this introduction. The 
mass analysers covered within this thesis will include quadrupole (Q) and time 
of flight (TOF) analysers and tandem mass analysers.
1.3.2.1 Quadrupole
Quadrupole mass filters are commonly used on smaller instruments or in 
conjunction with other mass analysers as a tandem instrument (Morris et al., 
1997). Quadrupole mass filters consist of 4 metal rods connected in pairs 
running parallel to each other. Across these rods an RF voltage is applied in 
pairs along with a DC voltage which is applied along the length of the 
quadrupole. Applying these voltages and by varying the RF voltages ions can 
be selected to transverse the quadrupole. Ions which are not the correct 
mass-to-charge end up colliding with the metal poles.
Figure 1.11 schematic of a quadrupole mass analyser red ion is of the correct mass-to- 
charge and is able to exit the quadrupole, the yellow ion is a different mass-to-charge 
that ends up being neutralised on the metal rods.
1.3.2.2 Time o f  flight
Time of flight (TOF) mass analysis is a very common form of mass analysis 
used within MALDI experiments. TOF mass analysers accurately measure 
the time it takes an ion to transverse a field free drift tube, after the ions have 
been accelerated using a voltage. Because each ion has the same kinetic 
energy larger ions travel slower than smaller ions. The simplified equation
showing the relationship between time and mass/charge ratio is shown below 
in equation 1.1
Equation 1.1 Equation showing the relationship between time and mass-to-charge 
within a TOF analyser, t =  time taken to transverse the drift tube, k  =  is an instrument 
related constant calculated by the total length of the drift tube divided by the square root 
of twice the voltage applied to accelerate the ions into the flight tube, m is the mass of the 
ion and z is the charge on the ion.
There are two ways in which the TO F analyser is orientated compared to the 
ions original direction of motion these are linear or axial and orthogonal.
Linear or axial TO F ions are accelerated in their original direction of travel into 
the TO F analyser. One of the issues with this arrangement is that any slight 
variation in the initial sample height may alter their effective time of flight and 
hence could reduce the mass resolution of the instrument.
Orthogonal TO F instruments accelerate the ions into the drift tube at ~90° to 
their original direction of travel hence removing any experimental differences 
in the original starting height of the ions.
Also the mass resolution can further be improved with the use of reflectron 
TO F (Franzen 1997). Reflectron TO F instruments use a set of ring electrodes 
each with increasing potential voltage which reflects the ion back down the 
length of the flight tube doubling the length the ions have to travel. This also 
corrects for any differences with the kinetic energy for ions with the same 
mass-to-charge. Ions with a higher kinetic energy travel further into the 
reflectron and hence travel a slightly longer flight path to ions with a lower
kinetic energy. Some of the many commercial TOF analysers can be run in 
"V" or "W" mode this represents the flight path of the ions, by using this 
method the distance for TOF separation can be doubled within the same 
length flight tube. (Figure 1.12)
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Figure 1.12 Schematic of the TOF portion of a Synapt HD MS system (Waters 
Corporation, Manchester, UK) showing the flight path of ions in the time of flight tube 
when in "V" or "W" mode of operation.
1.3.2.3 Tandem  instrum ents
There are two types of tandem instruments. These are tandem in time which 
account for ion trap mass spectrometers, which can trap ions and then 
selectively release them. The second type is tandem in space which involve 
multiple mass analysers. Tandem in Space is the type of mass spectrometers 
covered briefly within this thesis.
Several commercial instruments are tandem instruments which contain two 
mass analysers. Both instruments used throughout this thesis are Q-TOF 
hybrid instruments. This means the instrument has a quadrupole mass
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analyser (or hex/octo-pole) followed by a TO F mass analyser. Other tandem  
instruments include TO F-TO F (Falkner-et al., 2007) or another arrangement is 
triple quads, which employ Q1 and Q3 as mass selectors or mass analysers 
and Q2 as a collision cell.
1.3.3 MALDI Lasers
There are essentially only a few lasers used within MALDI instruments. The  
two most common lasers used are the N2 lasers and the Nd:YAG lasers. 
However IR lasers have been used.
1.3.3.1 Afc lasers
This is traditionally the most common MALDI laser and one of the cheapest 
laser options for MALDI. This laser has an output of 337nm which is suitable 
for many MALDI matrices. One problem with N2 lasers is the limited repetition 
rate, normally 20Hz-50Hz. N2 lasers were initially the most common laser 
used within MALDI due to their relatively low cost and previously were much 
smaller than other laser options.
1.3.3.2 Nd. YAG lasers
Matrix assisted laser desorption was first reported using a frequency 
quadrupled Nd:YAG laser at 266nm (Karas et al., 1985). Since then the 
further development of these lasers, allowing the size and cost to be reduced 
has enabled the inclusion of this laser system as a direct replacement for 
conventional N2 laser systems. Frequency tripled Nd:YAG lasers have a
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wavelength output of 355nm. This laser system allows repetition rates 
between 200Hz-2KHz.
1.3.3.3 Nd:YV04 lasers
Frequency tripled N d:Y V04 lasers also have a wavelength of 355nm but allow 
much higher repetition rates with the possibility of reaching 100 KHz repetition 
rates. The use of a N d:Y V 04 laser forms part of this thesis. This laser was 
used for high repetition rate MALDI imaging, allowing the use of raster 
imaging whilst maintaining a significant number of laser shots per pixel 
(Further work on this laser can be seen in Chapter 6 of this thesis). Tojo et al., 
2008 have also presented work using a N d:Y V 04 laser for MALDI, within this 
work the authors demonstrate the characteristics of a N d:Y V04 laser, but they 
have not shown any results using this laser for MALDI.
1.3.3.4 Infra Red lasers
Infra red lasers have also been employed for MALDI analysis, the first results 
published from an IR MALDI experiment were from Overberg et al., 1990, 
within in this work they utilise a Er:YAG laser at 2.94pm wavelength, the same 
group also presented work using a C 0 2 laser in 1991 (Overberg et al., 1991). 
IR MALDI has been used for a variety of applications since its development 
especially large biomolecules including intact proteins. (Berkenkamp et al., 
1997)
IR LDI and IR MALDI all rely on the absorption of photons at IR laser
wavelengths by O-H, C-H, N-H, C -0  and C = 0  bond stretching and bending.
A  lot of IR MALDI experiments utilise glycerol as a matrix.
IR MALDI is a softer ionisation than UV-MALDI producing less metastable ion 
fragmentation (Dreisewerd et al., 2003).
1.3.3.5 IR and UV combined lasers.
Huang et al., 2008 have reported the use of a combined IR-LD and UV- 
MALDI instrument. Within this work the use of a pulsed optical parametric 
oscillator (OPO) IR laser, which has a tuneable wavelength was described. 
They utilised two wavelengths 2.94pm and 3.05pm to ablate the sample and 
this was then followed by a UV laser pulse at 351 nm to ionise the plume 
generated by the IR laser. The UV laser was fired 50ps after the IR laser 
parallel to the sample. Different delay times between the two laser shots 
markedly changed the ion signals and this time delay is clearly a critical step, 
as would be expected due to the plume expansion.
The use of IR MALDI /  LDI has also been reported with an ion mobility cell by 
Woods and Jackson 2006. Within this work they also describe the use of a 
OPO IR laser and for comparison a Nd:YLF laser for UV MALDI. Comparison 
of both UV and IR spectra showed that the IR MALDI resulted in less 
fragmentation of the analyte, they also showed that IR MALDI and IR LDI are 
similar for the analysis of phospholipids in rat brain tissue.
1.3.3.6 Multi-frequency lasers
Su et al., 2006 presented some initial experiments using a multi-frequency 
laser within a MALDI experiment. The multi-frequency laser used within this 
work emits multiple wavelengths including 355nm. It was shown that using
aCHCA as a matrix similar results were obtainable using a 355nm laser and 
the multi-frequency laser, this was also true with the use of SA as the matrix. 
However with activated charcoal a more intense peak of cytochrome C was 
observed at m/z 12327 using the multi-frequency laser compared to a 355nm  
Nd:YAG laser.
1.3.4 Instruments
1.3.4.1 Q-Star Pulsar-/
In this thesis, for small molecule MALDI-MSI one of the main instruments 
used was an Applied Biosystems/MDS Sciex hybrid quadrupole time-of-flight 
instrument (Q-Star Pulsar-/) fitted with an orthogonal MALDI ion source. 
Three different lasers have also been used during the course of this work: a 
337nm N2 laser, a 355nm frequency tripled 1 KHz Nd:YAG laser (Chapter 2) 
and a 355nm frequency tripled 1-20 KHz Nd:YV 0 4  laser (Chapter 6). The Q- 
Star itself has a MALDI source, to create the ions, followed by a quadrupole 
mass filter for precursor ion selection, followed by a 2-D quadrupole ion trap 
which gates ions into the orthogonal reflectron TO F for mass analysis. The 
2D quadrupole ion trap also acts as a collision cell.
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Figure 1.13 Schematic of an Applied Biosystems/MDS Sciex hybrid quadrupole time-of- 
flight instrument (Q-Star Pulsar-i). Adapted from Baldwin et al., 2001.
1.3.4.2 MALDI Synapt HDMS
A Waters “Synapt” HDMS system was used for MALDI - ion mobility 
separation -  MSI, within this thesis (Chapters 3, 4 & 5). The Synapt HDMS 
system is a MALDI hybrid quadrupole/travelling wave IMS/oa-ToF instrument. 
A schematic of this instrument is shown in figure 1.14.
Figure 1.14 Schematic of the Synapt HDMS system (Waters Corporation, Manchester, 
UK) (Oppenheimer et al 2009).
Within this instrument the region of the instrument responsible for the ion 
mobility is the Tri-Wave region. This region comprises of three distinct parts 
the “Trap” acts as an ion guide and the last set of electrodes gate the ions into 
the travelling wave ion mobility separation (T-WAVE IMS) cell, releasing a 
packet of ions into the T-WAVE IMS cell which then undergo ion mobility 
separation (this will be covered further later in this introduction). Once the 
ions have been separated within the T-WAVE IMS cell they enter the 
“Transfer” region which is another ion guide which transfers the ions into the 
TOF analyser. This can be operated in "V" or "W" reflectron modes as 
previously described.
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1.3.5 Ion M obility  Separation.
The addition of ion mobility separation (IMS) adds another dimension of 
separation to mass spectrometric analysis. Conventional mass spectrometers 
can only separate ions based on their mass-to-charge whereas ion mobility 
either separates purely on averaged collisional cross sectional area within 
traditional IMS drift tubes, or by their averaged collisional cross sectional area 
to charge within the travelling wave IMS. This additional dimension of 
separation has proved to be highly advantageous within mass spectrometry. 
The use of ion mobility itself has also markedly grown over the past decade 
and during 2008 there were over 50,000 stand alone ion mobility 
spectrometers throughout the world employed for the detection of explosives, 
drugs and chemical warfare agents (Kanu et al., 2008). IMS and mass 
spectrometry complement each other very well and IMS can now be 
incorporated into nearly all mass spectrometers if it is desired.
There are four types of IMS used within mass spectrometry they will each be 
briefly discussed here, and a more in-depth discussion will be made of the 
travelling wave IMS, which was extensively used in the work reported in this 
thesis.
1.3.5.1 Drift Time Ion Mobility Spectrometry (DTIMS)
DTIMS is performed by measuring the time taken for an ion to “drift” through a 
drift tube which contains a buffer gas and a low electric field, in these 
conditions the velocity of the ion is directly proportional to the electric field and 
this proportionality constant is called the ion mobility constant “K” and is 
related to the average collisional cross section by equation 1.2.
Equation 1.2 Ion mobility constant “K” equation where q is the charge on the ion, N  is the 
number density of the buffer gas, k is Boltzmann’s constant, T is the absolute 
temperature, m is the mass of the buffer gas, M  is the mass of the ion and Cl is average 
collisional cross section
There are two types of DTIMS the first of these is ambient pressure drift time 
ion mobility spectrometry (APIMS). Incorporation of APIM S into mass 
spectrometers has the advantage of high IMS resolving power but this is at 
the cost of a low duty cycle and reduced sensitivity. APIM S is commonly 
employed as a field instrument for the detection of explosives, drugs and 
chemical warfare agents (Kanu et a/., 2008).
The other type of DTIMS is reduced pressure drift time ion mobility 
spectrometry (RPIMS), using reduced pressure drift tubes allowed for more 
efficient transfer of ions from the drift tube into the mass spectrometer or vice- 
versa as the RPIMS can be placed before or after the mass spectrometer. 
This means that it can perform IMS prior to mass analysis or mass selected 
ion can be subjected to IMS to determine their average collisional cross 
section.
1.3.5.2 Aspiration Ion Mobility Spectrometry (IMCell)
Within an IMCell the mobility of each ion is determined by the distance it 
travels in the direction of the electric field before it collides with an electrode 
ring. This movement is orthogonal to a flow of buffer gas and hence the 
buffer gas deflects the ions from their flight path. Since the ions can travel 
both directions within the electric field this allows the IMS of both positive and 
negative ions simultaneously.
1.3.5.3 Differential Mobility Spectrometry (DMS)
DMS utilises two electrodes, between these a dispersion voltage (DV) is 
applied. In one direction the electric field strength is twice the strength of the 
other direction but the duration of the electric field is only half the time of the 
other direction, and the field direction is alternated. Ions are introduced 
orthogonally to the field direction in a flow of buffer gas. The effect of a DV  
causes separation of the ions depending on their different mobility’s within 
each field. Within the drift tube an additional voltage is then scanned on one 
electrode, this is the compensation voltage (CV). This C V causes ions with 
different mobilities to be transferred into a mass spectrometer for mass 
spectrometric analysis. This type of analysis has been called many different 
names including alternating field IMS (AFIMS), Field ion spectrometry (FIS). 
It is sold commercially by Thermo Scientific as high field asymmetric 
waveform ion mobility spectrometry (FAIMS) (Kolakowski and Mester 2007).
1.3.5.4 Travelling Wave Ion Mobility Spectrometry (T-WAVE IMS)
Within a T-W AVE IMS cell a sequential series of low voltage waves propel the 
ions through a drift tube filled with a buffer gas and hence separate the ions 
based on the averaged collisional cross sectional area to charge.
Within T-W AVE IMS instruments it takes milliseconds for ions to travel along 
the IMS and it takes microseconds for the TOF MS analysis so the two parts 
can marry up together producing hundreds of TOF MS spectra for each IMS 
run therefore the sensitivity of the MS is not compromised by the duty cycle of 
the IMS.
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Figure 1.15 Schematic of the Tri Wave IMS cell within the Synapt HDMS (Waters, 
Manchester, UK) shown are the locations of the three travelling wave stacked ring ion 
guides (TW-SRIG). (Pringle et a!., 2006)
Within the T-W AVE IMS cell the electrodes are connected in repeat sections 
of six pairs of electrodes. Each ring electrode has two voltages applied to 
form the travelling wave, a radially confining RF voltage (to reduce scattering 
effects), and the travelling wave voltage, a third DC bias voltage can be 
applied for fragmentation if required this is done within the SYNAPT in the 
trap and transfer regions. The T-W AVE IMS cell contains 61 electrodes and 
has a total length of 185mm, flanked each side by the trap and transfer 
travelling wave ion guides (TW IG or TW -SRIG ) consisting of 33 electrodes 
and 100mm in length. All the electrodes have 1.5mm centre to centre spacing 
with ion transmission apertures of 5mm and each electrode is 0.5mm thick. 
The T-W AVE IMS is operated with gas pressures up to 1mbar with waves of 
up to 25V  with velocities ~300-600m /s (Pringle et al., 2006). These waves 
can be computer modelled to demonstrate how the T-W AVE IMS works. 
Figure 1.16a shows a computer model of the SRIG which forms the T-W AVE  
IMS cell. The potential gradient exists across the aperture and increases 
markedly near the electrode walls. Figure 1.16b shows the same SRIG  
animation but from a different angle showing the waves that form which the 
ions “su rf (Giles et al., 2004).
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Figure 1.16 a) A computer model of the SRIG which forms the T-WAVE IMS cell. The 
potential gradient exists across the aperture and increases markedly near the electrode 
walls, b) The same SRIG animation but from a different angle showing the waves that 
form which the ions “surf. (Giles et al., 2004)
Figure 1.17 Shows a series of SIM ION plots demonstrating how the ions surf 
the travelling wave and then roll over the top of the wave and get collected by 
the following wave, this process is repeated numerous times. The number of 
times each ion rolls over the top of the wave is dependent on the wave 
characteristics (Height and Speed) and also on the effective drag caused by 
the surrounding gas. Hence the ions are separated based on their average 
collisional cross sectional area because all the ions experience the same 
wave characteristics, but the number of collisions between the ions and the 
background gas changes based on their average collisional cross sectional 
area.
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Figure 1.17 SIM ION plots of the Ion trajectory within the T-WAVE IMS cell showing the 
ion surfing the wave and then rolling over the top of the wave and being collected by the 
following wave. (Giles etal., 2004)
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Results obtained from T-wave IMS TO F MS instruments often show trend 
lines, when the mobility drift time is plotted against the m/z. Classes of ions 
regularly follow a trend line (Jackson et al., 2007), these trend lines can be 
due to structural differences and hence differences in the average collisional 
cross sections of isobaric ions. Trend lines are also formed by charge states 
of ions because multiply charged ions travel through the T-wave IMS faster 
than isobaric singly charged ions (Pringle et al., 2007).
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Figure 1.18 Ion Mobility separation of singly charged and multiply charged peptides. 
(Pringle et al., 2007)
Initially T-wave IMS gave one of the lowest resolutions of IMS instruments but 
recent advances in the T-wave IMS which have been incorporated in the 
SYNAPT G2 (Waters corporation, Manchester, UK) have markedly improved 
the ion mobility resolution. This has been achieved within the T-W ave IMS  
cell by increasing the length of the cell and increasing the operating pressure
within the T-W ave IMS by using a helium filled entry cell, (www.waters.com) 
This results in increased numbers of collisions between ions travelling within 
the cell and the buffer gas, increasing the ion mobility resolution.
1.4 MALDI Introduction
Biological samples for MALDI-MSI are usually in the form of thin tissue 
sections. In preparation for MALDI MSI analysis these tissue sections are 
coated with an organic acid matrix solution. The organic acid co-crystallises 
with analytes on the tissue surface and in the same way as with conventional 
MALDI the matrix is ablated from the surface along with the associated 
analyte molecules by means of a pulsed laser. Matrices are chosen that 
absorb electromagnetic radiation at the specific wavelength of the laser e.g. a 
N2  laser with a wavelength of 337nm, or a frequency tripled Nd:YAG laser 
with a wavelength of 355nm (Demirev et al., 2005).
When acquiring a mass spectrometric image using microprobe mode MALDI, 
the laser is fired at the sample for a pre-selected length of time at a series of 
predetermined points. At each x, y coordinate, a full scan mass spectrum is 
recorded or ms/ms if required. Images are then produced by plotting the 
spatial dimensions against the relative abundance of a selected ion (Prideaux 
et al., 2007). A  slight variation of this method is the use of "dynamic Pixel". 
Dynamic pixel moves the target plate during each acquisition within the 
defined spatial resolution (Simmons 2008). A  further development on this 
method is the use of continuous raster imaging, this method markedly 
improves the image acquisition time. This is achieved by continuously firing 
the laser at the target for a complete row of the image, during which the
software collates the acquired data at known intervals depending on the 
spatial resolution requested and the sampling speed selected, only at the end 
of each row is the laser stopped and then moved to the start position of the 
next row.
Two of the most important steps in acquiring a MALDI-MS image are sample 
acquisition and preparation. Techniques employed should ensure that the 
spatial localisation and integrity of the analyte compounds are maintained. 
Schwartz et al., 2003 recommended that the tissue should be surgically 
removed and the native shape of the tissue preserved. Once the tissue has 
been removed it must be snap frozen, there are a number ways to achieve 
this. These include, wrapping the tissue lightly in aluminium foil and slowly 
submerging the tissue in to liquid nitrogen (Schwartz et al., 2003, Chaurand et 
al., 2005, Reyzer and Caprioli 2005), direct tissue freezing by placing the 
tissue in powdered dry ice (Sugiura et al., 2006), and submerging the tissue in 
dry ice cooled hexane (Hsieh et al., 2006) for 15-30 seconds. An alternative 
method is to use isopentane cooled to -30°C for 15-20 seconds (Wang et al., 
2005). Within the work reported here a similar technique to that of W ang et 
al., 2005 was used, this involves liquid nitrogen cooled isopentane into which 
the fresh tissue is submerged for 15-20 seconds. After snap freezing the 
frozen tissue is stored at -80°C. At this temperature tissue can be stored for 
long periods of time. It has been shown by Schwartz et al., 2003 that tissue 
stored in this way shows no significant degradation for at least a year.
When required tissue is sectioned in a cryostat between -5 to -25°C (Schwartz 
et al., 2003). The thickness of the tissue sections used for MALDI-MS  
imaging have been shown (Sugiura et al., 2006) to make a significant 
difference to the images obtained from high molecular weight proteins. Within 
this work a tissue section thickness of 5pm is recommended, for ionisation 
and detection of high molecular weight proteins. Two main reasons have 
been described to explain this effect; the first is that charging effects are lower 
in thinner tissue sections, the second is the washing of thicker tissue sections 
to remove the salts and lipids which reduce the spectra quality of high 
molecular weight proteins is not sufficient in thicker sections. In contrast 
Schwartz et al., 2003 state that tissue sections 10-20pm thick are optimal due 
to thicker sections being more robust and easier to handle.
Schwartz et al., 2003 also claim that the way in which tissue sections are thaw  
mounted affects the spectral quality. Thaw mounting tissue by pressing a 
room temperature target plate onto the section and thaw mounting the tissue 
on the target is one method, however this leaves a residue of ice crystals on 
the cryostat surface possibly leaving soluble proteins behind. The method 
preferred by Schwartz et al., 2003 is to cool the target plate down in the 
cryostat and then place the frozen section on the cooled target plate using an 
artist brush, and then warming both up which results in the section being thaw  
mounted without loss of any analytes.
Some applications require tissue sections to be washed to remove some of 
the salt and lipids from the tissue surface prior to matrix deposition. The
methodology for this step varies considerably between different experiments 
and this step also needs optimising for each project. When imaging proteins it 
has been found (Chaurand et al., 2006) that the best washing step was to 
wash with, 70%  ethanol followed by 90% ethanol: 9% glacial acetic acid: 1% 
deionised water (v:v:v). W hereas they had previously reported (Chaurand et 
al., 2004) that the best method was not to wash the tissue at all but to place it 
in a desiccator for 1-2 hours. In lipid studies (Woods and Jackson 2006) no 
washing step was employed.
1.5 Matrices for MALDI MS
There are several matrices used for MALDI MS and each , has different 
applications. Matrix selection is a critical parameter for imaging experiments 
and there are a wide selection of matrices available for this application. The 
three most common matrices used for imaging are aCHCA, mainly for low 
molecular weight peptides, (Schwartz et al., 2003), sinapinic acid, for higher 
molecular weight proteins, and DHB for lipids (Jackson et al., 2007). These 
matrices are also used for many other applications. As well as these common 
matrices several groups have reported the possible benefits of combining 
different matrices. Laugesen and Roepstorff 2003 reported the combination 
of DHB and aCHCA for the analysis of peptides and proteins. The use of 
solid ionic matrices have also recently been reported. Snovida et al., 2008  
have demonstrated the combination of DHB with aniline or N,N- 
Dimethylaniline for carbohydrate analysis. Aniline has also been combined 
with aCHCA for a variety of applications by Calvano et al., 2009.
Guo and He., 2007 have used aCHCA and 9-AA (9-aminoacridine) for the 
analysis of various small molecules including, PCs and IPs (inositol 
phosphates). This was found to reduce the background noise in the 
experiment as well as to allow switching between polarities without further 
sample preparation. Kim et al., 2005 have shown that the combination of 
aCHCA with nitrilotriacetic acid also reduces the background noise of the 
matrix adducts. Another method for reducing the chemical noise created by 
aCHCA matrix clusters has been demonstrated for conventional MALDI 
analysis by Smirnov et al., 2004. Within this work the authors washed the 
matrix/sample co-crystallised spots with either water or ammonium salt 
solutions, this helps to remove the alkali matrix salts from the sample due to 
their higher solubility in water compared to the aCHCA crystals. They also 
report the inclusion of monoammonium phosphate into the matrix solution 
which suppressed the formation of matrix clusters and improved sensitivity.
There have been many other matrices reported some of which are shown in 
table 1.1
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Matrix Structure Application Reference
aCHCA 0
j§ H A°HHO 11 N
Peptides, Small 
Proteins and 
lipids
Guo and He 2007, 
Schwartz et al., 2003
SA
0I
c h 3
Proteins, Peptides 
and lipids
Beavis etal., 1989a, 
Beavis etal., 1989b
DHB 0
HC> Jl
0H
Proteins, peptides 
and lipids
Strupat etal., 1991, 
Jackson et al., 2007
DHA G ^ C H 3
HO> J ^ O H
Lipids Jackson et al., 2005b
THAP OH O
hoA^Aoh . h,o
Oligonucleotides Gyemant etal., 2001
ImCHCA (1-
methylimidazole-
CHCA) C H 3  N
Gangliosides Chan et al., 2009
ANI-CHCA
(Aniline-CHCA) 6 W -
Amino acids, 
peptides, 
proteins, lipids.
Calvano et al., 2009.
3-HPA
Y
OH
ssDNA oligomers, 
peptides and 
glycoproteins
Wu et al., 1992, Tang et 
al., 1994.
4-NA (4- 
nitroaniline) ifYNH2
o 2n ^
Lipids, other small 
molecules
Batoy et al., 2008
9-AA (9-Amino 
acrodine)
nh2 Lipids, other small 
molecules
Guo and He 2007
Graphite C Gerebrosides Cha and Yeung 2007
DHBB (2,5- 
dihydroxy-benzoic 
acid butylamine)
I  0
\  HO. JL
O ' s S v v  £
Pullulans
(polysaccharides)
Schnoll-Bitai et al., 
2008.
CICCA (4-chloro- 
a-cyanocinnamic 
acid)
0jOrY"™h3c ' ^ ' nh2 II0^ ^  ft
Phosphatidyletha
nolamine
Chloramines
Jaskolla et al., 2009.
Table 1.1 Some matrices commonly used for MALDI-MS including their structure and an
example of their applications. This is not an exhaustive list as novel matrices and matrix 
combinations are reported every year.
Matrix selection is also influenced by the laser type to be used. For example, 
when a 355nm laser is used, because of the absorption profiles of SA and 
DHB, poor desorption/ionisation results (Allwood eta l., 1996).
Matrices that are currently employed within MALDI-MS have been shown to 
change their absorption wavelengths when dry compared to when they are in 
solution. These matrices generally shift the absorption profile towards longer 
wavelengths when dry compared to in solution (Wu et al., 1993). The  
absorption profile of 3-HPA has an absorption maxima at approximately 
308nm and hardly absorbs at 355nm when in solution, but when 3-HPA is a 
dry powder it shows good absorption/ionisation performance at wavelengths 
between 266-355nm. Horneffer et al., 1999 showed that various positional 
isomers of DHB nearly all showed an absorption shift towards longer 
wavelengths when dry compared to in solution. This shift in the absorption 
profiles of matrices can be very important within MALDI-MS, since generally 
spectrum quality increases with absorption until a level where the spectrum  
quality compared to absorption level out.
Matrices are chosen that absorb electromagnetic radiation at the specific 
wavelength of the laser and ionisation is generally thought to occur in a two 
stage process, firstly by a collective absorption and ablation event of the 
matrix and analyte, followed by an active role of the matrix in the ionisation of 
the analytes (Gluckmann et al., 2001). The desorption and ionisation events 
within MALDI will be further discussed later in this introduction.
1.6 Matrix application
1.6.1 Manual spotting
Manual spotting of matrix is not used for imaging experiments due to the low 
spatial resolution obtainable by manual spotting caused by analyte spreading. 
This technique is generally used for profiling experiments (Schwartz et al., 
2003, Chaurand et al., 2005, Reyzer et al., 2005, Chaurand et al., 2004, 
Chaurand eta l., 2006, Woods and Jackson 2006). Manual spotting does tend 
to provide higher sensitivity compared to a matrix sprayed section. This is 
most likely due to the time that the analyte has to co-crystallise with the 
matrix. Generally with spotting experiments the drying time is much longer 
than spray coating, and due to the volume of matrix spotted generally the 
analyte can be redistributed within the spot and hence a larger area is used to 
form the co-crystals.
Matrix application is one of the most important stages in imaging experiments 
a uniform matrix coating is required for reliable imaging experiments, this can 
be achieved using several techniques.
1.6.2 Manual Spray
Manual spray coating is probably the cheapest method available for the 
application of matrix for MALDI MSI. As well as being one of the cheapest 
methods it is also one that can give some excellent results. Hence manual 
spray coating is one of the preferred methods for MALDI imaging (Prideaux ef 
al., 2007, Schwartz et al., 2003, Chaurand et al., 2005, Reyzer et al., 2005,
Hsieh et al., 2006, Hsieh et al., 2007, Chaurand et al., 2004, Jackson et al., 
2007), because it forms a uniform matrix deposition. However, the results 
depend on the operator, and therefore, reproducibility between operators may 
be poor. A skilled operator can make this one of the best and most reliable 
methods of matrix coating. The key aspect to observe and control when 
manual spray coating, is the wetness of the sample. There is a fine balance 
between sufficiently wetting the sample, allowing for matrix and analyte co­
crystallisation, and allowing sufficient time to allow this process to occur 
increasing the sensitivity of the technique. If the sample is too wet, analyte 
redistribution can occur resulting in reduced spatial resolution and the integrity 
of the imaging results is affected. Figure 1.19 shows a kidney section 
manually spray coated with aCHCA. An even matrix coating can clearly be 
seen across the sample.
mr
Figure 1.19 Kidney section after manual spray coating with aCHCA matrix.
1.6.3 Sublimation
Sublimation as a method of matrix application has been shown (Hankin et al., 
2007) to be suitable for matrix deposition when imaging phospholipids in brain 
tissue. The benefits of matrix coating when using vacuum sublimation have 
been described (Jaskolla eta l., 2009), compared to conventional dried droplet 
preparations. Using scanning electron microscopy (SEM) the matrix surface 
after application was imaged.
The method employed (Hankin et al., 2007) used dry matrix (~300mg) placed 
in the bottom of a flask, inside the flask a cooling finger was placed until it 
rested about 1 inch above the matrix. At the end of this the section to be 
matrix coated was placed and maintained at 15°C. The whole unit was 
placed under a low vacuum pressure 0.05Torr, and the base of the flask 
where the matrix was then slowly heated to 120°C and held at that 
temperature for approximately 15-20mins. This resulted in the sublimation of 
the matrix, giving a fine coating of matrix on the sample without the use of 
solvents. This completely removes the possibility of analyte redistribution. 
They also demonstrated that good homogeneous matrix crystallisation on a 
glass slide can be achieved using this method and have shown that this 
method can improve the signal of a glycerophosphocholine 16:0/18:0 spot on 
a glass slide compared to electro-sprayed matrix. Images obtained using this 
method has shown good correlation to stained tissue sections. Figure 1.20 
shows the set up required for matrix sublimation.
MALDI 
Plat© with 
Tissue slice
Figure 1.20 Image of the apparatus required for matrix sublimation. (Hankin et al., 2007) 
1.6.4 A u tom ated  Pneum atic Spraying
An example of an automated pneumatic sprayer is the SunCollect MALDI 
Spotter (KR Analytical Ltd) (Figurel .21). This instrument can be operated in 
two modes and depending on the operation required it can be utilised as a 
spotting device which can spot volumes >1 Onl per spot, the solution is 
deposited via a capillary on an X, Y, Z movable arm. This can also be 
exchanged in a few minutes with the addition of a compressed air line into a 
sprayer.
Figure 1.21 SunCollect matrix spotter/sprayer
(http://www.sunchrom.de/pdf/SunChrom%20SunCollect english.pdf)
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The SunCollect is best suited to MALDI imaging when used as a sprayer 
(Wolstenholme et al 2009). Automated sprayers have the advantage of 
reproducible matrix application, with visually improved homogeneous matrix 
covering compared to manual spraying. Homogeneous matrix coverage is 
only one of the critical parts of MALDI sample preparation. Another is the 
time allowed for the formation of matrix analyte co-crystallisation, which is 
controlled by the duration of the drying time. Due to the limited drying time 
obtained using automated pneumatic sprayers the time allowed for analyte 
matrix co-crystallisation is limited, reducing the sensitivity for some analytes.
1.6.5 V ibrational Vapourisation
An example of matrix coating using vibrational vapourisation is the ImagePrep 
(Bruker Daltonics, Germany). This instrument utilises vibrational vaporisation 
technology to form a cloud of matrix which is left to settle on the sample 
surface (Kaletas et al., 2009).
Figure 1.22 ImagePrep matrix applicator.
(http://www. bdal. com/uoloads/media/lmaqePrep-2008-eBook. pdf)
Using this technology a spatial resolution determined by the matrix crystal 
size formed by the droplets is <50pm. The average crystal size created using
this vaporisation technology is ~20pm (Kaletas et al., 2009). The image prep 
has an optical sensor which measures the amount of light that is scattered 
from the matrix crystals on the sample slide. Using this method the amount of 
matrix deposited onto the sample can be controlled. This system also allows 
for monitoring of the wetness and drying rate of the matrix. During matrix 
application the matrix becomes wet on the surface of the sample resulting in 
the scattered light intensity fading, as the matrix crystals form and the matrix 
layer dries the amount of light scattered increases, when the matrix layer is 
completely dry this is a direct indication of the thickness of the matrix layer.
1.6.6 A coustic  D rop let Ejection.
An example of the use of acoustic droplet ejection technology for matrix 
application is the Portrait 630 reagent multi spotter (Labcyte Inc. CA) (Figure 
1.23) is a Matrix spotter which deposits 170pL droplets by using acoustic 
ejection technology (www.labcyte.com, Kaletas et al., 2009). One of the 
major advantages of this instrument is the fact that there are no tips, nozzles 
or capillaries that can become blocked or add contamination to a sample. 
Using this technology allows the Portrait to spot any concentration of matrix. 
The only limiting factor is the solubility of the matrix. If it can be dissolved into 
solution then effectively the Portrait can spot it.
Figure 1.23 Portrait 630 multi reagent spotter.
(http://www.labcyte. com/portrait®_630_spotter/default. 92.html)
The Portrait records the position of each spot within an experiment. The  
number of droplets per spot per cycle can be set a/ong with the delay/drying 
times between each drop or cycle. Using this system allows the deposition of 
almost any solution and with the accurate location of each spot recorded 
within the method file allows for an enzyme to be printed, incubated and then 
the application of a MALDI matrix in exactly the same location. This prevents 
the possibility of analyte migration throughout a sample because the matrix is 
applied in discrete spots. Unfortunately this instrument is currently the most 
expensive available on the market, retailing at approximately £120,000 in 
2009.
1.6.7 Ink-Jet Printers.
An advanced ink-jet printer used for the application of matrix is the CH IP-1000  
Chemical Printer (Shimadzu Corporation, Tokyo.) (Figure 1.24). This is a 
matrix printer which deposits 87pL droplets using a Piezo printing head 
(Kaletas et al., 2009). The CHIP-1000 records the location of each spot and 
can reprint matrix and enzymes in the same location.
Figure 1.24 ChiP matrix printer
http://www. shimadzu-biotech.net/paaes/Droducts/2/chip. ohp
One of the major drawbacks with the CHIP-1000 is the use of a fine printer 
head which can block depending on the matrix concentration and the solvent 
used. The matrix concentration that can reliably be used is <10mg/ml.
There have also been reports of “homemade” ink-jet matrix printers (Baluya et 
al., 2007) for MALDI matrix application. Better quality and more reproducible 
mass spectral images compared to electrospray and airbrush matrix 
application methods were obtained.
A quick reference table is shown below for some of the Matrix coating 
techniques.
Technique Droplet
diameter
Advantages Disadvantages
Droplet 
deposition 
by hand
Variable, 
mostly large 
(>900 t^m)
Fast, simple, cheap No spatial information,.poor 
reproducibility
Pneumatic
nebulization
(airbrush)
Variable,
mostly
small
(aerosols)
Fast, simple, homogenous 
layer, cheap
Limited environmental control, 
low concentrations of matrix 
solution can be used, quality 
varies from person to person, 
droplet size not constant
SunCollect Variable,
mostly
small
(aerosols)
Fast, simple, homogenous 
layer, cheap, removes 
personal variation, flow rate 
control.
Limited environmental control, 
low concentrations of matrix 
solution can be used, limited 
drying/co-crystallisation time
ChIP — 150 t^m 
(100 pL)
Uniform droplets, precision of 
placement, conditions can be 
controlled, automated, high 
signal quality, reproducible
Slow, nozzle tip clogging, 
expensive
Portrait
630
reagent
multi­
spotter
180-230 ^  
m (170 pL)
Uniform droplets, precision of 
placement, automated, no 
clogging, fast, good 
reproducibility
Matrix applied as droplets, 
expensive.
ImagePrep Variable, 
but small ( 
-20-50 V* 
m)
Conditions can be varied and 
controlled, automated, 
homogenous layer
Slow, small area, membrane 
clogging, droplet size not 
constant, expensive
Sublimation Very small Cheap, very homogenous, 
high purity of organic matrix, 
reproducible, fast
Limited time for analyte:matrix 
interaction, only lipids detected 
so far
Table 1.2 Quick guide to some of the available matrix coating techniques showing some
of the advantages and disadvantages, (adapted from Kaletas et a l, 2009.)
1.7 Desorption and Ionisation in MALDI
1.7.1 Desorption
Desorption is the process of solid to gas phase transition. The emitted 
material contains few particles, droplets or clusters. However in MALDI, 
ablation is possibly a better description of the process, because at ablative 
laser fluences sample overheating and subsurface nucleation occurs leading 
to phase explosion (Knockenmuss 2006). The ablation process is explained
thus; when the energy density is large enough, an explosive transition from a 
solid phase into a gas phase occurs. This causes a “gas jet” with a large 
initial ion velocity and velocity spread (Karas et al., 2000 & Karas et a/., 2003). 
This initial ion velocity is partially matrix dependent and to a lesser extent 
analyte size dependent. Peak sample temperatures achieved during laser 
ablation can be between 600-1200K (Knockenmuss 2006). After the initial 
irradiation, the desorbed/ablated material rapidly cools and then more slowly 
as the gas plume undergoes a dramatic density reduction from a solid phase 
to high 'vacuum conditions within the mass spectrometer. The ablated 
material contains particles, clusters, molecules and ions. Particles are large 
aggregates of molecules similar to the bulk material, whereas clusters are 
small aggregates of molecules which may have different properties to the bulk 
material. Particles may not vaporise and hence are not normally analysed 
within MALDI (Knockenmuss 2006).
1.7.2 Ion Formation in MALDI
The ionisation process in MALDI is still not fully understood, ionisation was 
originally thought to be achieved purely by a proton transfer reaction, however 
it is now thought to be a very complex process involving several processes. It 
is generally accepted that not one mechanism can account for the observed 
signal but several mechanisms all contribute to overall ion formation and 
detection.
Ionisation in MALDI is generally thought to occur as a two stage process, 
including the desorption and primary ionisation of the sample during and
shortly following the laser irradiation (Knocknemuss 2006). This process is 
thought to result in the formation and ejection of particles, clusters and 
molecules from the sample into the surroundings (Karas et al., 2000, 
Dreisewerd 2003, Knockenmuss 2006). This stage is followed by secondary 
ion-molecule thermodynamic and kinetic reactions.
One phenomenon observed in MALDI-MS is the generation of predominantly 
singly charged ions compared to electrospray ionisation where multiply 
charged ions are commonly observed. In MALDI-MS there is a slight shift 
towards multiply charged states for high mass analytes and with certain 
matrices like aCHCA. This may not be a true representation of the sample 
because these large species can have a high kinetic energy and enhanced 
detection effiency (Karas et al., 2000).
An important consideration in the generation of ions within MALDI-MS is the 
initial starting conditions of the analytes within the matrix either as a surface 
preparation or as a solid solution. One paper (Karas et al., 2000) has 
suggested possible matrix -  analyte conditions within the matrix -  analyte 
preparation which could be associated with possible ions.
For neutral analyte in a pure uncontaminated matrix.
[°°T/Mn/Cat+/B']
or
[ooT /M n/Me'72B']
Neutral analyte with salt contaminated matrix 
[ooT/(Mn+xHX+)n/nxB-]
Precharged poly-protonated analyte in matrix
[ooT/(Mn-xHX')n/nxCat+]
Or
[°°T/(Mn-xHxVnx/2Me+]
Precharged poly-deprotonated analyte in matrix
°°T = Excess matrix
M = Analyte
Cat+ = Cation eg. Na+, K+ etc
Me+ = Doubly charged cation eg. Zn2+
H = Proton
B' = Anion eg. CP
These are some of the possible matrix-analyte conditions present in the 
MALDI preparations. It has also been shown (Kruger et al., 2001) that the
xixm±.j . L^napier i
inclusion of dyes into MALDI matrix crystals did not change the charge state 
of the analytes supporting the theory of the incorporation of charged analytes 
within matrix. This report demonstrated that a small amount of the solvent is 
incorporated within the matrix-analyte co-crystal formation allowing the 
generalisation that the analytes within a matrix are in the same charge state 
as the analytes within the solvent. The incorporation of solvent within the 
matrix could also be important with charge separation by ion solvation thus 
reducing the possibility of ion neutralisation. Also the evaporation of this 
solvent from within the matrix-analyte co-crystals could explain the 
degradation of MALDI signal over periods of time after preparation.
The ion clusters formed during the desorption/ablation event can be highly 
charged species when they are formed. However, some of these clusters can 
rapidly evaporate in a short period of time after ablation due to the loss of 
neutral molecules and as a result of the formation of neutrals from reaction 
products within the gas plume. Some clusters can form singly charged 
clusters diie to neutralisation in the gas plume by matrix ion interactions and 
trapped electrons which form during the matrix photo ionisation process,
(Karas et al., 2000). It has been shown that only a few nm’s of the matrix lose 
electrons resulting in low numbers of electrons in the gas plume. In the 
remaining material the electrons are captured by the matrix to form matrix 
anions (Knochenmuss 2006).
Within the ionisation process matrix is a competitor for charge and if the 
functional group of the analytes is for example a carboxylic acid and a 
carboxylic acid matrix was used then the charge transfer would favour matrix
ion formation because of its excess. Thus reducing the signal intensity for the 
analyte of interest. The matrix also benefits ion formation by providing 
collisional energy within the gas plume. These collisions help reduce the 
coulomb attractions between ion pairs and without the additional collisions 
due to the matrix some of these ion pairs would recombine resulting in the 
neutralisation of these ions and hence the loss of these ion signals.
Chemical noise is present in nearly all MALDI spectra except in some 
situations when the analyte concentration is high and the laser fluence is low. 
This effect could be caused by depleting matrix ions in the gas phase by 
deprotonation. The same effect is true for competing analytes, where 
different analytes can suppress the signal from other analytes or matrix in the 
positive ion mode. This is the case if one or more of the analytes are strongly 
basic. Almost all other spectra contain chemical noise this is often composed 
of charged clusters with a high matrix content (Krutchinsky et al., 2002).
In the preceding section, the proposed method of cluster formation and 
ionisation was discussed. However, another concept of ion formation is 
photoexcitation and energy pooling. This involves the photoexcitation of 
neighbouring molecules to an excited state, if the two neighbouring molecules 
have significant interactions due to wavefunction overlap, the energy could be 
redistributed between the molecules.
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Figure 1.25 Schematic representation of photoexcitation and energy pooling.
By this energy pooling effect energy can also be mobile across the matrix with 
energy hopping. These events are treated as pseudo-particles called 
“excitons”. The time per hop of an exciton is ~50psec this allows ample time 
for energy redistribution within the 0.5-1.5nsec excited state lifetime within 
MALDI (Knockenmuss 2006). Analytes with a lower excited states than the 
matrix can act to reduce the efficiency of MALDI.
Energy pooling and cluster generation are thought to be the two primary 
ionisation mechanisms in MALDI but there are several other mechanisms 
thought to contribute to MALDI imaging. These include direct multi-photon 
ionisation of matrix or matrix-analyte complexes, excited state proton transfer 
(Breuker et al., 2003), polar fluid model, pneumatic assistance, and electron 
transfer and cationisation (Knockenmuss 2006).
During the secondary reaction processes in the gas phase collisions of 
analytes with matrix ions and neutrals and matrix-matrix collisions result in the 
formation of many of the commonly observed ions eg. M+\  M H+, M Na+, A +\  
AH+, AN a+ etc.
1.8 Scope of this thesis.
There are two areas of small molecule MALDI-imaging that are covered within 
this thesis, these are lipid imaging and small molecule xenobiotic imaging.
1.8.1 Imaging lipids
Lipids can perform both structural and functional roles within the body and are 
known to be important mediators of cell signalling, acting as second 
messengers in cellular events such as cell growth, cellular proliferation and 
cell death. Alterations in lipid metabolism are associated with many disorders 
and disease states throughout the body. Therefore the study of lipid 
distribution and abundance is an important area of research (Woods and 
Jackson 2006, Jackson et al., 2007, Adibhatia et al., 2006, Jackson et al., 
2005, Fahy et al., 2005). One of the most lipid rich organs is the brain. In the 
brain lipids account for approximately 50%  dry weight, deregulation in lipid 
metabolism in the brain is commonly associated with many brain disorders 
and diseases including, bi-polar disorders, schizophrenia, Alzheimer’s, 
Parkinson’s and Niemann-Pick diseases (Adibhatia et al., 2006).
Woods and Jackson (Woods and Jackson 2006) demonstrated how the 
relative abundance of lipids within different areas of the brain can change. 
They demonstrated that PC 32:0 has a different distribution between the 
cerebellar cortex and cerebellar peduncle, and that different classes of lipids 
can been observed using positive and negative ion mode MALDI. Within this 
work DHA was used as the matrix. This work follows on from earlier studies 
(Jackson et al., 2005a) in which they showed the relative abundance of 
various different lipid species in white and grey brain matter. Stubiger and 
Belgacem (Stubiger and Belgacem 2007), demonstrated the use of a novel 
matix for lipid analysis using MALDI-MS. Within this work 2,4,6- 
Trihydroxyacetophenone (THAP) was used, and it was shown that this matrix 
was very good for lipid profiling. They also demonstrated that the THAP  
tolerates high salt concentration and shows excellent cationisation properties. 
This is beneficial because the addition of salt has been shown to reduce the 
spectral complexity in complicated mixtures of lipids. MALDI-ion mobility- 
TO FM S imaging of lipids has been reported (Jackson et al., 2007). It was 
shown that lipids, peptides and matrix related ions tend to form individual 
trend lines when plotted as mobility drift time against m/z. DHB clusters have 
a shorter drift time followed by peptides and finally lipids. In this study it was 
shown that peptides were consistently around 12% slower in drift time, than 
isobaric lipids. This technology is highly beneficial in imaging applications 
because it allows for the separation of isobaric ions resulting in image 
generation of an ion of interest without interference from isobaric matrix ions.
A high proportion of the published lipid analysis work involving MALDI, lipid 
species are reported using simple nomenclature i.e. PC 32:0 or PC 36:2. This 
nomenclature gives the basic information about the lipid species. PC 36:2 
states that this is a phosphatidylcholine lipid with fatty acids totalling 36 
carbons and 2 double bonds. There are several possible lipids species which 
could equal PC 36:2 including PC 18:0/18:2 or PC 18:1/18:1. Using MALDI 
these can sometimes be difficult to tell apart due to limited MS and M S/M S  
information in positive ion mode for the M+H ions. It has been shown 
(Jackson et al., 2005b) that the addition of alkali metals to the matrix can aid 
in the fragmentation and formation of informative ion species within MALDI 
M S/MS analysis. The doping of the matrices is commonly performed using 
Na, K or Li as alkali metals to aid in the formation and fragmentation of these 
adducts (Jackson et al., 2005b). An alternative method is the use of 
enzymes. Phospholipase A2 (PLA2) is an enzyme that selectively cleaves 
the fatty acid at the Sn2 position of glycerophospholipid prior to mass 
analysis, this allows the identification of the fatty acid chains by their mass 
differences and the location of each chain (Fuchs & Schiller 2008).
1.8.2 Imaging Xenobiotic compounds
A major area for the application of MALDI-MS imaging is imaging xenobiotics, 
drugs and metabolites. It has been shown (Prideaux et al., 2006) that indirect 
MALDI imaging of xenobiotic compounds in skin can be achieved by blotting 
the tissue onto solvent soaked cellulose membrane, followed by spray coating 
the membrane with matrix instead of using tissue sections. This work 
concluded that the use of solvents in the blotting method can increase analyte
extraction by up to 80 fold, however, this technique can lead to analyte 
redistribution.
In other reports, the distribution of clozapine in rat brain tissue has been 
reported (Hsieh et al 2007). The autoradiographic images and the MALDI- 
M S/MS images were in almost compete agreement demonstrating the huge 
potential for this technique for drug and metabolite studies. However, drug 
distribution studies by MALDI-MSI are in an early stage and the continual 
advancement of instrumentation, matrices and methodologies will continue to 
increase the sensitivity and specificity of this technique.
1.9 Aims of this project.
The aims of this PhD Project can be summarised as follows.
1. To asses the use of MALDI imaging for the identification and spatial 
distribution analysis of endogenous small molecules, including the use 
of statistical analysis to identify differences within histologically different 
tissues. Demonstrate the benefit of PCA statistical analysis for the 
reduction in the complexity of the data obtained within MALDI imaging, 
allowing the rapid identification of possible ions of interest.
2. To investigate the use of MALDI imaging for the direct analysis of 
xenobiotics within tissue sections. Further expand MALDI imaging into 
whole body tissue section analysis and combine new advances in 
MALDI MSI with the incorporation of a further separation step of ion
mobility. Using this technique to demonstrate the potential for this 
technology to improve the drug discovery process by eliminating the 
need for the synthesis of expensive radiolabelled compounds for 
distribution analysis and also reduce the number of animals required in
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CHAPTER 2
MALDI-MS Imaging of Lipids in Rat 
Brain Tissue with Integrated 
Unsupervised and “Supervised” 
Multivariant Statistical Analysis.
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2.1 Introduction
2.1.1 Lipids
Lipids can perform both structural and functional roles within the body and are 
known to be important mediators of cell signalling, acting as second 
messengers in cellular events such as cell growth, cellular proliferation and 
cell death. An alteration in lipid metabolism is a factor associated with many 
disorders and disease states throughout the body, therefore the study of lipid 
distribution and abundance is an important area of research. Adibhatia et al., 
2006 have presented work on the role of lipids and Lipidomics in brain injury 
and disease. Lipid analysis can experimentally observe ~100 molecular 
species within a given class of glycerophospholipids from crude tissue 
extracts. There are estimated 300 -  400 distinct species of sphingolipids 
within human tissue. Mammalian cells may contain ~1000 -  2000 lipid 
species overall.
The main topic covered by Adibhatia et al., 2006 involves an overview of the 
roll of lipids in cerebral ischemia (stroke). They describe the significant loss of 
phosphatidylcholine (PC) in the brain of stroke model animals. In brain tissue, 
PC synthesis is predominantly via the cytidine-5’-diphosphocholine pathway. 
Inhibition of this pathway by the inactivation of cytidylyltransferase causes cell
death. Lipid peroxidation has been shown to occur early in the pathogenesis 
of Alzheimer's disease. By products of lipid peroxidation include acrolein 
which is a very strong electrophile, which reacts with DNA bases. The 
resulting changes to the DNA bases can result in mutagenesis and 
carcinogenesis.
Jackson et al., 2007 published work using ion mobility MALDI for the detection 
and separation of lipids in brain tissue, using this technique they were able to 
separate the ions associated with lipids from similar or isobaric ions 
associated with peptides and DHB matrix related ions, they have also 
demonstrated the use of gold nanoparticles as a possible matrix for the 
detection and imaging of cerebroside. One of the most lipid rich organs is the 
brain, lipids account for approximately 50% dry weight of the brain, 
deregulation in lipid metabolism in the brain is commonly associated with 
many brain disorders and diseases including, bi-polar disorders, 
schizophrenia and Alzheimer’s, Parkinson’s and Niemann-Pick diseases 
(Adibhatia et al., 2006).
Fahy et al., 2005 have presented a comprehensive classification system and 
nomenclature for lipids. They define lipids as "hydrophobic or amphipathic 
small molecules that may originate entirely or in part by carbanion-based 
condensations o f thioesters and/or by carbocation-based condensations of 
isoprene units." using this system of classification most lipids can be sub­
classified into 8 categories, fatty acyls, glycerolipids, glycerophospholipids, 
sphingolipids, sterol lipids, prenol lipids, saccharolipids and polyketides.
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Figure2.1 Generic structures of several lipid species, a) Fatty acids, b) Glycerolipids, c) 
Glycerophospholipids, d) Shingolipids, e) Sterols, f) Prenois, g) Saccharolipids, h) 
polyketides.
Within each of these categories there are several classes and subclasses of 
molecules. The main class of lipids studied in this work are 
phosphatidylcholines which are a subclass of the glycerophospholipids 
category.
Phosphatidylcholine
Phosphatidylcholine is a class of glycerophospholipids.
Figure2.2 Phosphatidycholine structure.
2.1.2 MALDI Statistical Analysis
In the work reported here the use of principal component analysis (PCA) to 
aid the interpretation of MALDI-MSI data, using as a model system lipid 
variations within brain tissue has been investigated. To date MALDI-MS 
image analysis has been largely concerned with mapping the distribution of 
known analytes in tissues. An important step in the progression of its 
application is the determination of unknown variants for metabolite and protein 
profiling in both clinical and disease studies. PCA is a statistical approach 
that can be used as a means of determining latent variables in multivariate 
data sets. Van den Berg et a!., 2006 have presented work on the comparison 
of data pre-treatment of a metabolomic data set prior to PCA. Shown in table
2.1 are some of the possible pre-treatments used for multi dimensional 
complex data sets, including MALDI-MS imaging data (Van den Berg et al., 
2006).
.a. ± . m i  m  ^
Class Method Formula Unit Goal Advantages Disadvantages
I Centering x ij = x ij ~ x ( 0 Focus on the differences and not the similarities in the data
Remove the offset 
from the data When data is heteroscedastic, the effect of this pretreatment method is not always sufficient
II Aucoscaling
x ij ~ x t 
x i} =  .  
s(
(*) Compare metabolites based on correlations All metabolites become equally important Inflation of the measurement errors
Range scaling x ii ~ x i* iJ =  (  ,  - •  \  V "''fin in /
(•) Compare metabolites relative to the biological response range
All metabolites become equally important. Scaling is related to biology
Inflation of die measurement errors and sensitive to outliers
Pareto scaling
Xij ~ Xi  
X« =  #
0 Reduce the relative importance of large 
values, but keep data structure partially intact
Stays closer to the original measurement than autoscaling
Sensitive to large fold changes
Vast scaling
r. _ (-V‘I ~ Xi ) x i 
x i j ~ 5, 5(
(-) Focus on the metabolites that show small fluctuations
Aims for robustness, 
can use prior group knowledge
Not suited for large induced variation without group structure
Level scaling
z  _ x ij ~ x t 
x tj ~  -  
x i
(-) Focus on relative response Suited for identification of e.g. biomarkers Inflation of the measurement errors
III Log transformation 
Power transformation
x i j - °  lo g (^ )
Xij =  X i j - X j
* i j  =  \ l ( xv )
x ij =  x tj ~ x i
LogO Correct for heteroscedasticity, pseudo scaling. Make 
multiplicative models additive 
Correct for heteroscedasticity, 
pseudo scaling
Reduceheteroscedasticity, multiplicative effects 
become additive
Reduceheteroscedasticity, no 
problems with small values
Difficulties with values with large relative standard deviation and zeros
Choice for square root is arbitraiy.
Table 2.1 List of statistical processing methods used within MALDI-MS imaging data 
processing with advantages and disadvantages, (reproduced from Van den berg et a l, 
2006)
Van den berg et al., 2006 have found that for their application autoscaling and 
range scaling seem to perform better than other methods based on biological 
expectations from the experiment. However they found that pareto scaling 
remained closer to the original measurement than autoscaling and that the 
data does not then become dimensionless.
Skrobot et al., 2007 presented work using PCA and LDA (Linear Discriminant 
Analysis) to identify the presence of four different contam inant solvents in 
gasoline. Due to the complex nature of the gasoline mass spectrometry data,
there was a need for data pre-treatment to reduce the dimensionality of the 
data set before LDA. The authors used Fisher weights and PCA to reduce 
the complexity of the data before LDA. Govorukhina et al., 2006 have 
demonstrated the use of CODA (component detection algorithium) for data 
pre-treatment of an LC-MS data set obtained from a human serum sample. 
The data set was then analysed using PCA. This allowed the separation of 
cytochrome C spiked and non spiked samples. The use of PCA for the 
analysis of MALDI-MSI data has been reported previously by McCombie et 
al., 2005. In this work the coefficients of principal components were plotted as 
images in order to identify regions of tissue that were different. In our own 
groups previous work applying PCA to MALDI-MSI data issues arising from 
inhomogeheous matrix coverage and salt concentration in tissue were 
discussed and possible solutions suggested (Prideaux ef a/., 2007).
2.1.3 Brain Tissue Analysis
Figure 2.3 shows a schematic image of the brain indicating the regions 
selected for PCA comparison. These regions were identified from the 
histological section (not shown) using The Rat Brain in stereotaxic 
coordinates (Paxinos et al., 1998). One of the objectives of this work was to 
see if mass spectrometry could differentiate between white and grey matter. 
Brain grey matter is composed of cells called neurons specialised in 
transmitting information. Brain white matter is composed of Glial cells, 
astrocytes and oligodendrocytes. Astrocyte have been demonstrated to 
participate in "neurotransmission", oligodendrocytes facilitate electrical 
signalling because of their myeline sheaths which are mainly composed of
lipids. These myelin sheaths aggregate together and are responsible for the 
pale colour typical of the white matter.
In figure 2.3 certain regions of the brain are identified and colour coded, the 
cerebral cortex (yellow) is involved with cognitive function e.g sensory and 
motor. The corpus callosum (red) represents the white matter of the cerebral 
cortex and is made of oligodendrocytes and connects the cerebral cortex to 
the rest of the brain. The hippocampal formation (purple) is implicated in 
processing and storage of memory. The thalamus (blue) acts like an essential 
link between the sensory inputs and the grey matter in the cerebral cortex. 
The grey cerebellar cortex (grey) is predominantly involved in movement 
coordination and partially in cognition. The white cerebellar cortex (green) is 
the white matter in the cerebellum and connects the cerebellum to the 
brainstem and thalamus.
The aim of the work presented in this chapter of this thesis is to use PCA in 
conjunction with histology to differentiate regions of tissue (in this case 
regions of the brain), using both unsupervised and “supervised” PCA.
fGrey Cerebellar Cortex ! Wh ite Cerebellar Cortex
Cerebral Cortex 1 Corpus Callosum
|H ippocam pal Formation H | Thalamus
Figure 2.3 Schematic diagram of the brain regions selected for the PCA. The 6 
highlighted regions of the brain displayed illustrate where each of the 10 MALDI mass 
spectra were acquired for subsequent multivariate analysis.
2.2 Experim ental
2.2.1 Preparation o f  Tissue Sections fo r M ALD I-M S A nalysis
Male Wistar rats were sacrificed by schedule one method according to Home 
Office (UK) regulations. The rats were then decapitated and the connective 
tissue was cut between the skin and the top of the skull. The skin and 
connective tissue were pealed back to reveal the top of the skull and forceps 
were slid into the base of the skull through the hole at which the spinal cord 
exits the skull. The forceps were kept in contact with the interior surface of 
the skull at all times resulting in the brain carefully being moved away from the 
skull, the back of the skull was then broken out away from the brain tissue 3- 
4mm at a time until the back of the skull had been removed. The forceps 
were then slid inside the skull just to the left of the centre line, ensuring that
contact with the interior of the skull was maintained resulting in the brain 
tissue remaining undamaged. The left part of the skull was then broken away 
from the brain revealing the cerebral cortex of the left hem isphere, the same 
procedure was then repeated for the right side of the skull revealing the entire 
brain, a small round ended spatula was then slid under the brain and gently 
moved backwards and forwards to sever the nerves and blood vessels 
including the optic nerves, until the brain was freed, the brain was then 
removed from the skull and immediately snap frozen for 15 seconds in liquid 
nitrogen cooled isopentane, the frozen tissue was then stored at -80°C until 
required.
When required the tissue was mounted onto a 2.5mm thick cork disc in the 
desired orientation and held in place with a minimal amount of optimum 
cutting temperature (OCT) embedding medium, ensuring that no O CT  
embedding medium was near the region to be sectioned figure 2.4. This has 
been shown by Schwartz et al., 2003 to markedly reduce the spectral quality 
in MALDI MS, because OCT contains a polymer which ionises very well within 
MALDI MS and hence reduces the information that can be obtained (Figure 
2.5). Tissue sections (12pm) were cut using a Leica CM 1510 cryostat (Leica 
Microsystems, Wetzlar, Germany) set at -12°C, each section was thaw  
mounted onto cleaned aluminium plates.
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Figure 2.4 Image of a rat brain mounted on cork using OCT.
1450.16OCT related Peaks (m/z of 44 
difference)360340 1406.12
320
1362.07
300
280 1318.02
379.09260
240
1273.97220
200
180 1229.91
160
140
861.22120 1185.87650.10
100
1097.87 .114' 66.15335.I 423.07
145.07
.-461.03 
i 79.05 _^ 507,31
500
1- 22.1C5.11578.75 1053.82 34.00
825.23 1009.77 .^ 
^ 4)i-24 965.74
l ^ V e l  10554
145 i.
45.91C 34.11— 841,2U 
B.05 |48|09^771.5:;|
700 1500300 400 600 900800 1000 1100 1200 1300 1400
m /z, amu
Figure 2.5 Spectra obtained from OCT contaminated sample, OCT related peaks appear 
as a polymer with peaks at regular m/z 44 intervals.
2.2.2 Sample Preparation
The tissue sections were washed in graded ethanol solutions at 50%, 70%, 
90% and 100% (ethanol/water) for a period of 30 seconds at each grade and 
briefly air dried between washes in order to remove excess salts from the 
tissue prior to matrix application. After washing, the tissue was air dried for 
20m ins and then spray coated with 10ml of 25mgml'1 a-CHCA in ethanol with 
0.1% TFA. Spray coating was performed using a gravity fed pneumatic air 
spray gun, Iwata studio series compressor fitted with an Iwata Eclipse gravity 
feed airgun (Iwata-Media Inc., Portland, OR, USA) set at 40psi. The samples 
were spray coated at a distance of 25cm, for 20 series of 2 passes of the air 
brush, with 30 second intervals, this was carried out to obtain an even matrix 
coating whilst avoiding sample over wetting which would result in analyte 
migration.
The aluminium sample plates were cut to size and mounted onto an Opti-Tof® 
LC MALDI target plate (Applied Biosystems/MDS Sciex, Concord, Ontario, 
Canada) using double sided carbon conductive tape.
2.2.3 Mass Spectrometric Analysis
The samples were analysed in positive ion mode using an Applied 
Biosystems/MDS Sciex hybrid quadropole time-of-flight instrument (Q-Star 
Pulsar-i) fitted with an orthogonal MALDI ion source, using the oMALDI server 
5.0 software. A  355nm frequency tripled 1KHz Nd:YAG laser which has an 
elliptical laser spot of approximately 150 x 100 pm was used at an energy of 
40%  (4.0pJ) and a repetition rate of 1kHz. The laser was fired at the sample 
with 150 pm spatial resolution, with the laser firing for approximately 3
seconds per spot. The “dynam ic pixel” feature of the software that moves the 
laser within the defined pixel dimensions during acquisition was on (Simmons 
2008). A further comparison of the data obtained from white and grey matter 
has been made using unwashed brain tissue which has been analysed using 
a 5KHz Nd:YVC> 4  laser. This data was compared to show the differences 
between white and grey matter without, washing the tissue prior to matrix 
application. Within this comparison the matrix has been printed using a 
Portrait multi reagent spotter (LabCyte Inc, CA).
2.2.4 Principal component analysis
Principal component analysis (PCA) was carried out using the MarkerV iew™  
statistical analysis package (Applied Biosystems/MDS Sciex, Concord, 
Ontario, Canada). Ten Spectra were randomly selected from each of the 6 
distinct brain regions identified in figure 2.3, i.e the cerebral cortex (yellow), 
corpus callosum (red), hippocampal formation (purple), thalamus region 
(blue), grey cerebella cortex (grey) and white cerebella cortex (green). The 
spectra were imported into the MarkerV iew™ software with a mass tolerance 
of 0.1 amu (i.e. the bin size the data was grouped into), and a minimum signal 
count of 4.0 which removed background noise. The data was normalised 
against m/z 190 the protonated molecule of the matrix and then m/z 184 the 
Phosphatidylcholine head group. In order to reduce the number of ions 
shown in the loadings plots that were not related to the lipid mass region all 
peaks below m/z 500 were excluded from the analysis. PCA was carried out 
using Pareto scaling. Pareto scaling uses the square root of the standard 
deviation as a scaling factor to reduce the dom inance of large scale intensity 
changes in the matrix and other high abundance ions (Van den Berg et al.,
2006). These may mask the variation in lower abundance ions during PCA. 
The overall outcome of PCA is greatly affected by the masking of the 
underlying relevant information by ions relating to matrix coating and other 
endogenous molecules. Since these molecules were not of interest within the 
context of this work the data pre-treatment described above was used. PC1 
verses PC2 was chosen for display since these components resulted in the 
highest overall degree of separation of the spectra within the PCA scores 
plots.
Within this work both unsupervised and “supervised” PCA was carried out and 
compared. W ith unsupervised PCA each spectra is classed as an individual 
so the principal components are selected which account for the greatest 
separation of each of the individual spectra. In “supervised” PCA each 
spectra is assigned manually to a specified group, the software then selects 
the principal components which account for the greatest variation between 
each of the groups. (Van den Berg et al., 2006). A possible better description 
of this mode of operation of the software is PCA-DA (discriminate analysis). 
On the version of the software used within this work “supervised” PCA was 
used however this terminology has been changed in later versions of the 
software to PCA-DA.
In the header for each of the scores and loadings plots (figures 2.6a-2.6d) the 
principal components that have been plotted are shown with the percentage 
variance (Van den Berg et al., 2006), or the percentage of the variance 
accounted for from each of the principal components shown in brackets. Also 
shown is the type of scaling used (Pareto) and if “use groups” shows that the
corresponding scores or loadings plot was taken from a “supervised” PCA 
data set.
2.2.5 Im age Processing
The imaging data sets were then converted into analyze 7.5 file format using 
oMALDI server 5.0 software
All images were processed using 'BioMap' ion imaging software 
(http://www.maldi-msi.org) resulting in the production of a 2D ion density map. 
Images were normalised against the matrix ion at m/z 190 and the 
phosphatidylcholine head group m/z 184.
2.2.6 Profile Data acqu isition.
Following the acquisition of the Nd:YV04 laser (Described in chapter 6) some 
of these experiments were repeated. MALDI-MS mass spectra were acquired 
as profiles and are shown in figures 2.11, 2.12, 2.13 and 2.14 demonstrating 
the increased amount of information that can now be obtained from tissue 
samples. The brain tissue sections where obtained in the same manner as 
mentioned above but were not washed in ethanol prior to matrix application. 
Matrix application was performed using a Portrait multi reagent spotter 
(LabCyte Inc. CA) to print the matrix on the tissue. This data has been 
included into this chapter to demonstrate the advances in the methodology 
and technology that has enabled the improvement in quantity and quality of 
data obtainable from MALDI-MS experiments within recent years.
2.3 Results and D iscuss ions
2.3.1 PCA Analys is
Principal component analysis has been used here to attempt to identify 
hidden variables between spectra taken from the regions of brain tissue. 
Figures 2.6a and 2.6c shows the scores plot for unsupervised and 
“supervised” PCA respectively, each shows some differentiation between 
sample groups taken from each of the brain regions. Brain regions more 
associated with white matter are shown predominantly on the left side of the 
scores plot in both the unsupervised and the “supervised” PCA, and regions 
more associated with grey matter are shown predominately on the right side. 
It was found upon interpretation of the loadings plot for unsupervised and 
“supervised” PCA shown in figure 2.6 b and d respectively, the variance 
between spectra taken from these two groups of tissue regions is 
predominantly accounted for by two main lipid associated ions at m/z 734.45  
PC 32:0 [M+H]+ and m/z 788.48 PC 36:1 [M+H]+. The 2D ion density maps 
produced from the Biomap software (http://www.maldi-msi.org) are shown in 
figures 2.7a and 2.7b for the two ions of interest m/z 734.45 and m/z 788.48  
respectively. Ion m/z 734.45, shown in figure 2.6a has a positive PC1 loading 
correlating with the positive PC1 scores of the grey matter associated brain 
region spectra, the image clearly shows elevated levels of this ion in the brain 
grey matter. Ion m/z 788.48, shown in figure 2.7b, has a negative PC1 
loading correlating with the negative PC1 scores of the white matter 
associated groups of spectra, the image clearly shows that this ion is elevated 
in brain regions associated with white matter.
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2.3.2 Image Analysis
The ion image of m/z 762.47 shown in figure 2.7d illustrates the potential 
advantage of “supervised” PCA over unsupervised PCA in this application. 
Using unsupervised PCA, the grey cerebellar cortex and cerebral cortex 
groups are not clearly distinguished from each other, in the corresponding 
loadings plot it appears that the m/z 762.47 ion may be equally associated 
with both regions. Using “supervised” PCA, the grey cerebellar cortex and the 
cerebral cortex are more clearly distinguished and the m/z 762.47 ion displays 
correlation with the positioning of the grey cerebellar cortex group in the 
scores plot. On imaging the m/z 762.47 ion, shown in figure 2.7d, it appears 
the assumptions derived from the “supervised” PCA are more beneficial than 
those derived from the unsupervised PCA as the m/z 762.47 ion is shown to 
be more elevated in the grey cerebellar cortex region of the brain.
JL X 1 1 1 1  X  .%/
Figure 2.7 a) 2D ion density map of m/z 734.45 which has a highly positive PC1 loading and has been 
shown to be associated predominantly with regions of grey matter within the brain, b) 2D ion density map 
of m/z 788.48 which has a highly negative PC1 loading and has been shown to be associated 
predominantly with regions of white matter within the brain, c) 2D ion density map overlay of m/z 734.45 
(GREEN) which has a highly positive PC1 loading overlaid with 2D ion density map produced from imaging 
ion m/z 788.48 (RED). Complimentary images can be seen areas shown in yellow are areas associated to 
both white and grey matter, d) 2D ion density map of ion m/z 762.47 which has a positive PC1 loading and 
a positive PC2 loading and is shown to be elevated in the region of the brain relating to the grey cerebellar 
cortex, e) 2D ion density map of m/z 772.40 which has a positive PC1 loading and a negative PC2 loading 
and is shown to be elevated within the grey cerebeller cortex, a section of the cerebral cortex, partially in 
the thalamus and especially in the hippocample formation. The area with the highest intensity includes the 
striatum, ventral pallidum and other ventral nuclei that have not been included in the PCA analysis within 
this work.
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Other possible ions of interest show from the PCA analysis include m/z 
772.40. The image of this possible ion of interest is shown in figure 2.7e, the 
image of m/z 772.40 shows a slightly elevated abundance of this molecule 
within the grey cerebeller cortex, cerebral cortex and especially in the 
hippocample formation, tentative assignment of this ion shows it to be PC 
32:0 [M+K]+ this distribution is possibly from the washing process, showing 
that the removal of surface salts was not uniformly achieved, however, this 
distribution pattern has been seen in subsequent experiments, also the image 
of the potassium adduct of the matrix ion does not show this distribution which 
may be expected if this was a result of inadequate washing.
2.3.3 Lipid Analysis
Tentative assignment of the lipid identifications has been performed based on 
their masses and according to previously published data (Jackson et al., 
2005). Figure 2.8 shows a representative mass spectrum with the 
phospholipid region enlarged and inset. PC 32:0 [M+H]+ at m/z 734.45, PC 
34:1 [M+H]+ at m/z 760.46, PC 34:0 [M+H]+ at m/z 762.47, PC 32:0 [M+K]+ 
m/z 772.40 and PC 36:1 [M+H]+ at m/z 788.48 have been identified, Table 1 
shows a comparison of the calculated mass and the experimentally observed 
mass for each of the lipids.
Total mass spectra with inset enlarged and labelled lipid region
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Figure 2.8 Total mass spectra obtained with the phospholipid region enlarged and inset, 
shown with the tentative phospholipid assignments according published phospholipid 
data (Jackson et al., 2005) Peaks have been assigned to the following 
phosphatidylcholines, PC 32:0 [M+HJ* at m/z 734.45, PC 34:1 [M+HJ* at m/z 760.46, PC 
34:0 [M +Hf at m/z 762.47, PC 32:0 [M +Kf at 772.40 and PC 36:1 [M +Hf at m/z 788.48.
Lipid Form ula Calculated mass Observed m ass
PC 32:0 [M+H]+ c4oH8i NOsP 734.57 734.45
PC 32:0 [M+K]+ C4oH8oN08PK 772.53 772.40
PC 34:0 [M +H]+ c 42H85N08p 762.60 762.47
PC 34:1 [M+H]+ c42h 83n o 8p 760.59 760.46
PC 36:1 [M+H]+ c 44h 87n o 8p 788.62 788.48
Table 2.2 Comparison of the observed lipid masses and the calculated mass.
Figure 2.9 and figure 2.10 show two randomly selected mass spectra taken 
from two distinct areas of the brain, figure 2.9 is taken from the cerebral cortex
(grey matter) and figure 2.10 is taken from the corpus callosum (white matter) 
from these spectra it can be clearly seen the difference in abundance of m/z 
734.45 and m/z 788.48, this is in agreement with Woods and Jackson 2006, 
showing that PC 32:0 abundance is primarily responsible for the identification 
of grey matter, and PC 36:1 abundance is greatly increased in brain regions 
associated with white matter, within this work it has been further shown that 
brain regions can be further subdivided using MALDI MSI and observing 
changes in lipid abundance, as shown in figure 2.7d of m/z 762.47 which 
shows higher abundance within the grey cerebeller cortex.
PC 34:1
PC 32:0
PC 36:1
Figure 2.9 Single spectra showing the lipid region with spectral location inset, taken from the 
cerebral cortex (grey matter) tentative lipid assignments are given for the prominent lipids.
PC 34:1
PC 36:1
PC 32:0
Figure 2.10 Single spectra showing the lipid region with spectral location inset, taken from the 
corpus callosum (white matter) tentative lipid assignments are given for the prominent lipids.
From the data obtained in this work, it appears that “supervised” PCA has 
advantages over unsupervised PCA for the interpretation of MALDI-MS image 
data in some instances. Using unsupervised PCA the samples are separated 
by principal components, treating each sample individually. In “supervised” 
PCA, samples are grouped prior to PCA. This leads to a more effective 
separation of the groups from each other.
Specific rat brain regions were identified from sections using the histological 
data. Analysis of 10 selected spectra acquired from each of the regions using 
“supervised” PCA has been shown to separate the regions into distinct groups 
in the scores plot in contrast to unsupervised analysis. The PCA scores plots 
of PC1 versus PC2 for both the unsupervised and “supervised” analysis show 
that it is possible to partially separate white and grey matter; white matter 
regions have a predominantly negative PC1 score and grey matter has a
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predominantly positive PC1. This indicates that ions with a negative PC1 
loading will be associated more with the white matter regions of the brain. 
This is shown in figure 2.7b the image of PC 36:1 m/z 788.48; in contrast 
figure 2.7a shows the image of the PC1 positive ion m/z 734.45 relating to PC 
32:0 which is more associated with grey matter.
The data sets sampled from the thalamus region of the brain have a negative 
PC1 score, indicating that the thalamus is comprised of white matter. This is 
not entirely the case since the thalamus is known to be comprised of both 
white and grey matter regions. The profiles obtained from 10 locations within 
the thalamus may have been randomly taken from areas of the thalamus 
associated more with white matter and may not show a true representation of 
this region.
It is possible to identify ions of interest from the loadings plot which are likely 
to be more prominent in the different regions of grey matter especially the 
grey cerebellar cortex from the hippocampal formation, due to the grey 
cerebellar cortex having a positive PC2 and the hippocampal formation having 
a negative PC2 score, this is only possible in the “supervised” PGA data set 
because with unsupervised PCA the two regions overlap. Ions with a positive 
PC1 and a positive PC2 loading are more likely to be higher in the grey 
cerebellar cortex. Figure 2.7d shows the respective image of the ion m/z 
762.47 which represents lipid PC 34:0, showing that this lipid is elevated 
within this region of the brain. From the PCA, using this data set and PC1 
versus PC2, it is not possible to distinguish different regions of the white 
matter.
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2.3.4 Profile Data Analysis
The methodology and technology within this field is rapidly improving. Shown 
in figure 2.11 is an example of the data obtainable from a brain tissue section 
using some of the latest matrix application technologies (Portrait multi reagent 
spotter from LabCyte Inc. CA)
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Figure 2.11 Combined Profile obtained from areas of white and grey cerebellar cortex, 
using the Portrait multi reagent spotter for matrix printing. The array of data within the 
lipid rich region of the spectra can be seen.
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Figure 2.12 Enhanced view of the lipid region within figure 2.11. Several lipid species 
have been tentatively identified based on their mass.
Table 2.3 below contains the mass data shown in figure 2.12 and a 
comparison of the theoretical and measured mass is made and the PPM 
mass error is shown.
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Calculated Mono­
isotopic m/z
Observed m/z PPM error (2dp) Possible Lipid 
species
Ion Species
731.6067 731.6029 -5.19 SM 36:1 [M+Hf
734.5622 734.5588 -4.63 PC 32:0 [M+Hf
756.5519 756.5558 5.15 PC 32:0 [M+Naf
760.5856 760.5783 -9.60 PC 34:1 [M+Hf
762.5935 762.5916 -2.49 PC 34:0 [M+H]+
772.5259 772.5217 -5.44 PC 32:0 [M+Kf
782.5700 782.5714 1.79 PC 36:4 [M+H]+
788.6169 788.6181 1.52 PC 36:1 [M+Hf
798.5415 798.5428 1.63 PC 34:1 [M+Kf
810.6013 810.5972 -5.06 PC 38:4 [M+Hf
826.5728 826.5732 0.48 PC 36:1 [M+Kf
Table 2.3 Comparison of the theoretical and measured mass taken from the spectra 
shown in figure 2.12. Identified are the possible Lipids species and the PPM  mass error. 
All the PPM  mass errors are below 10PPM.
PC 32:0
149
130
120
110 PC 34:1
760 6836100
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Figure 2.13 MALDI spectra obtained from a grey matter brain tissue using the Portrait 
multi reagent spotter for matrix printing.
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Figure 2.14 MALDI spectra obtained from white matter brain tissue using the Portrait 
multi reagent spotter for matrix printing.
The mass spectra shown in figures 2.13 and 2.14 are in agreement with the 
previous work showing a marked difference in the relative abundance of PC 
32:0 and PC 36:1 between the white and grey matter brain tissue this is in 
agreement with Woods and Jackson 2006, showing that PC 32:0 abundance 
is increased in regions of grey matter, and PC 36:1 abundance is increased in 
brain regions associated with white matter.
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2.4 Conclusions
Whilst unsupervised PCA is useful when analysing samples of unknown 
origin, where some information on the grouping of samples, based on 
histology is known, “supervised” PCA i.e. PCA-DA may be advantageous. 
Shown is a reliable method for the determination of ions of interest associated 
with distinct tissue regions. This technique could be further utilised for the 
identification of possible biomarkers of disease from known diseased and 
control populations of samples. Also for the determination of tumour markers 
within tissues, for imaging of tumour progression and detection of the 
chemical tumour margin.
Also shown in this chapter is an indication of the level of improvement within 
the technology and with sample preparation and data acquisition techniques. 
This shows how MALDI-MS methodologies have advanced within the last 
three years during which this PhD project was completed.
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CHAPTER 3
Matrix Assisted Laser Desorption 
Ionisation -  Ion Mobility Separation 
-  Mass Spectrometry Imaging of 
Small Molecules.
A New Dimension in MALDI 
Imaging.
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Matrix Assisted Laser Desorption Ionisation -  Ion Mobility Separation -  
Mass Spectrometry Imaging of Small Molecules.
3.1 Introduction
3.1.1 A New Dimension in MALDI Imaging.
In this chapter examples of the benefits of MALDI- ion mobility separation -  
mass spectrometry imaging (MALDI-IM S-MSI) of small molecules compared 
to conventional MALDI-MS imaging. Described are several examples of the 
benefits arising from the additional separation step obtained by M ALDI-IM S- 
MSI. Several analytes have been chosen to demonstrate this.
3.1.2 Introduction into MALDI Imaging of small molecules.
Biological MALDI MSI of small molecules is a rapidly developing field. Within 
the field of biological MALDI MSI of small molecules there are several areas, 
often the two most widely studied are perhaps lipidomics and xenobiotic 
imaging
3.1.2.1 Lipidomics.
Lipidomics is the study of lipids within biological systems. Lipids are a large 
class of bio-molecules with several classes and sub classes. They play 
essential structural and functional roles. This includes for example the role of 
phospholipids as key constituents of biological membranes (Fuchs & Schiller
2008). Fatty acid oxidation is essential for the generation of energy, 
Lysophosphatidylcholines have been shown to be important biomarkers of 
diseases like atherosclerosis and rheumatoid arthritis (Matsumoto et a/,. 2007  
and Fuchs et al,. 2005). Sphingolipids have been shown to have important 
roles within cellular processes including apoptosis, cellular growth and 
proliferation and drug resistance (Fuchs et al., 2007, Ogretmen 2006 and 
Modrak ef a/., 2006).
The field of lipidomics has grown considerably in the last few years. The first 
“Lipidomics” paper was published by Han et al., 2003, within The Journal of 
Lipid Research. This was not the first paper published on lipids, but it was the 
first paper to use the term "Lipidomics". In this work the authors demonstrate 
the detection of multiple lipid species from an extract of mouse myocardial 
tissue. They also present a review of the analysis of lipidomes from biological. 
samples using ElectroSpray Ionisation - Mass Spectrometry (ESI-MS).
3.1.2.2 Xenobiotic imaging.
A second important area of interest within small molecule imaging is the study 
of xenobiotics; primarily drugs and their metabolites. The use of MALDI-MSI 
imaging within this area has grown considerably and it has been used for the 
study of xenobiotics within excised tissue sections and whole body analysis 
(Reyzer et al,. 2003, Stoeckli et al 2007). This application of MALDI-MSI to 
xenobiotics has allowed the study of drugs and their metabolites 
simultaneously and also the possibility to study the biological effect of these 
substances within whole body sections. This ability to image multiple analytes
simultaneously with limited sample preparation is the key to the success of 
MALDI Imaging within this field. MALDI-MSI can aid in the drug development 
process to provide evidence of specific drug and metabolite localisation within 
tissues, and aid in the determination of drug efficacy and toxicity (Khatib- 
Shahidi et al., 2006).
th e  first work presenting the detection of xenobiotics directly from biological 
tissue sections using MALDI was presented by Troendle et al., 1999. Within 
this work they demonstrate the detection of the anticancer drug paclitaxel 
from rat liver tissue sections, showing the detection and ms/ms identification 
of the paclitaxel [M+K]+ ion at m/z 892. Also demonstrated was the detection 
of paclitaxel [M+H]+ and [M+Na]+ within ovarian tumour xenograph sections 
and the confirmation by ms/ms from a known standard.
The first xenobiotic MALDI-MSI experiments were published by Reyzer et al., 
2003. Reyzer et al., 2003 presented work showing the distribution of 
SCH226374 within mouse tumour sections. The sections were coated in SA 
and the detection and imaging of SCH226374 was achieved by single 
reaction monitoring (SRM). SRM involved the monitoring of the transition of 
m/z 695 -  228. Reyzer et al., also presented an image of an undisclosed 
compound A within a coronal rat brain section.
This technology has been used for whole body MALDI-MSI as reported by 
Stoeckli et al,. 2007. This group presented work on the distribution of a 
compound within a whole body rat section. They mapped the distribution of
the compound and its metabolites and compared these data to the results of a 
whole body autoradiography study carried out using a C 14 labelled compound.
Conventional xenobiotic distribution studies utilise whole body 
autoradiography (WBA). This technique can take several days to complete 
depending on the isotope used. W BA is relatively expensive compared to 
MALDI, due to the need to develop radio labelled drug compounds whilst 
maintaining the drug efficacy. There is also a need for special control 
measures for the handling of radioactive material. Another disadvantage is 
the inability to determine the molecular species (whole drug or metabolite) 
because only the distribution of the isotope is imaged.
3.1.2.3 MALDI-lon mobility-MS
Ion mobility mass spectrometry has been shown to be beneficial for the 
analysis of lipids. Jackson et al., 2005 have presented work on the analysis 
of phospholipids in rat brain using conventional MALDI-TOFMS and MALDI- 
lon Mobility -  TOF-MS. Within this work they concentrated on phospholipids 
because they are a major component in brain tissue, and altered levels of 
phospholipids within tissues have been associated with many disease states.
Jackson et al., 2005 used a prototype M ALDI-IM -TOFM S instrument which 
included a 15cm drift cell at 1600V and containing helium at a pressure of 
5torr. The resultant mass spectra acquired with this instrument obtained from 
the rat brain showed that PC32:0, PC34:1 and SM 18:0 ions were the most 
dominant. This is expected because PC’s and SM ’s (sphingomyelin's)
account for more than 50% of the membrane phospholipids in eukaryotic 
cells.
Jackson et al., demonstrated that structurally different biomolecular ions form 
distinct familial trend lines with a 2D plot of drift time against m/z (as shown in 
figure 3.1). Within these trend lines there are a few percent of variation in drift 
time between some familial ions. They found that lipid trend lines are 
generally about 12% slower in drift time than isobaric peptides. They have 
shown drift time separated familial trend lines corresponding to lipids, 
peptides, aromatics and oligonucleotides. This ability to separate ions based 
on their class prior to mass analysis aids in the identification of analytes within 
the low mass window. Specifically the ability to separate isobaric ions prior to 
mass analysis. Jackson and colleagues demonstrated this with the 
separation of a CHL isotope ion from an isobaric peptide.
Figure 3.1 2D MALDI-ion mobility-TOFMS plot showing the familial trend lines associated 
with ion molecule class taken from Jackson et al., 2007.
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This work has been further expanded into an imaging technology by the same 
group (Jackson et al., 2007). The use of a MALDI-ion mobility-TOFMS 
imaging instrument was reported. This comprised a periodic focusing MALDI- 
IM -TOFMS instrument with a 15cm ion mobility drift cell operating at 3.5 torr 
He pressure and 1700V. Using this instrument the ion mobility drift time took 
several milliseconds, while the TO F flight times took tens of microseconds. 
This time differential allows good integration of ion mobility into a TO F mass 
spectrometer, because several TO F analysis can be performed per mobility 
separation cycle. Within this work the distribution of lipids within coronal brain 
sections are reported after ion mobility separation. The distribution of PC 34:1 
[M+K]+ is reported. This is the most abundant lipid in rat brain tissue. Also 
shown are the distributions of PC 36:1 [M+K]+ and PC 38:6 [M+K]+. Not 
shown are the same ion images without the ion mobility separation. This 
prevents a comparison of the mobility separated data from the conventional 
data. Therefore the true benefit of the ion mobility separation can not be 
assessed. Within this study the authors also demonstrate the use of gold 
nanoparticles as a MALDI matrix for the analysis of cerebrosides in rat brain 
tissue. One of the issues with the use of M ALDI-IM S-M S imaging is 
discussed i.e. the size of the data files obtained. Since such an image 
contains several mass spectra at different ion mobility drift times, this adds 
another dimension of data to already large data files obtained via conventional 
MALDI-MS imaging. The authors excluded all ions outside of the mobility and 
mass region of interest, thus limiting their data size.
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3.1.3 MALDI Synapt HDMS system
The work presented here was conducted on a Synapt HDMS system (Water 
Corporation, Manchester, UK). This system is a quadrupole ion mobility 
separation time of flight mass spectrometer (Q-IMS-TOF-MS). A detailed 
description of this instrument can be found in the introduction to this thesis 
and has been given by Giles et al,. 2004.
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Figure 3.2 Schematic of the instrument configuration of the MALDI Synapt HDMS system 
(Water Corporation, Manchester, UK)
Figure 3.3 schematic of the inside of the ion mobility cell within the Synapt HDMS 
instrument (Water Corporation, Manchester, UK), shown are ions “surfing” the travelling 
wave along the stacked ring ion guides, (www.youtube.com)
Figure 3.2 shows a schematic of the Synapt HDMS system (Waters 
Corporation, Manchester, UK) with inset a zoomed view of the schematic of 
the Tri-Wave region of the instrument containing the ion mobility cell. 
Indicated on the schematic are the regions where ms/ms fragmentation can 
be achieved. If ion fragmentation is performed in the Trap region of the 
instrument then the resultant fragment ions can be separated within the IMS 
cell, alternatively fragmentation can be performed in the Transfer region of the 
instrument. In this case all the fragment ions maintain the same drift time as 
the precursor ions because these ions have already been separated within 
the ion mobility cell. There is a third option and that is to effectively remove 
the ion mobility separation step from the system, if this is done the Tri-Wave 
region of the instrument acts as a series of ion guides transferring the ions to 
the TOF analyser.
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3.2 Experimental methods.
All animal studies were subject to ethical approval and all the animal use and 
handling in this work abides by UK Home Office Regulations and Guidelines.
3.2.1 Organ Sample Preparation
Organs were harvested and snap frozen by submersion in liquid nitrogen 
cooled isopentane for 30 seconds, once snap frozen the tissues were stored 
in a -80°C freezer until required. When required the tissues were removed 
from the freezer and placed in a CM 1510 cryostat (Leica Microsystems, 
Wetzlar, Germany) set at -18°C and allowed to acclimatise for 30 minutes. 
Tissues were mounted onto cork discs in the desired orientation and fixed in 
place using the minimal amount of OCT, ensuring that no OCT embedding 
medium was near the area to be sampled. Sections (12pm) were cut and 
thaw mounted onto cleaned aluminium plates.
3.2.2 Large Tissue Section Preparation.
The euthanised animal was placed in a metal restraint this ensured the nose, 
spine and the base of the tail were aligned. This restraint was then frozen in a 
hexane/Cardice bath for 40mins. The animal was then placed into a frozen 
frame and surrounded with Carboxymethyl cellulose (CMC) and lowered back 
into the Hexane/Cardice bath for a further 20mins resulting in a solid block for 
sectioning.
Sections (30pm) were obtained using a Leica CM 3050 cryostat (Leica 
Microsystems, Wetzlar, Germany) and placed onto cleaned aluminum plates
using the Macro-tape-transfer system (Instrumedics Inc, St Louis, MO), this 
involves coating the cleaned aluminum plates with a thin adhesive coating 
and allowed to dry. A 30pm whole body section was cut and adhered to an 
adhesive transfer tape, the section was then laid on the pre-coated aluminum 
plate. The sample was then covered and subjected to a UV light which causes 
the adhesive coating on the aluminum plate to polymerise bonding the section 
to the aluminum plate, the tape was then removed, leaving the section 
adhered to the aluminum plate, which was cut to size and spray coated with 
matrix.
3.2.3 Matrix Application.
Tissue sections were cut to size and spray coated with 5mgml'1 aC HC A in 
50:50:0.1 ethanol:water:TFA (v:v:v) for positive ion mode and for negative ion 
mode the sections were spray coated with 5mgml'1 aCHCA in 50:50 
ethanol:water (v:v), both matricies were spray coated using a SunCollect 
automatic sprayer (SunChrom, Friedrichsdorf, Germany) by spraying an initial 
seeding layer at 1 pi min'1 followed by an additional layer sprayed at 2.5pl min' 
1 and a further 3 layers at 5pl min'1 until a uniform matrix layer was achieved 
without sample overwetting. Matrix coated tissue sections were then mounted 
onto Waters MALDI imaging targets (Waters Corporation, Manchester, UK) 
using double sided tape.
3.2.4 Mass Spectrometric Imaging.
Sections were optically scanned using a CanoScan 4400F flatbed scanner 
(Canon, Reigate, UK) the digital image of the tissue section was imported into
MALDI Image Pattern Creator (Waters Corporation, Manchester, UK) In this 
software, the instrument was taught the dimensions of the image by locating 
the four corners of the image plate, this allowed the creation of the image area 
around the sample. The pattern was then uploaded into MassLynx (Waters 
Corporation, Manchester, UK) and the parameters of the image experiment 
were created. The instrument was operated in positive ion V -mode using a 
frequency tripled Nd:YAG (355nm) laser firing at a repetition rate of 200Hz. 
Prior to imaging analysis, the mass spectrometer was calibrated using a 
mixture of poly ethylene glycol (PEG) standards (Sigma-Aldrich, Gillingham, 
UK) with average molecular weights of 400 and 600, providing coverage of 
the m/z range studied. Image resolution was set to 150pm in both x and y 
directions, and the mass range was set to m/z 100-1500, to ensure a wide 
coverage of possible ions of interest.
3.2.6 Ion Mobility Data Analysis.
Ion mobility data analysis was performed using MassLynx 4.1 and DriftScope
2.1 software (Waters Corporation, Manchester, UK). DriftScope allows the 
visualisation of the imaging or profiling data by showing it as a colour map of 
drift time against m/z and the relative intensity as a colour change. This 
allows identification of ions of interest and the ability to show if there are any 
interfering isobaric ions which can be separated by their respective drift times. 
Isobaric ions which do show mobility separation can be selectively imaged by 
extracting the drift time information and converting the file to an Analyse 7.5  
file format using MALDI image Converter software (Waters Corporation, 
Manchester, UK). MS/MS ion mobility separation data analysis was
preformed by extracting the drift time information, and using MassLynx to 
show the MS/MS spectra for individual drift times allowing easier identification 
of ions by removing isobaric interferences.
3.2.7  Im age visualisation
All images were processed using 'BioMap' ion imaging software 
(http://www.maldi-msi.org) resulting in the production of a 2D ion density map.
3.2.8 Mass Resolution
The mass spectral resolution required to separate two ions at a similar mass- 
to-charge can be calculated using the following equation. This has been 
performed for some of the ions which have been imaged.
m /z  o f  lowest ionMass Resolution required = ----------——:-------------7 7---------------mass d ifference between the two ions
This is conventionally written as:
m
Am
Equation 3.1 Mass resolution (R) required to separate two overlapping ions, the lowest 
ion m/z (m) and with a mass difference (Am).
3.3 Results
3.3.1 Lipid analysis
Lipid analysis provides a good platform to demonstrate some of the 
advantages of MALDI-IMS-MSI. Figure 3.4 shows a driftscope plot between 
m /z700-750 from an image of a tumour xenograph imaged in situ in the dorsal 
flank of a whole body mouse section. At least 3 trends can be selected. 
Figure 3.5 shows the mass spectra of each of the trend lines highlighted in 
Figure 3.4. The ions associated with the shortest drift time consist primarily of 
chemical noise. The second trend line contains primarily 
phosphatidylinositols (PI) species and the final trend line contains primarily 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE) lipids. This 
ability to separate ions based on their relative cross sectional area is a huge 
benefit for small molecule imaging applications.
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Figure 3.4 Driftscope plot of m/z700 -  750 indicating the possible separation o f lipid 
classes and chemical noise and matrix ions.
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Figure 3.5 Mass spectra obtained from each of the 3 regions highlighted in figure 3.4 and 
a total mass spectra of the same region without IMS.
Assignment of the predominant lipid class within each of the IMS mass 
spectra shown in figure 3.5 is based on the mass-to-charge of some of the 
ions present. This possibility of separating lipid classes using ion mobility 
could improve the detection of certain lipids by positive ion MALDI-MS. Due 
to their excellent desorption/ionisation efficiency PC lipids dominate positive 
ion MALDI-MS mass spectra. This can cause some of the other ions to be 
masked. By using ion mobility the PC lipids can be separated from the rest of
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the mass spectra allowing easier detection and visualisation of some of the 
lower abundance lipids.
3.3.2 Removal of matrix interference.
One of the major issue in small molecule imaging using conventional MALDI- 
MSI is interference caused by matrix related ions within the low mass region. 
This is especially true when aCHCA is used as the matrix, because there are 
several matrix clusters in the low mass region with associated sodiated and 
potassiated adducts. This advantage, of MALDI-IMS-MSI can be seen in the 
mass spectra presented in Figure 3.6a Two ions of similar mass-to-charge 
can be observed. One is a 13C isotope of a possible matrix related ion at m/z 
401.072. This ion is interfering with the imaging of a potentially important ion 
of interest at m/z 402.012 associated with rat kidney. Figure 3.6b & c also 
shows the biomap images for each ion.
A 3 f le 4
Figure 3.6 a) MALDI mass spectrum of rat kidney in the region m/z 400 -  405, showing 
two overlapping peaks selected for imaging, b) 2D ion plot of ion m/z 402.012 showing 
primary distribution of this ion within the kidney, and some surrounding signal, c) 2D ion 
plot of ion m/z 402.072 showing its spatial distribution primarily in the surrounding matrix, 
and not in the kidney tissue.
The 2D ion plots shown in Figure 3.6 clearly show that the two ions have 
different distributions with conventional MALDI-MSI, Figure 3.6b shows the 
distribution of m/z 402.012 that would be produced. One issue with the 
imaging mass resolution is due to Biomap binning the data into 0.2Da mass 
bins this markedly reduces the effective mass resolution of the image. This 
distribution is not the correct distribution for the ion m/z 402.012 it is a 
combination image from m/z 402.012 and interference from m/z 402.072 due 
to the overlapping nature of the peaks within the mass spectra. Separation of 
these ions within this imaging experiment would be difficult.
The mass resolution required to separate these two ions can be calculated 
using equation 3.1.
mR = t —Am
402.012 
(402.072-402.012)
402.012 R — — —0.06
R = 6700 to 0 dp
From this calculation the mass resolution required to separate these two 
different ions using conventional mass spectrometry requires an instrument 
with a mass resolution above ~6700. The Q -Star Pulsar-/ has a specified 
mass resolution of ~10,000 at FW HM (Full Width at Half Maximum) at m/z 
850 (Baldwin et al., 2001) and therefore should be able to separate these two 
ions. The Synapt HDMS also has a specified mass resolution of ~10,000 at 
FW HM at m/z 1172 (Bagal et al., 2008) and therefore should be able to 
separate these two ions based solely on their mass. The FW HM resolution at
m/z 401.068 is 7864 showing that these peaks should be resolved, but they 
are only partially resolved.
This can be overcome with the inclusion of ion mobility. Each of these two 
ions have a different drift time within the T-wave ion mobility cell of the Synapt 
(W ater corporation, Manchester, UK).
The Driftscope plot for these ions is shown in figure 3.7a each ion has been 
encircled and the respective mobilagram which is a plot of drift time against 
intensity, is shown in figure 3.7b the differences in the two ions mobility can 
clearly be seen by the two peaks.
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Figure 3.7 a) drift scope plot with the highlighted region of interest, b) Mobilogram of the 
two ions encircled in (a), c) mass spectra extracted from the Mobilogram showing the 
different ions associated with the differences in drift time.
With IMS separation No IMS separation
Figure 3.8 a) MALDI-MS image of m/z 402.01 in a rat kidney section obtained a) with ion 
mobility separation on, b) without ion mobility separation. The ion mobility separation has 
removed the interference surrounding the kidney caused by unresolved chemical noise. 
Blue line indicating tissue margin, (Signal outside margin primarily due to chemical noise)
Figure 3.8 demonstrates the advantage of MALDI-IMS-MSI when analysing 
small molecules. The ion mobility has been shown to separate a matrix 
related ion from an endogenous species. This separation allows a more 
representative image of the distribution of the desired ion to be obtained.
3.3.3 Separation o f  ions o f interest.
Shown above is an example of the ability to separate matrix related ions from 
endogenous species. This is not the only type of interference found within 
MALDI MSI. Another common problem is the interference of two or more 
potentially relevant endogenous ions. Providing the ions which are observed
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have a difference in their respective average collisional cross sectional area 
then they normally can be separated using ion mobility.
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Figure 3.9 Partial MALDI mass spectrum obtained from a tissue section containing a 
DU 145 tumour xenograph, highlighted is a peak at m/z 527.916 with a shoulder of a 
second peak. Inset is the 2D ion plot of peak m/z 527.916.
From the mass spectrum shown in figure 3.9 a peak at m/z 527.916 can be 
seen with the shoulder of a second peak at m/z 528.035 masked by the 
dominant peak. If this peak at m/z 527.916 is imaged with a mass window of 
0.2Da without the use of ion mobility the 2D ion map that is produced shows a 
relatively uniform distribution of this ion within the tissue section with a lower 
relative abundance within the tumour xenograph.
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The same region of the mass spectra can be viewed using Driftscope 2.1, 
this allows the visualisation of the ion mobility separation. Figure 3.10 shows 
the Driftscope plot, encircled is the area of the driftscope plot containing the 
ion at m/z 527.916 and the ion at m/z 528.035. The two ions can be clearly 
seen within this region and that each has a slightly different drift time. The 
ions are separated based on their drift time even though they are not mass 
spectrally resolved.
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Figure 3.10 Driftscope plot of the same mass region as shown in figure 3.9, encircled is 
the ions that account for the peak at m/z 527.916 there are at least 2 ions which are 
accounting for this peak.
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The Mobilogram plot of the drift time for the two ions at m/z 527.916 and m/z
528.035 are shown in figure 3.11. Two different drift times can be seen for 
these ions, however base line separation does not occur. The drift time 
associated spectra are shown in figure 3.12 (a and b)
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Figure 3.11 Mobilogram from the peak at m/z 527.9, this shows two different drift times 
associated with this mass range.
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Figure 3.12a) MALDI mass spectra obtained after ion mobility separation showing the 
ions accounting for the faster drift time, b) Mass spectra accounting for the peak with the 
slower drift time shown in figure 3.11
The resolution required to resolve these peaks can be calculated using 
equation 3.1.
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From this calculation the mass resolution required to separate these two 
different ions using conventional mass spectrometry requires an instrument 
with a mass resolution above -4436. As mentioned above the Q-Star Pulsar-/' 
has a specifed mass resolution of -10,000 at FWHM at m/z 850 (Baldwin et 
al., 2001) and therefore should be able to separate these two ions. The 
Synapt HDMS also has a specified mass resolution of -10,000 at FWFIM at 
m/z 1172 (Bagal et al., 2008) and therefore should be able to separate these 
two ions based solely on their mass.
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Figure 3.13 Mass spectra of the overlapping ions at m/z 527.916 and 528.035 after ion 
mobility separation showing the measurements at FWHM.
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From the ion mobility separated spectra the resolution obtainable at m/z 
527.916 is 5279.16 at FW HM showing that these two peaks can be 
separated. The separation of these peaks can be seen in figure 3.13. These 
peaks are not base line resolved but there is a clear valley between the two 
peaks. The smaller peak at m/z 528.035 has a resolution of ~4190 (FW HM ) 
which is less than the required resolution to separated these two peaks at half 
maximum, hence the over lapping nature of these peaks.
Figure 3.12 shows the mass spectra selected from the drift times determined 
in figure 3.11. The mass spectra now show that there is definitely two peaks 
present, one at m/z 527.916 and the other peak which was accounting for the 
shoulder of the previous peak at m/z 528.035. Because the two ions have 
been separated their drift times were used to extract the data for the images. 
Figure 3.14a shows the 2D ion plot which is created from the ion mobility 
separated data for the ion at m/z 527.916 it can now be seen that the area in 
the top right hand side of the image is now missing. This image is the 
opposite of the image created by imaging the ion mobility separated ion at m/z
528.035 where this ion is localised solely within the bone tissue of the mouse 
section.
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Figure 3.14a) 2D ion plot of the ion mobility separated ion at m/z 527.916. b) 2D ion plot 
of the ion mobility separated ion at m/z 528.035 each of these two ions have very 
different distributions within the tissue, c) 2D ion plot of m/z 527.8 - 528.0 without ion 
mobility separation.
3.3.4 Separation of endogenous and xenobiotic species.
The separation of endogenous/matrix ions from ions relating to xenobiotics is 
possibly one of the most important areas for the application of M ALDI-IM S- 
MSI. This topic will be discussed in detail in chapters 4 and 5 of this thesis.
3.4 Conclusion
In this work, some of the benefits of MALDI-IMS-MSI have been 
demonstrated compared to conventional MALDI-MSI, using a MALDI Synapt 
HDMS system (Water Corporation, Manchester, UK). Separation of lipid 
classes based on their mobility has been shown which can simplify spectra 
from complex samples, by the removal of ion classes not required in the 
analysis. Also shown is the use of MALDI-IMS-MSI for the removal of 
interfering ions from imaging results thus increasing the confidence in the 
spatial distribution observed for ions of interest within MALDI imaging 
experiments. Demonstrated is the removal of matrix related ions affecting 
imaging of endogenous ions allowing the removal of the matrix ring of 
interference surrounding tissue sections and other matrix interferences. The  
benefit of the additional separation step obtained by ion mobility has been 
shown to be highly effective in separating endogenous ions of interest with 
different average collisional cross sectional areas which could have 
completely different distribution which when using conventional MALDI-MSI 
could be missed and the distribution differences could be overlooked.
MALDI-IMS-MSI allows for increased confidence of the images acquired and 
allows for a true representation of ion distribution within tissue sections.
The resolution of the Synapt HDMS (Waters Corporation, Manchester) is 
reported as being 10,000 at m/z 1172 FW HM (Bagal et al., 2008), within the 
work reported here the best calculated resolution was 7864 at m/z 401.068. 
The reduction in the mass resolution obtainable from MALDI-MSI of tissue 
frequently observed. This is possibly due to the complexity of the signals 
observed from on tissue MALDI, resulting in overlapping peaks. The work 
reported here was also based on summed spectra from an image which 
causes slight broadening of the peaks due to slight statistical mass variation 
hence increasing the full width at half maximum and reducing the calculated 
resolution. Also compression of the data within Biomap software may be an 
issue.
It is accepted that these ions could be imaged on conventional MALDI-MSI 
platforms using ms/ms techniques however the ion mobility allows this 
separation without ms/ms. This could allow the imaging of multiple ions of 
interest with similar specificity as ms/ms techniques without the compromises 
in the number of analytes that can be imaged within a single imaging 
experiment.
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Matrix Assisted Laser Desorption Ionisation - Ion Mobility Separation - 
Mass Spectrometry Imaging of Vinblastine in Whole Body Tissue 
Sections.
4.1 Introduction
4.1.1 MALDI-MSI
Since the development of MALDI imaging it has been used for the study of the 
distribution of a variety of biomolecules. In addition to imaging, statistical 
packages have been used to assist in the identification of tissue markers. 
McCombie et al., 2005 presented work using clustering and multivariant 
analysis for the improved imaging of rat brain sections. Van de Plas et al., 
2007 showed the use of PCA statistical analysis to aid tissue morphology 
assessment using MALDI imaging. Within this work each principle 
component of a data set obtained from a rat spinal cord was imaged showing 
some of the morphological features. Prideaux et al., 2007 presented work 
using PCA to distinguish between control and hydrocortisone dosed porcine 
skin, identifying ions associated with each of the two groups. Within chapter 2 
of this thesis the possibility of using PCA to identify possible ions of interest 
from a MALDI imaging data set obtained from a rat brain sagittal section has 
been shown, using PCA ions associated with white or grey matter were 
identified, as well as ions predominantly associated with distinct brain regions. 
Such packages can be used to overlay drug distribution patterns and to 
clearly identify the localisation of a drug or metabolite within a tissue section.
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4.1.2 Xenobiotic MALDI-imaging
The first demonstration of the use of MALDI to directly study pharmaceutical 
compounds in animal tissue was published by Troendle et al., 1999. In this 
work, the matrix was applied to the tissue surface by pipetting and 
electrospraying followed by analysis using MALDI quadrupole ion trap mass 
spectrometry. The technique was employed to detect the anti-cancer drug 
paclitaxel in a human ovarian tumour and the anti-psychotic drug spiperone in 
spiked sections of rat liver tissue.
Caprioli's group have worked on studies of drug distribution in collaboration 
with Schering-Plough. They have reported a study of the distribution of anti­
tumour drugs in mouse tumour tissue and rat brain (Reyzner et al., 2003). In 
these experiments, the matrix was applied to intact tissue by either spotting 
small volumes of the matrix in selected areas, or by coating the entire surface 
by pneumatic spraying. MALDI images were created by using the tandem  
mass spectrometric technique of selected reaction monitoring (SRM ) to 
specifically monitor the drug under study. Such an approach minimises the 
potential for ions arising from either endogenous compounds or the MALDI 
matrix to interfere with the analyte signals. The brain has in fact been the 
most common target for MALDI-MSI studies of drug distribution, Hsieh et al., 
2006 & Hsieh et al., 2007, have reported the detection and imaging of 
clozapine in rat brain tissue by an SRM approach and Wang et al., 2005 have 
reported the localisation and analysis of chlorisondamine and cocaine in rat
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brain following either intracranial or intraperitoneal injection, although imaging 
was not attempted in this work.
Rohner et al., 2005 reviewed MALDI imaging and described imaging work 
being carried out at Novartis. In this article they demonstrated for the first time 
the use of MALDI-MSI to study drug distribution in a whole body mouse 
section. In a more recent report this group describe some of the practical 
aspects of obtaining MALDI-MSI data for drug and metabolite distributions in 
whole body sections and report on some of the limitations of the technique 
(Stoeckli et al., 2007). This pioneering work was extended by Khatib-Shahidi 
et al., 2006 who combined this approach with their own work on protein 
imaging to produce whole body images showing the location of drug, drug 
metabolites and endogenous markers for various organs of the body. The  
exciting possibility of imaging markers of efficacy along with the analytes to 
provide in-vivo pharmacodynamic data is discussed in their article. Atkinson et 
al., 2007 showed in a study of the distribution of the bioreductive anti-cancer 
drug AQ4N in H460 lung tumour xenografts, that not only could the pro-drug 
and its active form be imaged in one experiment, but that imaging the 
distribution of ATP co-localised the active reduced form of the drug to regions 
of hypoxia.
Another application of MALDI-MSI in drug and xenobiotic distribution has 
been the study of trans-dermal absorption (Bunch et al., 2004). Here it was 
demonstrated that the absorption of the anti-fungal agent ketoconazole into 
skin could be examined by MALDI-MSI by the use of an indirect tissue blotting
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approach. This work has been subsequently extended to show that the 
absorption of a wide range of xenobiotics into skin can be studied, but the 
sample preparation technique required i.e. direct or indirect imaging, and the 
choice of substrate for indirect imaging, is hugely influenced by the analyte 
(Prideaux et al., 2007). In the same paper this group have also described 
some preliminary data from a combined solvent assisted 
transfer/derivatisation approach to sample preparation that may be useful for 
particularly intractable analytes.
During early stage drug development, drug and metabolite distribution studies 
are carried out in animal tissues using a range of techniques including Whole 
Body Autoradiography (WBA), this technique images the spatial distribution of 
a radiolabelled isotope within whole body sections. Whilst widely employed 
WBA has a number of limitations, firstly it requires the expensive synthesis of 
radiolabelled drugs (Ulberg et al., 1954). W BA does not distinguish between 
a parent drug and its metabolites as it only images the radiolabel, which in 
some cases may be one of the drug metabolites and not the whole drug, thus 
providing misleading results. Further analysis is usually required to obtain 
additional information on the chemical species i.e. whether it is the parent 
drug or a metabolite that is present. This invariably involves the 
homogenisation of tissues for subsequent HPLC-MS analysis, however, in 
this process spatial specificity is lost.
Recent improvements in MALDI-MS imaging have shown the possibility of 
imaging drug and metabolite distribution in tissue with previously unobtainable
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spatial resolution and analyte specificity. Several groups have presented data 
on xenobiotic distribution within whole body sections since the first report by 
Rohner et al., 2005 and they showed the distribution of an administered drug 
within the central nervous system of a whole body section of a mouse. This 
work has been extended by several groups, including Stoeckli et al., 2007  
who demonstrate a method for sectioning whole body sections and collecting 
them on adhesive tape, sections were freeze-dryed before mounting them on 
to MALDI target plates using double sided tape. Spray coating with matrix 
was finally followed by gold sputter coating. Their findings showed good 
correlation between the W BA and MALDI MSI data after an intra-tracheal 
administration of 0.5mg/kg of an undisclosed compound. The distribution of 
the parent drug and metabolite could be seen in the MSI data after oral dose 
but the W BA could not discriminate. Khatib-Sahahidi et al., 2006 presented 
whole body imaging of proteins within rat sections, to discriminate between 
different tissue regions and to identify protein signals related to mouse glioma 
tumour and healthy mouse tissue. This work also demonstrated the ability of 
whole body imaging to show the distribution of olanzapine and two of its 
metabolites, at different time points, showing the distribution differences 
between each metabolite and the whole drug.
4.1.3 M ALDI-IM S-M S
One recent advance in MALDI MSI instrumentation is the addition of a further 
dimension of separation, namely ion mobility separation (IMS). IMS  
separates ions on the basis of not only charge and mass but also by the ions 
collisional cross sectional area, thus allowing the possible separation of
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isobaric ions (Jackson et al., 2007). MALDI-lon Mobility Separation-MS 
imaging has the ability to improve the imaging of some drugs and metabolites 
by separating xenobiotic related ions from endogenous or matrix related 
isobaric ions, thus improving the confidence in the image interpretation. Ion 
mobility separation within MS/MS experiments allows a range of precursor 
ions to be admitted into the ion mobility cell to undergo ion mobility 
separation, which can then be followed by dissociation within the transfer 
region, resulting in the product ions all having the same drift time as their 
respective precursor ion. This allows multiple M S/MS data to be acquired 
within a single experiment or laser shot. In this work we have studied the 
distribution of vinblastine (C 4 6 H 5 8 N4 O 9 ) in rat whole body tissue sections, 
using a commercial quadropole time of flight instrument incorporating ion 
mobility separation in order to compare MALDI-MS, MS/MS, IMS-M S and 
MALD1-IMS-MS/MS. A comparison of the various MALDI imaging modalities 
with whole body autoradiography employing tritiated (3 H) vinblastine has also 
been conducted.
4.1.4 Synapt HDMS
TMA full description of the MALDI Synapt HDMS (Waters Corporation, Milford, 
USA) instrument is given elsewhere (Pringle et al., 2006 and within Chapters 
1 & 3 of this Thesis), but a brief description will be given here. This instrument 
has a quadrupole orthogonal acceleration time-of-flight geometry and is 
equipped with an ion mobility separation device located between the 
quadrupole and the time-of-flight analyser. The ion mobility separator used 
consists of three consecutive travelling wave ion guide (TW IG) regions
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(Figure 4.1). Giles et al., 2004  give a detailed description of travelling wave 
ion guides. Ion mobility separation is performed in the middle travelling wave 
ion guide device. The first travelling wave ion guide is used to store ions 
when an ion mobility separation is performed and gate ions into the ion 
mobility separation TW IG  when required. This maximises the duty cycle of 
the ion mobility separation. This region is referred to as the trap T-wave. The 
final travelling wave device is used to transfer ions from the ion mobility 
separator to the time-of-flight mass analyser and is referred to as the transfer 
T-wave. Collision induced dissociation can be achieved in either or both the 
trap or transfer T-wave. The middle TW IG  is where the ion mobility 
separation occurs. This is achieved using travelling low voltage waves which 
transverse the TW IG  in the presence of a low pressure inert gas.
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Figure 4.1 Schematic of the MALDI HDMS SYNAPT system, this instrument has a 
quadrupole orthogonal acceleration time-of-flight geometry and is equipped with an ion 
mobility separation device located between the quadrupole and the time-of-flight 
analyser. The ion mobility separator used consists of three consecutive travelling wave 
regions: The Trap T-Wave, Ion Mobility separation T-Wave and the transfer T-wave. 
Collision induced dissociation can be achieved in either or both the trap or transfer T- 
wave. (Waters, Manchester, UK)
The instrument used for the study reported here was equipped with an 
interchangeable MALDI source, which can be replaced with atmospheric 
pressure ionisation sources, such as electrospray ionisation, atmospheric 
pressure chemical ionisation etc. Matrix assisted laser desorption/ionisation 
was performed in an intermediate pressure environment (9x1 O'2 mbar) using a 
frequency tripled Nd:YAG laser (355 nm). Imaging data was obtained by
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moving the tissue sections in a raster pattern on an x/y-stage relative to the 
laser position, which remained fixed.
4.1.5 Vinblastine
Vinblastine (C 4 6 H 5 8 N4 O 9 ) is a chemical analogue of vincristine (C 4 6 H 5 6 N4 O 1 0 ) 
(Figure 4.2) and was first isolated from the Madagascar periwinkle plant. Both 
Vinca alkaloids vinblastine and vincristine act by binding to tubulin and inhibit 
microtubule assembly thus arresting cell growth during metaphase (Zhigaltsev 
et al., 2005). Tellingen et al., 1993 have also shown vinblastine by HPLC-M S  
to be extensively distributed within the body, and retained within several body 
tissues including the Gl tract where it has been detected 72 hours after 
administration of a 6 mg/kg I.V. dose. The retention of vinblastine and its 
major metabolite desacetylvinblastine within certain tissue type is thought to 
be the reason behind vinblastine's efficacy against certain tumour types 
derived from malignant transformations of these tissue types (GE Healthcare 
UK Limited, 2006).
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Figure 4.2 Structures of Vinblastine (C46H58N40 9i mono isotopic mass 810.420) and
vincristine (C46H56N4 O10 mono isotopic mass 824.400) structures. These compounds are 
chemical analogues of each other with a difference on one group between a CH3 and 
COH. Indicated is the difference between the two molecules.
The overall aims of this work were to image the distribution of vinblastine 
within rat whole body sections 1  hour post dose, to show the initial distribution 
of vinblastine, and to show the spatial distribution of the drug within the 
tissues. Also a comparison of W BA with MALDI imaging for direct drug 
distribution analysis within rat whole body sections was made along with an 
investigation of any advantages arising from combining ion mobility separation 
with MALDI MSI for imaging xenobiotic distributions within tissues.
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4.2 Experimental
All animal studies were conducted in accordance with UK Home Office 
Regulations and Guidelines.
4.2.1 Preparation of Tissue Sections
4.2.1.1 Sample Preparation for non radiolabelled vinblastine.
The dose formulation was 5.974mg of the Vinblastine sulfate salt in 1ml of 
saline, purity was checked by HPLC using a Gemini 5pm column (C18, 
250,4.6cm) with mobile phases 25mM ammonium acetate in water and 25m M  
ammonium acetate in methanol.
In this cold dose experiment two Sprague-Dawley (Crl: CD®BR -  Albino) rats 
(265g and 251 g) were injected intravenously with 6 mg/kg Vinblastine and 
euthanised 1  hour post dose.
4.2.1.2 Sample Preparation for radiolabelled 3H vinblastine.
Tritiated Vinblastine was purchased from GE Healthcare (Buckinghamshire 
UK) as a solution in methanol and was stored at -20°C until required, radio 
chemical purity was 98.4%  and the specific activity was 333MBq/mg 
(9.01mCi/mg) (Tellingen et al., 1993), the dose formulation was made by 
adding 0.0055pg of the radiolabelled vinblastine to 12.04mg of the non 
radiolabelled vinblastine, and dissolving this in 2 ml saline, resulting in a final 
concentration of ~ 6 .0 2 mg/ml.
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Two Sprague-Dawley (Crl: CD®BR -  Albino) rats (351 g and 387g) were 
injected intravenously with 6 mg/kg 3 H-Vinblastine and euthanised 1 hour post 
dose.
4.2.1.3 Sample Oxidation.
The brain, liver, kidney and the plasma were harvested from two animals 1 
and 4 hours following the administration of the 3H Vinblastine. These organs 
were then homogenised using a bench top homogeniser. After 
homogenisation 163.9mg brain homogenate, 197.2mg kidney homogenate, 
207.2mg liver homogenate and 503.1 mg of plasma were each placed into 
ashless combustion cones (Perkin-Elmer), each cone was then combusted 
using a 307 Packard Oxidise (Perkin Elmer Life Sciences), the sample 
remaining after combustion was mixed with 10ml Monophase Solution and 
5ml water to produce a scintillation cocktail. The radioactivity within each 
cocktail was then counted using a Tri-carb 2300TR liquid scintillation counter 
(Perkin Elmer Life Sciences) giving a result in dpm for each sample, this was 
then converted to pg equiv/g using the known specific activity.
4.2.1.4 Sample Preparation.
Each euthanised animal was placed in a metal restraint this ensured the nose, 
spine and the base of the tail were aligned, this restraint was then frozen in 
hexane/Card ice bath for 40 mins. The animal was then placed into a frozen 
frame and surrounded with Carboxymethyl cellulose (CMC) and lowered back 
into the Hexane/Card ice bath for a further 20 mins resulting in a solid block for 
sectioning.
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Sections (30[jm) were obtained using a Leica CM3050 cryostat (Leica 
Microsystems, Wetzlar, Germany). Sections were taken at a set level through 
the sample to show the kidney, liver, heart (Figure 4.3).
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Figure 4.3 a) Optical image of the whole body section used for the MALDI imaging 
experiments, showing the anatomical features and their relative locations within the 
section before matrix coating, b) MALDI-MSI image of the same tissue section, 
highlighting the anatomical features by imaging the distribution of specific ions, the 
varying colour is only an aid to visual identification and not intended to show relative ion 
intensity.
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4.2.1.5 MALDI Imaging section handling.
The whole body sections were transferred to clean aluminium foil plates using 
a Macro-Tape-Transfer-System® (Instrumedics Inc. St. Louis, MO) and freeze 
dried for 45 mins and then stored at -80°C until imaged.
Tissue sections were thawed and spray coated with 50ml of 25mg.ml'1 a- 
CHCA in 70:30 (v/v) ethanokwater (0.1% TFA), matrix was applied to the 
sections using a gravity fed pneumatic air spray gun, Iwata studio series 
compressor fitted with an Iwata Eclipse gravity feed airgun (Iwata-Media Inc., 
Portland, OR, USA) set to 40psi. Samples were sprayed from a distance of 
25cm. 20 series of 2 passes of the airbrush at 45 second intervals to avoid 
sample wetting.
4.2.1.6 Mass Spectrometric Analysis.
The whole body sections were optically scanned for future reference and the 
sample plates were cut to 44mm x 40mm in order to fit onto the MALDI 
Imaging Target plates (Waters Corporation, Milford, USA) the aluminium 
sample plates were then stuck to the target plates using double sided tape.
In order to set the tissue area to be analysed a digital image of the tissue, on 
the MALDI sample support, was generated using a CanoScan 4400F flatbed 
scanner (Canon, Reigate, UK). The digital image produced was imported into 
MALDI Imaging Pattern Creator (Waters Corporation, Milford, USA). In this 
software, the instrument was taught the dimensions of the image by locating 
the four corners of the image plate, this allowed the creation of the image area
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around the sample. The pattern was then uploaded into MassLynx (Waters 
Corporation, Milford, USA) and the parameters of the image experiment were 
created. The instrument was operated in positive ion V-mode prior to imaging 
analysis, the mass spectrometer was calibrated using a mixture of 
poly(ethylene glycol) standards (Sigma-Aldrich, Gillingham, UK) with average 
molecular weights of 400 and 600, providing coverage of the m/z range 
studied. The spacing between points on the raster was 300 pm in both x and y 
direction. Imaging data were obtained by moving the tissue sections in a 
raster pattern on an x/y-stage relative to the laser position, which remained 
fixed. At each position, data were acquired for 400 laser shots (2 s).
All measurements including the calibration were performed with ion mobility 
separation activated.
The mass spectrometer was set up as follows: precursor ion selection was 
performed with the quadrupole, the precursor ion window was set between 
m/z 785 and 835. This wide selection window was chosen to allow the 
transmission of the protonated molecule of vinblastine parent drug (m/z 811) 
and endogenous lipids of interest simultaneously. Selected ions were then 
first separated using ion mobility and then collision induced dissociation 
occurred in the transfer T-wave. Collision induced dissociation occurred after 
the precursor ions were separated by ion mobility meaning that fragment ions 
retained the same ion drift time as their associated precursor ions. Therefore, 
it is possible to assign fragment ions to their precursor ions, because they 
have the same drift time (Figure 4.4).
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The ion mobility related data analysis was accomplished using "DriftScope" 
software (Waters Corporation, Milford, USA). This enables specific drift time 
and m/z regions to be extracted, the resultant data sets were then converted 
into Analyze 7.5 file format using MALDI Imaging converter software (Waters 
Corporation, Milford, USA). Image visualisation was performed using BioMap
3.7.5.5 (Novartis, Basel, CH) (http://www.maldi-msi.org).
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Figure 4.4 a) MALDI-IMS-MS/MS transfer m/z iation pattern of vinblastine spot on 
tissue, viewed within "DriftScope" showing the separation of vinblastine from endogenous 
lipid m/z 811. Two distinct product ion patterns are seen with different drift times, 
vinblastine has a shorter drift time (4.8-5.6ms) compared to that of the endogenous lipid 
(5.8-6.5ms). b) Product ion mass spectrum arising from the drift time of 4.8-5.6ms, from 
the known dissociation pattern of vinblastine it can be seen that this drift time relates to 
vinblastine, c) Product ion mass spectrum arising from the longer drift time 5.8-6.5ms, 
this clearly is derived from an endogenous PC lipid as indicated by the intense and 
characteristic product ion at m/z 184 corresponding to the PC head group 
(H2P 04CH2CH2N(CH3)3) \
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Product ions selected for imaging were chosen by the known dissociation of 
vinblastine under CID this is shown in figure 4.5 (Favretto et at., 1998). The 
product ions were then analysed in the orthogonal TOF.
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Figure 4.5 Chemical structure o f vinblastine and the main dissociation pathways leading 
to the formation of the observed product ions in the MS/MS spectrum. (Favretto et al., 
1998)
4.2.1 .7  Q uantitative W hole B o dy A utorad iography (QW BA) tissue  
handling, Im aging and  quantitation.
Sections for QWBA were obtained according to the methodology previously 
described under "sample preparation" within this section, but in this case the 
sections were placed onto tape strips and freeze-dried for 45 mins. A section 
from a CMC block containing blood spots spiked with known concentrations of 
tritiated vinblastine was treated in the same way. After freeze drying, the 
tissue section and the standards were placed directly onto an imaging plate 
with no protective film, due to the short emission length of tritium. The image
plates with the sections were then left for a two week exposure time in a lead 
box. After the two week incubation the plates were imaged using the Fuji 
BAS 1500 bio-image analyser (Raytek, Sheffield, UK). The electronic images 
were analysed using a validated PC-based image analysis package SeeScan  
Densitometry software (LabLogic, Sheffield). The set of [3H]-labelled blood 
standards were used to construct a calibration curve over a range of 
radioactivity concentrations.
The lower limit of quantification for the QW BA was defined as the lowest 
quantifiable standard (12.0 nCi/g). Individual tissue concentrations of 
radioactivity were expressed in nCi/g and converted to pg equivalents drug/g 
(pg equiv/g) using the calculated specific activity of test material in the dose 
formulation. This gave a lower limit of quantification of 12.20 pg equiv/g.
4.2.1.8 Tissue spiking.
In order to obtain the best results from the tissue imaging experiments using 
ion mobility separation, the mobility drift time of the whole drug needed to be 
established, this was achieved by spotting 2pl of 0.5mg/ml vinblastine onto 
an unwashed 12pm kidney tissue section, which was then spray coated in 
matrix to simulate the actual experiment. A spot profile was then obtained 
and the drug drift time established from the "Driftscope" plot.
4.3 Results and Discussion
4.3.1 MALDI-MS
The positive ion MALDI mass spectrum of vinblastine spotted on tissue showed 
that the protonated molecule of vinblastine had a m/z 811.4 this is within a signal 
rich region of the mass spectrum (Figure 4.6). This region included ions from 
alkali metal adducts and singly charged species of several lipids, as well as ions 
from other molecules such as matrix related ions. Thus, there was considerable 
interference from endogenous ions when vinblastine was imaged using MALDI- 
MS imaging as shown in figure 4.7a. To increase the specificity of a MALDI 
imaging experiment, M S/MS data is often obtained and converted to an image. 
The 2D ion density maps for vinblastine (m/z 811.4) and its product ions shown in 
figure 4.7 illustrate the distribution of the vinblastine within the tissue sections. 
The majority of product ion intensity distributions were in good agreement with 
each other, showing the higher distribution of vinblastine to be within the liver, 
renal cortex and tissue surrounding the Gl tract, with the exception of the 
distribution of the precursor ion at m/z 811.4 (Figure 4.7a) and the transition of 
m/z 811 - 751 (Figure 4.7c) which showed a slightly different distribution. This 
difference was most prominent within the kidney, the distribution of the precursor 
ion and the product ion m/z 751 showed a relatively high signal intensity within the 
renal pelvis, but the other 7 known product ions did not show this distribution, it is 
therefore proposed that this observed signal intensity was due to an isobaric 
interference.
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Figure 4.6 Total MALDI-MS mass spectrum of vinblastine spotted on tissue, showing the 
complexity of signals around the mass of vinblastine m/z 811.4. This region includes 
ions from alkali metal adducts and singly charged species of several lipids, as well as 
ions from other species such as matrix related ions.
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Figure 4.7 MALDI-MS/MS Images from the thoracic and abdominal cavities showing the 
distribution of the precursor and product ions of vinblastine, a) m/z 811.4, b) m/z 811- 
793, c) m/z 811-751, d) m/z 811-733, e) m/z 811-719, f) m/z 811-691, g) m/z 811-649, h) 
m/z 811-524, i) m/z 811-355. (For organ identification see Figure 4.3b)
Ion mobility adds an additional separation step within the MALDI imaging 
experiment. To establish the ion mobility drift time associated with 
vinblastine, a spiked tissue section was analysed using IMS-MS/MS. The 
resulting "DriftScope" plot showed the separation of more than one ion at m/z 
811 (Figure 4.8). Since the dissociation occurs within the transfer region of 
the instrument all the product ions share the same drift time as their 
respective precursor ions. If the product ion spectrum from the ion which has 
the shorter drift time of (4.8-5.6ms) is selected the product ion spectrum 
matches that of vinblastine (Figure 4.4b). The product ion spectrum which 
shows the longer drift time of (5.8-6.5ms) shows a strong peak at m/z 184
(H2P04CH2CH2N(CH3)3)+ (Figure 4.4c), indicating that the product ion 
originates from an endogenous phosphatidylcholine type lipid species.
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Figure 4.8 "DriftScope" plot of the data obtained from the vinblastine dosed whole body 
MALDI-IMS-MS/MS image, showing the complexity of signals within the data set, 
numerous ions can be seen with various drift times. Ion intensity is shown as a colour 
gradient. Precursor ions have been mobility separated and the fragment ions can be 
seen vertically aligned.
The same experimental parameters were used within the spot analysis and 
the image acquisition, which allows the application of the drift time separation 
to be used to process the MALDI IMS-MS/MS image data. The "DriftScope" 
plot for the MALDI-IMS-MS/MS whole body imaging experiment showed a 
complexity of signals (Figure 4.8), within the whole body section data set. 
Figure 4.9 shows a comparison of the MALDI-MS/MS image and the MALDI- 
IMS-MS/MS image obtained by extracting only those ions which have a drift 
time of 4.8-5.6ms, i.e. the same data set with and without ion mobility
mill r.j. v / i i u p i v i  t
separation. The removal of the interfering signal within the renal pelvis by 
incorporating IMS increases the specificity of the IMS MS and MS/MS images.
MM ©11 » 751
Figure 4.9 Comparison of m/z 811 and m/z 811-751 using MALDI-IMS-MS/MS and 
conventional MALDI-MS/MS clearly demonstrates the advantages of ion mobility 
separation within MALDI xenobiotic imaging. Indicated is the main difference with the 
distribution of the ion of interest within the renal pelvis, c) shows the whole body 
autoradiography plot of an corresponding section from a tritiated vinblastine dose, it can 
be seen that there is almost no signal in the renal pelvis, confirming the results of the 
MALDI-IMS-MS/MS.
4.3.2 W hole body autoradiography
3H distribution shown in the sample oxidation data could represent the whole 
drug or any of the metabolites which contain the radiolabel. The 
concentrations of the radiolabel in the liver (22.70 pg equiv/g) and in the
J. A1J.11 1 .J .  ■ I
kidney (30.15 |jg equiv/g) were highest at 1 hour post dose (Table 4.1), the 
MALDI image shows the largest relative concentration in the liver with less in 
the kidney (Figure 4.9). The reason for the discrepancy between the sample 
oxidation data and the MALDI Imaging data, is most likely due to the species 
specificity obtained using MALDI imaging.
6m g/kg IV  tritia ted  vinblastine
Sample
1 hour post dose
(pg equiv/g)
4 hour post dose
(pg equiv/g)
Plasma 0.53 0.27
Brain 0.23 0.34
Kidney 30.15 12.86
Liver 22.70 13.28
Table 4.1 The sample oxidation data following administration o f3H radiolabelled 
Vinblastine. Concentrations of radioactivity are greatest in all tissues and plasma except 
in the brain at 1 hour post dose. Highest concentrations of radioactivity were measured in 
the kidney at 30.2pg equiv/g 1 hour post dose. The concentration within the brain and the 
plasma are in the same order of magnitude at 1 and 4 hours post dose.
Using MALDI-IMS-MSI only the distribution of the parent drug has been 
imaged whereas in the sample oxidation data only the radioactivity has been 
measured and not solely the parent drug. The sample oxidation data shows a 
very small amount of radioactivity in the brain, this correlates to the MALDI 
image shown in figure 4.10, where vinblastine has been imaged using MALDI-
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MS/MS on a 12|jm brain section from a dosed animal and vinblastine is only 
distributed in the ventricle and not within other brain regions.
Figure 4.10 MALDI-MS I image of an axial brain section of a rat after 6mgkg~1 IV dose of 
vinblastine, imaged is the distribution of the product ion of vinblastine at m/z 355, overlaid 
onto a background of an endogenous lipid, showing that vinblastine is only present in the 
ventricle.
Within this work Quantitative WBA (QWBA) was carried out using tritiated 
vinblastine sulphate, there are some issues with the use of tritium as a radio 
labelled molecule that need to be accounted for, the main problem with using 
tritium in QWBA studies is the loss of the radioactivity through freeze-drying, 
this occurs through the formation of 3H20  within the sample and then the loss 
of this 3H20  during the freeze-drying process, to asses the extent of this a test 
sample was freeze-dried. This showed limited loss of radioactivity, and any 
loss of radioactivity during freeze-drying was accounted for by the inclusion of 
the known standards.
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The QWBA data was quantified using SeeScan Densitometry software 
(LabLogic, Sheffield). The measured photostimulated luminescence (PSL) is 
converted to nCi/g within the software. A calibration graph was constructed 
from the PLS values of the known samples within the software. Table 4.2  
shows the measured radioactivity in nCi/g of numerous tissues measured 
from the QWBA sections shown in figure 4.11, also shown is the calculated pg 
equiv/g of vinblastine and its metabolites. Table 4.2 shows that the areas with 
the highest concentration of radioactivity include the small intestine mucosa 
and contents, which is also in agreement with the 2D ion plots for both 
MALDI-MS/MS, MALDI-IMS-MS and MS/MS (Figure 4.9). One anomaly that 
arose was that the QW BA data gave a high concentration of radioactivity 
within the lung tissue but signal intensity for the MALDI imaging data for 
vinblastine within the lung tissue was relatively low. This may be due to a 
tissue suppression effect. This has been previously reported by Stoeckli et 
aI., 2007, or due to the chemical specificity of the MALDI technique and that 
the radioactive signal is not from the parent drug but a metabolite, however 
this is likely to only have a small effect because vinblastine is known to be 
present within the lungs after 4 hours as reported by Tellingen et a!.,. 1993.
aFigure 4.11 a) Whole body autoradiograph showing the distribution of 3H in a 1 hour post 
dose Rat dosed with 6mg/kg IV 3H Vinblastine, b) shows the areas selected for analysis 
and quantification using the "SeeScan" software.
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Tissue
Rat 33M Rat 33M
1 hour (nCi/g)
1 hour (pg 
equiv/g)
Adrenal gland 24.8 25.1
Blood 2.08 BLQ
Bone 0.0 BLQ
Bone marrow 15.1 15.3
Caecum
contents 15.9 16.1
Kidney 43.0 43.5
Kidney cortex 33.9 34.3
Kidney medulla 60.1 60.8
Kidney pelvis 14 14.2
Liver 31.1 31.5
Lung 59.8 60.5
Muscle 8.5 BLQ
Myocardium 19.8 20.0
Pancreas 28.1 28.4
Prostate 1.5 BLQ
Salivary gland 47.9 48.5
Small intestine 
contents 135.0 136.6
Small intestine 
mucosa 58.3 59.0
Stomach
contents 0 BLQ
Stomach
mucosa 21.0 21.3
Urinary bladder 41.1 41.6
Table 4.2 Tissue concentrations of radioactivity calculated from the WBA image using 
"SeeScan" software from the known standards and the calculated fjg equiv/g of the drug 
or metabolite. (BLQ - Below Limit of Quantification).
Confirmation of the vinblastine distribution in whole body sections was carried 
out by QWBA. As already discussed this technique does not have the 
chemical specificity that MALDI has, however, it does retain the spatial
irim r.j. v ^ n a p t v i  t
information for the distribution of the tritium radiolabel (3H). Figure 4.9 shows 
the QWBA image, when this image is compared to the MALDI images (figure
4.7 and 4.9) good spatial agreement is observed. The distribution of the 
radiolabel within the kidney shows a high intensity within the renal cortex 
(34.3 pg equiv/g) and a much lower signal within the renal pelvis (14.2 pg 
equiv/g), this is in agreement with the product ions within the MALDI-MS/MS  
data set excluding m/z 811 and m/z 811 - 751. In the kidney the QW BA data 
shows an area, which is a broken ring of higher intensity (figure 4.12d), 
corresponding to the position of the medulla. Comparison of the QW BA and 
MALDI images with the original tissue sections shown in figure 4.12, show 
that the area with the QWBA signal and the MALDI imaging signal may in fact 
be the area of tissue between the renal cortex and the medulla. This area 
contains a number of lymphatic ducts. As previously reported by Tellingen et 
al.,. 1993 vinblastine is retained within the lymphatic tissue for extended 
periods of time, and this is a possible explanation for the high concentration of 
vinblastine observed in the QWBA and the MALDI images in this region. The 
agreement between the QWBA, MALDI-IMS-MS and MS/MS data show the 
added specificity and confidence that can be obtained with the addition of ion 
mobility separation to MALDI imaging experiments.
Figure 4.12 Enhanced images of the kidney from the whole body sections, before and 
after imaging, a) an optical image of the kidney from the whole body section dosed at 
6mgKg1 IV vinblastine before matrix application, b) the same tissue section as shown in 
4.12a but imaged by MALDI-IMS-MS showing the distribution of vinblastine within the 
kidney, with the highest intensity (white) showing a broken ring of intensity between the 
cortex and medulla, c) optical image of the kidney within the whole body section dosed 
with 3H Vinblastine, d) Whole Body auto radiography of the tissue section shown in 
4.12c, indicated is the broken ring of slightly higher intensity (white) between the cortex 
and medulla is indicated.
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4.4 Conclusions.
Shown here is a method for the direct analysis of vinblastine within a rat 
whole body section. The combination of MALDI-IMS-MSI with M S-M S has 
been shown to improve the selectivity of MALDI-MSI experiments over and 
above that normally obtainable with MALDI-MSI.
M ALDI-IMS-MS imaging of vinblastine within rat whole body sections has 
been shown to correlate with the spatial distribution of 3H vinblastine in QW BA  
experiments and to show the analyte specificity comparable to that of earlier 
HPLC-MS experiments.
Ion mobility separation has been shown to separate isobaric interferences 
from MALDI imaging data obtained from highly complex biological samples as 
shown here from whole body tissue sections from dosed animals, increasing 
the confidence in the resulting image.
Image acquisition was achieved within a relatively short time period, without 
the need for radio labelled compounds, further development of this technique 
and integration within the pharmaceutical industry could dramatically reduce 
the cost of drug development by removing the need to synthesise 
radiolabelled drug candidates and the health and safety issues arising from 
handling radioactive material. This technique could also ultimately reduce the 
number of animal experiments required during early phase drug development. 
With further advances in MALDI-MSI instrumentation and methodology the 
potential for single experiments that show the spatial distribution of drug
inm r.j. \ ^ n c ip i . t i  -r
candidates and their metabolites along with indications of local and systemic 
biological effects with high analyte specificity may be realised.
Vinblastine distribution shown within this work correlates with previously 
published studies of the distribution of vinblastine (Tellingen et a l,  1993). 
These studies were carried out using tissue homogenates and HLPC-MS  
combined with QWBA. MALDI imaging of vinblastine specifically shows the 
spatial distribution of vinblastine.
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CHAPTER 5
Lipid Distribution within HCT116 
Tumours, Tumour Margin and 
Surrounding Tissue, and the Effects 
of a Chemotherapeutic drugs.
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Lipid Distribution within HCT 116, Tumour Margin and Surrounding 
Tissue, and the Effects of a Chemotherapeutic drug administration on 
Lipids.
5.1 Introduction.
There has been extensive research into identifying possible cancer markers 
using MALDI-MSI primarily focussing on proteins and peptides (Burnum et a!., 
2008). Schwamborn et at., 2007 presented work on the identification of 
prostrate carcinoma by MALDI-MSI. They have identified two ions 
predominantly associated with non cancerous glands at 2753 and 6704Da  
and two ions that are predominantly associated with cancerous glands at 
4964 and 5002Da, using Support Vector Machine (SVM) algorithm generated 
by ClinProTools Software (Bruker Daltonics, Germany). They were also able 
to discriminate between cancerous and non-cancerous tissue sections 
resulting in an overall cross validation of 88%, with a sensitivity of 85.21 % and 
a selectivity of 90.74% . The algorithm used was based on a set of 22 peaks 
(because these were identified as being the most prominent peaks 
accountable for the highest percentage of variation between the two groups) 
from which the four accounting for the greatest variation between cancerous 
and non-cancerous regions are those mentioned above.
5.1.1 Role of lipids in cellular processes within cancer
Lipids have been shown to have major roles within cellular processes, and to 
include both structural and functional roles. They are known to be important
mediators of cell signalling. Lipids act as second messengers in cellular 
events such as cell growth, cellular proliferation, cell death and apoptosis.
The field of lipidomics has grown rapidly in recent years, however, there is still 
some catching up to be done for it to be at the same level of research as there 
is in proteomics.
There have been several studies published looking at the role of lipids within 
cellular systems. Fuchs et a i,  2007 have reported changes in the 
glycerophospholipid composition of hematopoietic progenitor cells due to 
apoptosis using 31P NMR and MALDI. Apoptosis causes glycerophospholipid 
composition of the outer surface of the cell membrane to change, there is a 
loss of membrane asymmetry due to negatively charged phosphatidylserine 
transfer from the inner to the outer membrane layer. They also show a 
decrease in diacyl-phosphatidylcholine and phosphatidylethanolamine and an 
increase in ether-linked glycerophosphocholines and ether-linked 
glycerophosphoethanolamines in apoptotic cell membranes. The MALDI-MS  
experiments within this work were carried out using cellular lipid extracts. 
Analysis was carried out using a Bruker AutoFlex system (Bruker Daltonics, 
Germany) fitted with an N2  laser. As a matrix the authors used para- 
nitroaniline, because phosphatidylethanolamine is detectable as a negative 
ion and this removes the high intensity phosphatidylcholine peaks observed in 
positive ion MALDI.
Due to their role in cellular processes lipids have been investigated as 
possible targets for cancer therapeutics, this has been reviewed by Ogretmen
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2006 and Modrak et al., 2006. These reviews concentrate on the role of 
sphingolipids in pathogenesis and as possible targets for cancer therapeutics. 
Sphingolipids are a large group of lipids which include several subgroups 
derived from an aliphatic amino alcohol called sphingosine (figure 5.1). One 
of the main subgroups that have undergone investigation is ceramides and 
their synthesis and metabolism. Ceramides have a sphingosine backbone 
and a fatty acid chain which can be of various lengths. Within nature these 
fatty acid chains generally contain an even number of carbons, commonly 
either C12, C14, C16, C18, C22, C24 and C26 (Ogretmen 2006). The use of 
odd chain lengths can be useful for quantitation using HPLC or similar 
because synthetically made odd number carbon chain lengths can be 
incorporated into analytical samples, as internal standards.
a) HoC
b)
Figure 5.1 schematic structure of a) sphingosine, b) sphinganine
Apoptosis has two pathways, termed receptor mediated and non-receptor 
mediated. Both pathways use ceramides as an intracellular, pro-apoptotic 
signalling molecule.
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Ceramides have a role in the induction of apoptotic cell death and are 
produced by cancer cells prior to apoptosis due to exposure to 
chemotherapeutics or radiotherapy. Within this process ceramides act as an 
intracellular second messenger which activates certain enzymes which lead to 
apoptosis (Modrak et a/., 2006). The ceramides that increase due to cellular 
stress causing agonists are long chain ceramides. These are synthesised via 
the activation of the de novo synthesis pathway and/or via the hydrolysis of 
sphingomyelin by sphingomyelinases (Ogretmen 2006). Figure 5.2 shows the 
biosynthetic pathway of certain sphingolipids.
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Figure 5.2 The biosynthetic pathway of certain sphingolipids (Modrak et al, 2006)
The role of ceramides in apoptosis may be due to their possible self assembly 
into channels resulting in the outer membrane of mitochondria becoming 
permeable to small proteins, thus releasing intramembrane space proteins 
inducing apoptosis (Stiban eta l., 2006).
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Ceramide is pro-apoptotic however dihydroceramide has been shown by 
Stiban et a/., 2006 to act as an apoptotic inhibitor. Dihydroceramide only 
differs from ceramide by one bond. Dihydroceramide lacks a critical trans 
double bond at the 4, 5 position (Figure 5.1a&b). Stiban et a/., 2006 propose 
that the ratio between ceramide and dihydroceramide may be important in 
apoptosis. In this work they found that the addition of dihydroceramide 
markedly reduced the permeability of the mitochondrial outer membrane by 
ceramide. They have shown that dihydroceramide is not able to disassemble 
the ceramide channel once it was formed. However, dihydroceramide does 
inhibit the formation of ceramide channels. These data indicate that 
dihydroceramide has an effect on the formation of the ceramide channels, but 
does not actively disassemble them.
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Figure 5.3 Some of the roles of sphingolipids within cancer growth regulation and therapy 
(Ogretmen 2006).
A brief overview of the role of ceramides within the regulation of cellular 
processes and drug resistances is shown in Figure 5.3 (Ogretmen 2006). As 
well as having apoptotic effects ceramides can also undergo synthesis and 
breakdown into other molecules. Sphingosine-1-Phosphate (S1P) can be 
produced by the hydrolysis of ceramide by ceramidases into sphingosine, 
followed by the conversion of sphingosine into S1P by sphingosine kinase. 
S1P is considered to be a pro-survival lipid and is involved in cancer 
proliferation, inflammation, vasculargenesis, malignant transformation and 
resistance to apoptotic cell death (Ogretmen 2006).
5.1.2 Tumour Xenograft methodology
The cell lines used within this work to form the tumour xenografts were from 
the HCT 116 cell line. Brattain et a l,  1981 have shown the methodology for 
obtaining and establishing the HCT 116 cell line (as well as HCT 116a and 
HCT 116b). The HCT 116 cell line is derived from a human colonic 
carcinoma removed from surgery (Brattain et al., 1981). The tissue was 
minced into 1-2mm3 pieces. The small tissue pieces were then washed 
several times in a culture medium. The tissue pieces were then 
disaggregated with 0.25%  Trypsin. The cells obtained from this process were 
more than 90% viable cells. Primary cultures from these cells were found to 
have 3 morphological variants HCT 116, HCT 116a and HCT 116b. These 
morphological variants were separated by sedimentation and centrifugation.
The methodology used within this work separated the cells using 
centrifugation in a linear gradient of percall in tissue culture medium. HCT  
116 cells were found in the density range of 1.037 -  1.080 g/ml. The density 
range of HCT 116a and HCT 116b was 1.026 -  1.068 and 1.044 -  1.092 g/ml 
respectively. Due to the overlapping nature of each of the cell types the 
gradient between 1.050 -  1.074 g/ml was selected, plated and grown in cell 
culture to form the initial culture of predominantly HCT 116 cells. Several sub 
cultures were made from this original culture and grown until only the HCT  
116 cells were observed by phase contrast microscopy (Figure 5.4). HCT 116 
cells formed tumours in -5 0 %  of animals given an inoculation of 5 x 106 cells, 
with an average latency of 16 days to form a tumour of at least 1cm in 
diameter.
Figure 5.4 100x magnification of HCT 116 cells in culture (Brattain et al., 1981)
5.1.3 Vinblastine
Vinblastine is a chemotherapeutic compound that inhibits microtubule 
assembly during metaphase (Zhigaltsev et al., 2005) preventing cellular 
replication and hence tumour growth. Vinblastine is a chemical analogue of 
vincristine which was first isolated from the Madagascar periwinkle plant. 
Vinblastine has been shown by Caron & Herwood 2007 to inhibit 
palmitoylation of tubulin in vivo in CEM cells and vinblastine caused 
microtubules to disassemble and result in the cells becoming apoptotic. 
Vinblastine treatment was shown to decrease palmitoylation of tubulin, and 
caused apoptosis in approximately 30% of cells after a 15min incubation with 
vinblastine at a clinically relevant concentration. This adds evidence that 
vinblastine does not only affect mitotic cells, since only 3.5% of these cells 
were mitotic. The authors propose that the apoptotic response to vinblastine 
is caused by either the lack of microtubules, or a change in the relative 
orientation of microtubules in the plasma membrane. This in turn disrupts the
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organisation of protein complexes in the cell surface membrane, which 
initiates the apoptotic process. This is due to the effect of vinblastine on 
microtubule assembly and palmitoylation of tubulin.
The structure of vinblastine is shown in figure 5.5. Shown in figure 5.6 is the 
structure of desacetylvinblastine which is the major metabolite of vinblastine.
NH
'OCOCH3
HO
CH3
Chemical Formula: C46H58N4O9 
Exact Mass: 810.42
Figure 5.5 Structure of vinblastine
NH
rOH
HO
Chemical Formula: c 44h 56n 4o 8 
Exact Mass: 768.41
Figure 5.6 Structure of desacetylvinblastine the major metabolite of vinblastine.
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When vinblastine is analysed there always appears to be an associated ion at 
m/z 809.4 as shown in figure 5.7. The proposed structure for this ion is 
shown in figure 5.8.
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Figure 5.7 MALDI MS profile of vinblastine showing the [M+HJ+ peak at m/z 811.4 and 
the associated peak at m/z 809.4.
From the ion a proposed structure for the ion m/z 809.4 is given in figure 5.8 
this possible structure based on the mass and the proposed structure being 
the least energetic option.
I e  'c o o c h 3| HO
c h 3
Chemical Formula: C46H56N4O9 
Exact Mass: 808.40
Figure 5.8 Proposed structure for the ion observed at m/z 809.4. Highlighted in red is the 
bond believed to have changed from the onginal vinblastine structure.
5.1.4 Principle Component Analysis (PCA) in MALDI
PCA analysis is beneficial for processing MALDI imaging data. Within this 
work the PCA analysis was performed to try and identify possible markers for 
each of the tissue regions, we have previously discussed this method 
(Chapter 2 of this thesis). Other research groups have used PCA in a slightly 
different way Van de Plas et al., 2007 used PCA as a multivariate pre analysis 
tool to identify ions that are spatially related to form images of several ions 
based on their PCA loadings. This method can be useful as an initial step to 
determine differences within the tissue section.
Within this work positive ion MALDI was used for the detection and spatial 
distribution studies of phosphatidylcholine and sphingomyelin lipids.
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5.2 Methodology
All animal studies were subject to ethical approval and all the animal use and 
handling in this work abides by UK Home Office Regulations and Guidelines.
5.2.1 Sample Preparation HCT 116
HCT 116 cells were sourced from the National Cancer Institute, Tumour 
Repository (Maryland, USA). The cells were grown at 37°C in a high 
humidified atmosphere of 5% CO2 : 95% air, in a growth medium of PAA 
Gold: 1640 RMPI (PAA Laboratories GmbH, Pasching, Austria) with 2mM L- 
Glutamine and 5% Foetal Bovine Serum (FBS). Prior to inoculation the HCT 
116 cells were prepared as a single cell suspension. The adherent cells were 
removed from the flask by the addition of trypsin/EDTA. The cells were re­
suspended in incubation media containing plasma to deactivate the trypsin. 
This was followed by centrifugation to pellet the cells which were re­
suspended in plasma-free media at a density of 1 x 108 cells ml"1.
HsdHan™: RNU-Foxn1 - Rowett nude rats (Harlan UK Ltd, Oxon, UK) 
received a single subcutaneous injection of the HCT 116 cell suspension (300 
pi containing 15 x 106 cells) on the right dorsal flank. Following inoculation, 
rats were monitored regularly and bodyweight, general observations and 
tumour dimensions were recorded up to three times a week. Digital callipers 
were used in the measurement of the tumours, and the following algorithm 
used to determine tumour volume:
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(Length (mm) x width(mm)2)Tumour volume (mm5) = --------------------— ----------------------
Equation 5.1 Determination of tumour voiume (private communication with Quotient 
Bioresearch Ltd).
Once tumours had reached the target volume of around 1000 mm3, each 
animal was selected as either, Control, 2Hr post dose and 6 Hr post dose.
The control received no injection and the 2Hr and 6Hr animals were both 
dosed intravenously with 6mg/kg Vinblastine and euthanised 2 and 6 hours 
post dose respectively.
5.2.2 Xenograft sectioning
After the animal was euthanised the tumour xenografts were excised and 
snap frozen in a hexane cardice bath, once frozen the xenografts were stored 
in a -80°C Freezer until sectioned.
When required the tissues were removed from the freezer and placed in a 
CM1510 cryostat (Leica Microsystems, Wetzlar, Germany) set at -18°C and 
allowed to acclimatise for 30 minutes. Tissues were mounted onto cork discs 
in the desired orientation and fixed in place using OCT. Sections (12pm) 
were cut and thaw mounted onto glass microscope slides, and stored at -80°C  
until required.
5.2.3 Matrix Coating
When required the sections were removed from the freezer and allowed to 
warm to room temperature before opening, to prevent condensation on the 
sample. The samples were then spray coated with 5mgml*1 aCHCA in 
50:50:0.1 ethanol:water:TFA (v:v:v) using an ImagePrep station (Bruker
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Daltonics, Germany). This covered the tissue section with a fine matrix 
coating allowing time between matrix coats for co-crystallisation to occur 
between analytes and the matrix.
5.2.4 QStar Pulsar-i Image accusation
The glass slides were cut to size and mounted using double sided tape onto a 
recessed Opti-Tof® LC MALDI target plate holder (Applied Biosystems/MDS 
Sciex, Concord, Ontario, Canada). The recessed target holder enables the 
sample level to be maintained when using glass slides. This is essential 
because variation in the sample height alters the laser focus and the position 
that the laser fires.
The samples were analysed in positive ion mode using an Applied 
Biosystems/MDS Sciex hybrid quadropole time-of-flight instrument (Q-Star 
Pulsar-/) fitted with an orthogonal MALDI ion source, using the oMALDI server
5.1 software. A 355nm frequency tripled 1-20KHz Nd:YV04 laser (Elforlight 
Ltd, Daventry, Northants, UK). The laser was set to a repetition rate of 5KHz. 
The laser was fired at the sample with 150 pm spatial resolution, with the 
laser firing for approximately 3 seconds per spot.
5.2.5 Synapt Image accusation
In order to set the tissue area to be analysed a digital image of the tissue, on 
the MALDI sample support, was generated using a CanoScan 4400F flatbed 
scanner (Canon, Reigate, UK). The digital image produced was imported into 
MALDI Imaging Pattern Creator (Waters Corporation, Milford, USA). In this 
software, the instrument was taught the dimensions of the image by locating
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the four corners of the image plate. This allowed the creation of the image 
area around the sample. The pattern was then uploaded into MassLynx 
(Waters Corporation, Milford, USA) and the parameters of the image 
experiment were created. The instrument was operated in positive ion V- 
mode prior to imaging analysis, the mass spectrometer was calibrated using a 
mixture of poly(ethylene glycol) standards (Sigma-Aldrich, Gillingham, UK) 
with average molecular weights of 400 and 600, providing coverage of the m/z 
range studied. The spacing between points on the raster was 200 pm in both 
x and y direction. Imaging data were obtained by moving the tissue sections 
in a raster pattern on an x/y-stage relative to the laser position, which 
remained fixed. At each position, data were acquired for 400 laser shots (2 
s) using a 200Hz Nd.YAG laser.
All measurements including the calibration were performed with ion mobility 
separation activated.
5.2.6 PCA-DA Data Processing.
Principal components analysis - Discriminate Analysis (PCA-DA) was carried 
out using the MarkerView™ statistical analysis package (Applied 
Biosystems/MDS Sciex, Concord, Ontario, Canada). Ten Spectra were
randomly selected from each of the 6 tissue regions, viable tumour, necrotic 
centre and connective tissue from both the vinblastine dosed and the non 
dosed sections. The spectra were imported into the MarkerView™ software 
with a mass tolerance of 0.5 amu (i.e. the bin size the data was grouped into), 
and a minimum signal count of 4.0 which removed background noise. The 
data was normalised against m/z 379 the protonated dimer of the matrix. The
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matrix associated ions were then excluded from the analysis along with 
isotopic peaks using a function of the software. PCA-DA was carried out 
using Pareto scaling. Pareto scaling uses the square root of the standard 
deviation as a scaling factor to reduce the dominance of large scale intensity 
changes in high abundance ions (Van den Berg et al., 2006). These may 
mask the variation in lower abundance ions during PCA-DA. The overall 
outcome of PCA-DA is greatly affected by the masking of the underlying 
relevant information by high intensity ions. D1 verses D2 was chosen for 
display since these components resulted in the highest overall degree of 
separation of the spectra within the PCA-DA scores plots 22.9% and 21.9%  
respectively.
In the header for each of the scores and loadings plots (Figure 5.10 & 5.11) 
the discriminate components that have been plotted are shown with the 
percentage variance (Van den Berg et al., 2006), or the percentage of the 
variance accounted for from each of the discriminate components shown in 
brackets. Also shown is the type of scaling used which was Pareto (DA).
5.2.7 Image processing
The imaging data sets obtained using the Q-Star Pulsar-/'were converted into 
Analyze 7.5 file format using oMALDI server 5.1 software.
The ion mobility related data analysis obtained on a Synapt HDMS system 
was accomplished using "DriftScope" software (Waters Corporation, Milford, 
USA). This enables specific drift time and m/z regions to be extracted, the 
resultant data sets were then converted into Analyze 7.5 file format using 
MALDI Imaging converter software (Waters Corporation, Milford, USA).
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All Image visualisation and processing was carried out using BioMap 3.7.5.5 
ion imaging software (Novartis, Basel, CH) (http://www.maldi-msi.org) 
resulting in the production of a 2D ion density map. Images were normalised 
against the matrix ion at m/z 190.
5.2.8 Histological staining.
The tissue sections were retained after imaging for Haematoxylin and Eosin 
staining. This allows for a comparison between the MALDI imaging data and 
the histology.
After imaging, the tissue sections were washed at a 45° angle using 5ml of 
100% ethanol, this step completely removed the matrix which was left on the 
tissue. The tissue sections were then rehydrated using a series of graded 
alcohols. Each section was submerged in 100% ethanol for 3 minutes, 
followed by a further 3 minutes in 95% and 70% ethanol. The rehydrated 
tissue section were then repeatedly dipped into deionised water for 2 minutes 
until the ethanol had been removed. The initial stain of Haematoxylin was 
then applied by submerging the section into filtered haematoxylin for 1 minute. 
Haematoxylin stains basophilic structures within the cells predominantly the 
nuclei with a blue-purple colour. The tissue sections were then gently washed 
under running tap water for 3-5 minute until the water ran clear. The effects of 
the haematoxylin can be lightened using a 1-3 second dip in acid alcohol if 
required but this was not needed in this experiment. The tissue sections were 
washed in 70% ethanol followed by 95% ethanol for 3 minutes each prior to 
counterstaining for 20 seconds in 5% eosin in ethanol. Eosin stains 
eosinophilic structures pink. After counterstaining tissues sections were again 
washed in 95% ethanol twice, followed by 2 washes in 100% ethanol each for
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3 minutes. In order to dehydrate the section. Dehydrated sections were then 
placed in xylene for at least 10 minutes until cover slipped.
5.2.9 PPM mass error calculations
The PPM (Parts Per Million) mass error was calculated for each of the 
possible lipid species observed. The calculations were carried out using the 
equation shown in equation 5.2. Using data that had been recalibrated to the 
matrix ions.
Equation 5.2 PPM  mass error calculation.
5.3 Results and discussion.
To enable comparison between the mass spectrometric data and the actual 
tissue sections H&E staining was carried out on the same sections after mass 
spectrometric analysis. The sections are shown in figure 5.9 with inset an 
image obtained at 40x magnification to demonstrate the tissue regions.
Measured Mass — Theoretical Mass •)x 1000000PPM E rro r = Measured Mass
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non-dosed
Tumour
Necrotic Tumour
Connective Tissue
4— Viable /  Living TumourVinblastine
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Figure 5.9 a) H&E stained section of the Control, non-dosed tumour section after MALDI 
imaging, b) H&E stained section of the dosed tumour xenograft after MALDI imaging, c) 
A magnified image of the control tissue section showing the 3 distinctively different tissue 
regions.
The use of PCA has been shown to be beneficial for interrogating MALDI 
imaging data (McCombie et al., 2005. Prideaux et al., 2007) shown in figure 
5.10 and 5.11 are the scores and loadings plots respectively.
PCA DA is shown in figure 5.10 to nearly separate all six groups of 10 
randomly selected spectra from the viable tumour, necrotic centre and 
connective tissue from both the dosed and non-dosed tumour sections. There 
is some overlap between the connective tissue and some of the viable tumour 
spectra from the control non-dosed tissue section.
The Scores plot (figure 5.10) shows that one of the 6hr post dose MS spectra 
from the viable tumour (VT0) appears to be associated with the connective 
tissue MS spectra. This is probably due to the viable tumour being a thin ring
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of cells. This MS spectrum could have been taken from the connective tissue 
region and not the viable tumour, or possibly a combination of ions from both 
tissue regions due to the image resolution being at 150pm. PCA-DA allows 
incorrectly identified MS spectra to be discriminated.
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Principal Component Variance (% ) Total Variance (% )
PCI 22.87 22.87
PC2 21.94 44.80
PC3 21.23 66.03
PC4 19.99 86.02
PC5 13.98 100.00
Table 5.1 The percentage variance and total variance accounted for by each principle 
component selected by the PCA DA software.
6 Hr Post dose 4 
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Control Tumour^
6 Hr Post dose <j| 
Vinblastine tumour
Control Tumour!
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Vinblastine tumour
Control Tumour
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Vinblastine tumour
Control Tumour (f
Figure 5.11 2D ion plots showing the distribution o f some of the ions o f interest within 
the tissue sections selected from the loadings plot, with the corresponding H&E 
stained tissue section. Identifications have been made based on MS/MS data 
analysis.
Possible ions of interest accounting for the separation of the different tissue 
regions can be seen in the loadings plot figure 5.10b. Images generated from 
some of these possible ions of interest are shown in figure 5.11.
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MS/MS spectra were obtained and have been used to confirm the identity of 
some of these ions accounting for the major differences between the tissue 
types. Figures 5.12, 5.13, 5.14 and 5.15 show the interpreted MS/MS spectra 
used to identify m/z 756.4 one of the ions of interest.
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Figure 5.12 Product ion mass spectrum for m/z 756 and the interpretation identifying this 
ion as PC 32:0 [M+Naf
PT_090406_11 23 (0.466) Cm (1:42) TOF MSMS 734.50LD+
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Figure 5.13 Product ion mass spectrum for m/z 734 and the interpretation identifying this 
ion as PC 32:0 [M +Hf Fatty acid chains shown is only one option for this configuration, 
based on the mass.
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Figure 5.14 Product ion mass spectrum for m/z 758 and the interpretation identifying this 
ion as PC 34:2 [M +Hf: Note the fatty acid chains shown are only one option for this 
configuration, based on the mass.
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Figure 5.15 Product ion mass spectrum for m/z 760 and the interpretation identifying this 
ion as PC 34:1 [M +Hf Fatty acid chains shown is only one option for this configuration, 
based on the mass.
inmr.j. v^u
Another method of data processing that was used within this work was the 
interpretation of the results by directed image processing. This involves 
looking for the distribution of some possible ions of interest from the 
calculated m/z values for a set of lipid species. Table 5.2 shows a list of lipid 
species calculated m/z values and the observed values of the ions near those 
masses, and their possible assignments to lipid species, also shown in table
5.2 is the relative intensity of the ions simply depicted for rapid comparison 
between the tissue sections and the corresponding tissue regions. Very low 
to no signal observed this related to a signal count between 0 - 0.01 au and is 
shown by a (-), low relative abundance this related to a signal count between 
0.01 -  0.1 au and is shown by (+), followed by (++) which denotes medium 
relative abundance this related to a signal count between 0.1 -  0.5au, and a 
relatively high abundance which related to a signal count between 0.5 -  1au is 
shown by (+++) and a very high abundance (>1au) is denoted by (++++). This 
table is just as a visual comparison for a range of lipids throughout each 
tissue region, and the relative abundances are from visual comparison, all 
data used in the compilation of this table is from data normalised against the 
matrix ion m/z 190.
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C a lc u la te d
m /z
O b s e rv e d
m /z
P P M  E rro r  
( 2 d p )
P o s s ib le
s p e c ie s
Ion  S p e c ie s V ia b le  T u m o u r C o n n e c t iv e
T is s u e
N e c ro tic  C e n tre
Non-
Dosed
Dosed Non-
Dosed
Dosed Non-
Dosed
Dosed
3 0 0 .2 9 0 3 3 0 0 .2 9 1 8 5 .0 0 S p h in g o s in e [ M + H f - - - - + -
3 0 2 .3 0 5 9 3 0 2 .2 6 3 2 - 1 4 1 .2 7 S p h in g a n in e [M + H ]+ - + - - - -
3 2 2 .2 7 2 2 3 2 2 .2 8 7 5 4 7 .4 7 S p h in g o s in e [ M + N a ]+ - - - - - -
3 2 4 .2 8 7 8 3 2 4 .3 0 1 7 4 2 .8 6 S p h in g a n in e [M + N a ] + - - - - - -
3 3 8 .2 4 6 1 3 3 8 .2 5 9 6 3 9 .9 1 S p h in g o s in e [M + K ]+ - + - + - -
3 4 0 .2 6 1 8 3 4 0 .3 0 6 1 1 3 0 .1 8 S p h in g a n in e [ M + K f + + + + - + - -
3 6 9 .3 5 2 1 3 6 9 .3 5 0 1 -5 .4 1 C h o le s te ro l [M -H 20 + H ] + + + + + + + - + + - -
4 6 5 .3 4 5 7 4 6 5 .3 5 1 3 1 2 .0 3 S P P C [ M + H ]+ + + - + - -
4 8 2 .3 6 1 1 4 8 2 .3 8 5 5 5 0 .5 8 C -1 6 L y s o -P A F [ M + H ]+ + + + - - - -
4 8 7 .3 2 7 7 4 8 7 .2 9 1 1 -7 5 .1 1 S P P C [ M + N a ] + - - + - -
5 0 3 .3 0 1 6 5 0 3 .3 2 1 3 3 9 .1 4 S P P C [M + K ]+ - - + + + - -
5 1 0 .3 9 2 4 5 1 0 .3 8 0 3 -2 3 .7 1 C -1 8 L y s o -P A F [ M + H ]+ + + + + + + + - -
5 2 4 .3 7 1 6 5 2 4 .3 8 7 2 2 9 .7 5 C 1 6 - P A F [M + H ]+ + + + + + + + - -
5 5 2 .4 0 2 9 5 5 2 .4 1 2 7 1 7 .7 4 C 1 8 - P A F [M + H ]+ + + + + + + + + - -
Table 5.2 List of possible Sphingolipid species and whether they were detected within different tissue 
regions of the dosed and non dosed tissue sections. An arbitrary visual scale was used with the following 
indications of relative abundance, Very low to no signal observed is shown by a (-), low relative abundance 
is shown by (+), followed by (++) which denotes medium relative abundance, and a relatively high 
abundance is shown by (+++J and a very high abundance is denoted by (++++). This table is just as a 
visual comparison fora range of lipids throughout each tissue region. All data used in the compilation o f this 
table is from data normalised against the matrix ion m/z 190. (Possible lipid species not confirmed by 
MS/MS) SPPC = sphingosylphosphorylcholine, PAF = Platelet activating factor, LPC = Lyso 
phosphtidylcholine. PPM mass errors have been calculated and displayed, Red- >20ppm, Yellow - 1 0 -  
20ppm, Green - <10ppm.
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m/z 302.3
m/z 340.3
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Figure 5.16 2D ion plots o f the m/z values listed in Table 5.2
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C a lc u la te d  
M o n o ­
is o to p ic  m /z
O b s e rv e d
m /z
P P M
e rro r
(2 d p )
P o s s ib le
s p e c ie s
Ion
S p e c ie s
V ia b le  T u m o u r C o n n e c t iv e
T is s u e
N e c ro tic  C e n tre
Non-
Dosed
Dosed Non-
Dosed
Dosed Non-
Dosed
Dosed
6 4 7 .5 1 2 8 6 4 7 .4 5 4 1 -9 0 .6 6 S M  (1 8 :1 /1 2 :0 ) [ M + H ]+ - - - + - -
6 6 9 .4 9 4 7 6 6 9 .4 8 4 0 - 1 5 .9 8 S M  (1 8 :1 /1 2 :0 ) [ M + N a ]+ + + + + + -
6 7 5 .5 4 4 1 6 7 5 .5 1 5 5 ,,-4 2 .3 4 S M  (1 8 :1 /1 4 :0 ) [ M + H f + + - - - -
6 7 7 .5 5 9 8 6 7 7 .5 2 8 5 - 4 6 .2 0 S M  (1 8 :0 /1 4 :0 ) [M + H ]+ - - - - + -
6 8 5 .4 6 8 7 6 8 5 .4 6 6 9 - 2 .6 3 S M  (1 8 :1 /1 2 :0 ) [M + K ]+ + + + + - + - -
6 9 7 .5 2 6 0 6 9 7 .4 7 1 9 - 7 7 .5 7 S M  ( 1 8 : 1 /1 4 :0 ) [ M + N a ]+ + + + + + + + - -
6 9 9 .9 9 1 8 6 9 9 .9 6 5 4 -3 7 .7 2 S M  (1 8 :0 /1 4 :0 ) [ M + N a ]+ + + + + + -
7 0 3 .5 7 5 4 7 0 3 .5 6 8 5 -9 .8 1 S M  (1 8 :1 /1 6 :0 ) [M + H ]+ + + + + + + + - -
7 0 5 .5 9 1 1 7 0 5 .5 7 8 3 - 1 8 .1 4 S M  (1 8 :0 /1 6 :0 ) [M + H ]+ + + + + + + - + + -
7 1 3 .5 0 0 0 7 1 3 .4 4 8 6 - 7 2 .0 4 S M  (1 8 :1 /1 4 :0 ) [M + K ]+ + + + + + + + - -
7 1 5 .5 1 5 6 7 1 5 .4 6 6 9 - 6 8 .0 7 S M  ( 1 8 :0 /1 4 :0 ) [M + K ]+ + + - + - -
7 2 5 .5 5 7 3 7 2 5 .5 4 5 3 - 1 6 .5 4 S M  (1 8 :1 /1 6 :0 ) [M + N a ] + + + + + + + + + + -
7 2 7 .5 7 3 0 7 2 7 .5 5 7 5 - 2 1 .3 0 S M  (1 8 :0 /1 6 :0 ) [M + N a ] + + + + + + - - + + + -
7 2 9 .5 8 1 1 7 2 9 .4 7 1 3 -1 4 8 .4 8 S M  (1 8 :1 /1 8 :1 ) [M + H ]+ + + + + - + - -
7 3 1 .6 0 6 7 7 3 1 .6 0 3 7 -4 .1 0 S M  (1 8 :0 /1 8 :1 ) [M + H ]+ - - + + + - -
7 3 1 .6 0 6 7 7 3 1 .6 0 3 7 - 4 .1 0 S M  (1 8 :1 /1 8 :0 ) [M + H ]+ - - + + + - -
7 3 3 .6 2 2 4 7 3 3 .5 6 4 4 - 7 9 .0 7 S M  (1 8 :0 /1 8 :0 ) [ M + H ] + + + + + + + - + + - -
7 4 1 .5 3 1 3 7 4 1 .5 2 7 0 - 5 .8 0 S M  (1 8 :1 /1 6 :0 ) [M + K ]+ + + + + + + - -
7 4 3 .5 4 6 9 7 4 3 .5 4 3 6 -4 .4 4 S M  (1 8 :0 /1 6 :0 ) [M + K ]+ + + + + + + -
7 5 1 .5 7 3 0 7 5 1 .5 4 1 8 -4 1 .5 1 S M  (1 8 :1 /1 8 :1 ) [ M + N a ] + + + + + + -
7 5 3 .5 8 8 6 7 5 3 .5 8 8 6 0 .0 0 S M  (1 8 : 0 /1 8 :1 ) [M + N a ] + - - + + + - -
7 5 3 .5 8 8 6 7 5 3 .5 8 8 6 0 .0 0 S M  (1 8 : 1 /1 8 :0 ) [ M + N a f - - + + + - -
7 5 5 .6 0 4 3 7 5 5 .5 6 1 5 - 5 6 .6 5 S M  (1 8 :0 /1 8 :0 ) [M + N a ] + + + + + + - + + -
7 5 9 .6 3 8 0 7 5 9 .5 7 5 1 -8 2 .8 1 S M  (1 8 :1 /2 0 :0 ) [ M + H ]+ - - + + + + - -
7 6 1 .6 5 3 7 7 6 1 .5 8 8 6 - 8 5 .4 8 S M  (1 8 :0 /2 0 :0 ) [M + H ]+ + + + + + + + + + + - -
7 6 7 .5 4 6 9 7 6 7 .5 2 9 7 -2 2 .4 1 S M  (1 8 :1 /1 8 :1 ) [M + K ]+ + + + + + +
7 6 9 .5 6 2 6 7 6 9 .5 6 7 0 5 .7 2 S M  (1 8 :0 /1 8 :1 ) [M + K ]+ - + - + + + -
7 6 9 .5 6 2 6 7 6 9 .5 6 7 0 5 .7 2 S M  (1 8 :1 /1 8 :0 ) [M + K ]+ - + - + + + -
7 7 2 .5 8 6 1 7 7 2 .5 3 2 1 - 6 9 .9 0 S M  (1 8 :0 /1 8 :0 ) [M + K ]+ + + + + + + + + - -
7 8 1 .6 1 9 9 7 8 1 .5 7 4 2 -5 8 .4 7 S M  (1 8 :1 /2 0 :0 ) [ M + N a f + + + + + + + -
7 8 3 .6 3 5 6 7 8 3 .5 8 0 4 - 7 0 .4 5 S M  ( 1 8 : 0 /2 0 :0 ) [ M + N a f + + + - + + + -
7 8 7 .6 6 9 3 7 8 7 .6 2 3 2 -5 8 .5 3 S M  (1 8 :1 /2 2 :0 ) [M + H ]+ + + + + + - -
7 8 9 .6 8 5 0 7 8 9 .6 3 6 7 -6 1 .1 7 S M  (1 8 :0 /2 2 :0 ) [ M + H ]+ + + + + + + -
7 9 7 .5 9 3 9 7 9 7 .5 6 3 1 -3 8 .6 2 S M  (1 8 :1 /2 0 :0 ) [M + K ]+ - - + + + - -
7 9 9 .6 0 9 5 7 9 9 .5 5 9 3 -6 2 .7 8 S M  (1 8 :0 /2 0 :0 ) [M + K ]+ + + + + + + + -
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8 0 9 .6 5 1 2 8 0 9 .6 2 0 4 -3 8 .0 4 S M  (1 8 :1 /2 2 :0 ) [ M + N a f + + + + + + + -
8 1 2 .6 7 4 7 8 1 2 .6 2 8 1 -5 7 .3 4 S M  ( 1 8 : 0 /2 2 :0 ) [ M + N a f + + + + + + -
8 1 3 .6 7 7 1 8 1 3 .6 8 2 7 6 .8 8 S M  (1 8 : 1 /2 4 :1 ) [ M + H f - + + + + -
8 1 5 .7 0 0 6 8 1 5 .7 0 4 0 4 .1 7 S M  (1 8 : 0 /2 4 :1 ) [ M + H f + + + + + + -
8 1 5 .7 0 0 6 8 1 5 .7 0 4 0 4 .1 7 S M  (1 8 : 1 /2 4 :0 ) [ M + H f + + + + + + -
8 1 7 .7 1 6 3 8 1 7 .7 1 0 0 -7 .7 0 S M  (1 8 : 0 /2 4 :0 ) [ M + H f + + + + - - + + -
8 2 5 .6 2 5 2 8 2 5 .6 1 1 0 - 1 7 .2 0 S M  (1 8 : 1 /2 2 :0 ) [ M + K f + + + + + +
8 2 7 .6 4 0 8 8 2 7 .6 1 8 6 - 2 6 .8 2 S M  (1 8 : 0 /2 2 :0 ) [ M + K f + + + + + + + -
8 3 1 .7 3 1 9 8 3 1 .7 1 0 0 - 2 6 .3 3 S M  (1 8 : 0 /2 5 :0 ) [ M + H f + + + + + - -
8 3 5 .6 6 6 9 8 3 5 .6 7 0 7 4 .5 5 S M  (1 8 : 1 /2 4 :1 ) [ M + N a f + + + + + + -
8 3 7 .6 8 2 5 8 3 7 .6 8 6 6 4 .8 9 S M  ( 1 8 : 0 /2 4 :1 ) [ M + N a f + + + + + + + -
8 3 7 .6 8 2 5 8 3 7 .6 8 8 6 7 .2 8 S M  ( 1 8 : 1 /2 4 :0 ) [ M + N a f + + + + + + + -
8 3 9 .6 9 8 2 8 3 9 .6 9 5 2 - 3 .5 7 S M  ( 1 8 : 0 /2 4 :0 ) [ M + N a f - + - - + + -
8 4 1 .7 1 6 3 8 4 1 .6 8 8 0 - 3 3 .6 2 S M  ( 1 8 : 1 /2 6 :1 ) [ M + H f - + - - + + -
8 4 3 .7 3 1 9 8 4 3 .6 8 5 3 - 5 5 .2 3 S M  (1 8 :0 /2 6 :1 ) [ M + H f + + + + + -
8 4 3 .7 3 1 9 8 4 3 .6 8 5 3 - 5 5  2 3 S M  ( 1 8 : 1 /2 6 :0 ) [ M + H f + + + + + -
8 4 5 .7 3 9 7 8 4 5 .6 9 6 9 -5 0 .6 1 S M  ( 1 8 : 0 /2 6 :0 ) [ M + H f + + + + + + -
8 5 1 .6 4 0 8 8 5 1 .6 5 8 1 2 0 .3 1 S M  ( 1 8 : 1 /2 4 :1 ) [ M + K f - - - + + - -
8 5 3 .6 5 6 5 8 5 3 .6 7 8 2 2 5 .4 2 S M  ( 1 8 : 0 /2 4 :1 ) [ M + K f + + + + + + -
8 5 3 .6 5 6 5 8 5 3 .6 7 8 2 2 5 .4 2 S M  ( 1 8 : 1 /2 4 :0 ) [ M + K f + + + + + + -
8 5 3 .7 1 3 8 853.6782 - 4 1 .7 0 S M  ( 1 8 : 0 /2 5 :0 ) [ M + N a f + + + + + + -
8 5 5 .6 7 2 1 8 5 5 .6 9 5 6 2 7 .4 6 S M  ( 1 8 : 0 /2 4 :0 ) [ M + K f + + + + + + -
8 6 3 .6 9 8 2 8 6 3 .6 9 3 3 - 5 .6 7 S M  ( 1 8 : 1 /2 6 :1 ) [ M + N a f + + + + + + -
8 6 5 .7 1 3 8 8 6 5 .6 9 9 9 - 1 6 .0 6 S M  (1 8 : 0 /2 6 :1 ) [ M + N a f + + + - + -
8 6 5 .7 1 3 8 8 6 5 .6 9 9 9 - 1 6 .0 6 S M  (1 8 : 1 /2 6 :0 ) [ M + N a f + + + - + -
8 6 7 .7 2 9 5 8 6 7 .6 9 4 8 - 3 9 .9 9 S M  (1 8 :0 /2 6 :0 ) [ M + N a f + + + + + + -
8 7 0 .3 9 6 0 8 7 0 .5 5 0 0 1 7 6 .9 0 S M  ( 1 8 : 0 /2 5 :0 ) [ M + K f + + - + + + -
8 7 9 .6 7 2 1 8 7 9 .7 2 8 0 6 3 .5 4 S M  ( 1 8 : 1 /2 6 :1 ) [ M + K f + + + + + + -
8 8 1 .6 8 7 8 8 8 1 .7 5 0 6 7 1 .2 2 S M  ( 1 8 : 0 /2 6 :1 ) [ M + K f + + + + + -
8 8 1 .6 8 7 8 8 8 1 .6 8 7 8 0 .0 0 S M  (1 8 :1 /2 6 :0 ) [ M + K f + + + + + -
8 8 3 .7 0 3 4 8 8 3 .7 4 2 0 4 3 ,6 8 S M  (1 8 :0 /2 6 :0 ) [ M + K f + + - + + -
Table 5.3 List of possible Sphingomyelin (SM) species and whether they were detected within different tissue 
regions of the dosed and non dosed tissue sections. An arbitrary visual scale was used with the following 
indications of relative abundance, Very low to no signal observed is shown by a (-), low relative abundance is 
shown by (+), followed by (++) which denotes medium relative abundance, and a relatively high abundance is 
shown by (+++J and a very high abundance is denoted by (++++). This table is just as a visual comparison 
for a range of lipids throughout each tissue region. All data used in the compilation o f this table is from data 
normalised against the matrix ion m/z 190. PPM mass errors have been calculated and displayed, Red- 
>20ppm, Yellow- 10-20ppm, Green - <10ppm.
Non-
Dosed
Dosed 
Normalised 
against m/z 190
Figure 5.17 2D ion plots of the m/z values listed in Table 5.3
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Non- 
Dosed
Dosed 
Normalised 
against m/z 190
m/z 769.6m/z 769.6
m/z 789.6m/z 787.6
m/z 813.7
m/z 825.6
m/z 759.6
m/z 772.5*
m/z 761.6
m/z 781.6
m/z 797.6 m/z 799.6
m/z 815.7 m/z 815.7
m/z 831.7 m/z 835.7
Figure 5.18 2D ion plots of the m./z values listed in Table 5.3
m m  r.j.
Non- (f~.
Dosed
Dosed 
Normalised 1
against m/z 190
m/z 190
m/z 851.7m/z 845.7m/z 843.7
m/z 865.7m/z 863.7
m/z 870.6
m/z 883.7
Figure 5.19 2D ion plots of the m/z values listed in Table 5.3
There are several differences in the distribution within the tissues of some of 
the possible sphingolipids. There are several ions predominantly associated 
with the viable tumour region of each section. There are also possibly more 
interestingly ions which only appear or are present in higher relative 
abundance within the dosed or non dosed tumours. Several ions are present 
in the necrotic centre of the control tumour which do not appear to be present 
in the necrotic centre of the vinblastine dosed tumour including m/z 727.6,
839.6 and 841.6. This is possibly due to the control tumour xenograph being 
much larger than the dosed xenograph with a large necrotic centre compared
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to the necrotic centre of the dosed tumour. The size difference in the tumours 
is not a result of the dosing regime but due to the initial rate of tumour growth 
prior to dosing.
C a lc u la te d
m /z
O b s e rv e d
m /z
E rro r  P P M P o s s ib le
s p e c ie s
Ion
S p e c ie s
V ia b le  T u m o u r C o n n e c t iv e
T is s u e
N e c ro tic  C e n tre
Non-
Dosed
Dosed Non-
Dosed
Dosed Non-
Dosed
Dosed
7 1 8 .5 3 0 9 7 1 8 .5 6 7 4 5 0 .8 0 P C  31 :1 [ M + H ]+ + + + + - + - -
7 3 2 .5 5 4 3 7 3 2 .5 5 7 6 4 .5 0 P C  32 :1 [M + H ]+ + + + + - + + - -
7 3 4 .5 6 2 2 7 3 4 .5 6 4 7 3 .4 0 P C  3 2 :0 [M + H ]+ + + + + + + + + + - -
7 5 6 .5 5 1 9 7 5 6 .5 5 1 2 -0 .9 3 P C  3 2 :0 [ M + N a ]+ + + + + + + + - -
7 5 8 .5 7 0 0 7 5 8 .5 6 9 2 - 1 .0 5 P C  3 4 :2 [M + H ]+ + + + + + + - -
7 6 0 .5 8 5 6 7 6 0 .5 8 3 6 -2 .6 3 P C  3 4 :1 [ M + H ]+ + + + + + + + - -
7 6 2 .5 9 3 5 7 6 2 .5 9 6 1 3 .4 1 P C  3 4 :0 [ M + H ]+ + + + + - -
7 7 2 .5 2 5 9 7 7 2 .5 3 2 1 8 .0 3 P C  3 2 :0 [M + K ]+ + + + + + + - -
7 8 2 .5 6 7 6 7 8 2 .5 7 3 9 8 .0 5 P C  34 :1 [M + N a ] + + + + + + + - -
7 8 2 .5 7 0 0 7 8 2 .5 7 3 9 4 .9 8 P C  3 6 :4 [ M + H ]+ + + + + + + - -
7 8 4 .5 8 5 6 7 8 4 .5 8 6 2 0 .7 6 P C  3 6 :3 [ M + H ]+ + + + + + + + -
7 8 6 .6 0 1 3 7 8 6 .6 0 6 5 6 .6 1 P C  3 6 :2 [ M + H ]+ + + + + + - -
7 8 8 .6 1 6 9 7 8 8 .6 2 4 8 1 0 .0 2 P C  36 :1 [M + H ]+ + + + + + - -
7 9 8 .5 4 1 5 7 9 8 .5 5 3 4 1 4 .9 0 P C  34 :1 [M + K ]+ + + + + + - -
8 0 6 .5 7 0 0 8 0 6 .5 8 2 0 1 4 .8 8 P C  3 8 :6 [ M + H ] + - - - + + - -
8 1 0 .6 0 1 3 8 1 0 .6 1 2 2 1 3 .4 5 P C  3 8 :4 [ M + H ]+ + + + + - -
8 1 2 .6 1 6 9 8 1 2 .6 2 8 1 1 3 .7 8 P C  3 8 :3 [ M + H ] + + + + + + -
8 2 0 .5 8 5 6 8 2 0 .5 4 5 4 -4 8 .9 9 P C  3 9 :6 [ M + H ]+ - - - + + - -
8 2 6 .5 7 2 8 8 2 6 .6 1 1 0 4 6 .2 1 P C  36 :1 [M + K ]+ + + + + + -
8 3 4 .6 0 1 3 8 3 4 .6 2 2 9 2 5 .8 8 P C  4 0 :6 [M + H ]+ - - + + - -
Table 5.4 List o f possible PC lipid species and whether they were detected within different tissue regions 
of the dosed and non dosed tissue sections. An arbitrary visual scale was used with the following 
indications of relative abundance, (<0.1au) very low to no signal observed (-), (0.1-1au) low relative 
abundance (+), (1-5au) medium relative abundance (++), (>5au) relatively high abundance (+++). This 
table is just as a visual comparison for a range of lipids throughout each tissue region. All data used in 
the compilation of this table is from data normalised against the matrix ion m/z 190. (possible lipid 
species not confirmed by MS/MS). PPM mass errors have been calculated and displayed, Red- >20ppm, 
Yellow - 10-20ppm, Green - <10ppm.
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PPM mass error has been calculated, and has been shown within the tables 
5.2, 5.3 and 5.4. Some of the high PPM errors are due to unresolved peak 
overlapping, or peak masking due to higher abundance peaks masking the 
signal of lower abundance peaks. Another possibility is due to the observed 
peak relating to an ion other than the possible lipid suggested.
Non- 
Dosed
Dosed 
Normalised 4 
against m/z 190
m/z 190 m/z 718.5 m/z 732.6 L><» m/z 734.6
m/z 756.6 m/z 758.6 m/z 760.6 m/z 762.6 | 10U m/z 772.5
m/z 782.6 m/z 782.6 m/z 784.6
LLo.m
m/z 786.6 i-°« m/z 788.6
m/z 798.5 m/z 806 6 m/z 810.6 w
a LLcco
m/z 812.6 ■-«* m/z 820.6o
m/z 826.6 1 0« m/z 834.6
Figure 5.20 2D ion plots of possible phosphtidylcholine (PC) lipids species listed in Table 
5.4
Page | 207
i m n r . j .  v^u
A different scale was needed to tabulate the results of the PC lipids because 
of their high abundance and the ease with which this class of lipids is 
observed with positive ion MALDI-MS.
There are in fact thousands of possible ions of interest arising from 
endogenous compounds that can be detected from a single experiment. This 
is far too many to complete conventional MS/MS analysis and subsequent 
identification on within this work. However in the preceding sections an 
attempt has been made to identify some of the important lipid species 
present.
The determination of the distribution of vinblastine within whole body tissue 
sections is reported in chapter 4 of this thesis. It has been shown that for a 
true image of the distribution of vinblastine in tissue sections ion mobility is 
beneficial. For this reason sections were analysed on a Synapt HDMS 
system (Waters Corporation, Manchester. UK). The total drift time plot is 
shown in figure 5.21 for an area of the 6Hr post dose tissue section. Only a 
part of the tissue section is depicted within the driftscope plot due to the file 
size. The image data has been divided up into “functions” each function 
contains up to 2GB of information. The file size needs to be divided up into 
files each less than 2GB in size due to the file size constraints within Microsoft 
Windows (Microsoft Corporation. USA) (www.microsoft.com). This is the 
reason the data is assigned functions.
imil r.j.
□ cd.13_23.88)(1.oo_20o.oo) (100.00_1500.00) max: 1500 mft
20.0 40.0 60.0 80.0 100.0 120.0 140.0 1 60.0 1 80.0Drift Time (Bins)
Figure 5.21 DriftScope plot from the imaging data acquired from a portion o f a 6Hr 
post dose tumour tissue section. Familial trend lines can be seen.
Within the driftscope plot the intensity maxima form intense trend lines (red 
dots). These are familial trend lines each associated with a distinct group of 
species related ions. To image the distribution of vinblastine the ion mobility 
data must be retained as well as the retention time data or pixel location 
information. In order to retain both parts of information the data needs to be 
extracted from the dirftscope plot which shows the drift time but not the spatial 
information into a chromatogram which contains the spatial location 
information for each pixel prior to constructing an image. This is achieved by 
selecting the ions of interest within driftscope as indicated by the circles in 
Figure 5.22a this m/z and drift time combination is then extracted for each 
function within the image data file. The extracted file contains the retention 
time chromatogram for the individual mobility separated ion. This information
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can then be converted into a Biomap file so an image can be obtained (Figure 
5.22c &5.22e).
Dnfl Trre [Bm) Ion at 
similar m/z
(837;10569)Vinblastine 
related ion
Non-
Dosed
Dosed
Figure 5.22 a) DriftScope plot o f the region in which Vinblastine ions can be seen, encircled is an ion 
associated with vinblastine at m/z 809.4 and also encircled is the interfering ion. b) Mass spectrum  
showing the overlapping peaks of interest, c) Ion mobility separated 2D ion plot o f the vinblastine 
associated ion m/z 809.4. d) Biomap image created without ion mobility separation, clearly showing 
the effect o f ion masking due to interference, e) Biomap image of the interfering ion after ion 
mobility separation.
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It can be clearly seen in Figure 5.22c, d & e that in order to obtain a true 
distribution of the vinblastine associated ion at m/z 809.4 ion mobility 
separation is required. Using conventional MALDI MS imaging the image 
depicted in Figure 5.22d is obtained. It would appear from this image that 
only the distribution of the interference which has been imaged and it would 
be concluded on that there is no vinblastine related ion within the dosed tissue 
section. If the ion mobility separated image is obtained (Figure 5.22c) then 
the only ion present is in the dosed tissue section in the connective tissue 
region. This shows the benefit of the ion mobility separation within this 
application. The most likely reason that the vinblastine related ion is only 
distributed within the connective tissue is due to the limited penetration of the 
drug into the viable tumour due to the poor vasculature of the viable tumour 
hence the drug is not present in the main bulk of the tumour at the same level 
as the connective tissue.
5.4 Conclusion.
Shown here is a method for the analysis of lipids within dosed and control 
FICT 116 tumour xenographs. Data interpretation has been carried out using 
PCA-DA as a method for identifying ions of interest within the tissue sections. 
A manual directed imaging approach has also been carried out, by calculating 
the m/z of known lipids followed by the image acquisition of these masses.
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Several possible ions of interest have been imaged and statistical 
identification of ions of interest associated with distinct tissue regions have 
been achieved using PCA-DA.
MALDI-IMS-MSI has been shown to improve the specificity of MALDI-MSI 
experiments over and above that normally obtainable with MALDI-MSI. 
Showing the true distribution of a vinblastine associated ion at m/z 809.4, 
which was not observed using conventional MALDI MSI.
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CHAPTER 6
High Repetition Solid State Laser 
and Raster Imaging for High 
Throughput, High Resolution 
MALDI-lmaging.
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High Repetition Solid State Laser and Raster Imaging for High Throughput,
High Resolution MALDI-lmaging.
6.1 Introduction
6.1.1 How lasers work
Laser is an acronym for Light Amplification by Stimulated Emission of Radiation. 
Lasers rely on the absorption and emission of energy at particular energy levels. 
In order to understand how lasers work it is necessary to understand atoms, 
molecules and their electron configuration. An atom is composed of a nucleus 
containing protons and neutrons, which are orbited by electrons in distinct orbital's. 
Each orbital can only accommodate a set number of electrons. The innermost 
orbital can accommodate up to 2 electrons, the second orbital can accommodate 
up to 8 electrons, and each further orbital can accommodate increasing numbers 
of electrons. These orbital's are subdivided into smaller orbital's containing up to 
two electrons each occupying a different area within the space around the nucleus. 
Electron orbital's increase in energy the further away they are from the nucleus of 
the atom.. If all the electrons are in their lowest possible orbital energy 
combination this is called the ground state for that atom. There is a defined way in 
which electron orbital's fill based on their energy levels. The energy between two 
levels is constant. For an electron to change its electron configuration it needs to 
gain or lose a specific amount of energy dependant on the configuration it
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changes between. There also needs to be space for the electrons to move into. 
Electrons do not therefore continuously absorb energy but it is quantised energy 
absorption and emission resulting in a change in the electron configuration.
ener
9y
0
3s 3p
28 2P
Energy level
1s
m w w m
3d 4s 4p
Number of 
^  electrons
orbital shape
Figure 6.1 Electron configuration with respect to energy levels, this configuration would be 
written as 1s2, 2s2p6, 3s2p6d10, 4s2p6.
The Diagram shown in figure 6.1 shows the electron rings represented as boxes. 
Each box represents an electron orbital which can contain a pair of electrons 
which is indicated using up and down arrows (representing that the electrons may 
not be identical). The letters s, p and d represent the orbital's shape
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Nitrogen electron configuration Neodymium electron configuration
Is 2, 2s2p3 i s2f 2s2p6, 3s2p6d10, 4s2p6d10f4, 5s2p6, 6s2
Figure 6.2 A graphical shell model representation of the electron rings within nitrogen and 
neodymium. Each shell represents an energy level
Electrons can undergo a transition from one orbital or energy level to another 
higher level or lower level depending on whether energy is absorbed or emitted. 
Energy can be absorbed from collisions with other molecules, atoms or electrons 
or from the absorption of a photon that matches the energy quanta required to 
excite an electron from one energy level to another, this is shown by equation 6.1.
hv — E2 — E1
Equation 6.1 Relationship between frequency and energy levels, where h is Planck’s constant, 
v is the Frequency of the photon, E2 is the 2nd energy level (Excited state) energy and E1 is the 
ground state (original state) energy.
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The same energy photon is emitted when the electron returns to E-i from E2 the 
wave length of this photon (A) can be calculated by equation 6.2, this only occurs 
when only two energy levels are involved.
he
Equation 6.2 Calculating the wavelength (A) of an emitted photon due to decay from E2 to E-,.
Simulated emission / decay can occur when a neighbouring atom emits a photon 
of frequency v, when this occurs a pair of new photons identical to the absorbed
one in phase, frequency and direction are emitted unlike spontaneous emission 
which emits a photon with no phase or directional relationship. The phenomenon 
of simulated emission / decay is the principle of how lasers work.
Electrons are not restricted to a single increase or decrease in energy levels, most 
lasers rely on many energy levels, each molecule has characteristic energy levels 
and decay rates. Shown in figure 6.3 and 6.4 are the energy levels within the N2 
molecule, and Nd from the Nd:YAG laser two of the most common lasers used 
within MALDI.
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Figure 6.3 The energy levels within a N2 molecule responsible for the generation of a photon 
at337nm. (http://www.fineartradioaraphv.com/hobbies/lasers/nitrogen/)
Energy 
[eV]
0.5“
Group of 
Energy 
Levels 
for
Pumping
^3
Optical
Pum ping
0.73 (pm) 
0 8 [pm]
Fast 
(Non Radiative) 
Transitions
Laser Transitions 
1.06 (pmj
Figure 6.4 The energy levels within a Nd atom responsible for the generation of a photon at 
1064nm. (http://stwww. weizmann.ac.ii/Lasers/iaserweb/Ch-6/C6s2t2p2.htm) (Pumped at 
0.808pm)
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N2 lasers are based on the energy levels shown in figure 6.3. A pulse of high 
voltage is used to excite the electrons from the ground state to the upper laser 
level. This excites a large number of electrons to an excited state, and is rapidly 
followed by stimulated emission of a photon at 337.1nm. The initial energy level 
drop between the upper laser level and the lower laser level occurs very rapidly, 
followed by a slower decay down to the meta-stable level, after which it decays 
even more slowly back to the ground state.
Nd:YAG lasers are based on the energy levels of neodymium. This is doped into 
yttrium aluminium garnet (Y3AI50i2), usually at approximately 1%. At this 
concentration some of the neodymium can replace the yttrium within the crystal 
lattice. Traditional Nd:YAG lasers used to be pumped or excited by the use of 
flash lamps (Holle et a i, 2006) but modern Nd:YAG lasers are diode pumped. 
These are smaller and cheaper than previous flash lamp pumped lasers. Such 
laser diodes are similar to light emitting diodes, and emit light (which for this 
application is around 808nm) when an electrical current is passed through them. 
This results in the excitation of the neodymium to the excited state (E4), and then 
by non radiative decay they drop to a lower energy level (E3) which is shortly 
followed by simulated emission at 1064nm wavelength. This is then commonly 
tripled for MALDI to form a laser at 355nm. This wavelength tripling is achieved by 
a two stage process, initially by second harmonic generation by the combination of 
two photons into a single frequency doubled, half wavelength photon, by passing 
the initial laser light photon at 1064nm through a LBO crystal (Lithium TriBorate) in
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a type I process (type I, the two input photons enter the crystal vertically polarised, 
the resulting photon exits the crystal in an orthogonal (Horizontal) polarisation). 
The second stage is by sum frequency generation where two simultaneous input 
frequencies, one photon at 1064nm and the second frequency doubled photon at 
532nm from the second harmonic generation, are mixed in a second LBO crystal, 
in a type II process (Type II, The two input photons are orthogonally polarised and 
the output photon is polarised parallel to the IR input photon). This generates an 
output frequency photon at 355nm.
The Nd:YV0 4  laser works in the same way as the Nd:YAG laser since the active 
ion is still neodymium. The difference in the gain material, this results in a laser 
capable of much higher repetition rates than the Nd:YAG. This is due to the upper 
state lifetime of the gain materials. This upper state lifetime is the time taken by 
an excited electron to decay to the lower energy state, this is a measure of the 
ability of the material to store energy. The low repetition rate of the N2 laser is not 
due to the upper state lifetime of the gain material but most likely due to the 
degradation of the gas at higher frequencies. If a laser is pulsed faster than the 
upper state lifetime the laser output pulse energy reduces. This is hence a limiting 
factor for repetition rates for MALDI lasers. Vanadate has a shorter upper state 
lifetime than YAG and hence it is used for very high repetition lasers.
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6.1.2 Lasers in use for MALDI
Several laser types have been used in MALDI MS for the Laser 
desorption/ionisation process. MALDI was first reported using a frequency 
quadrupled Nd:YAG laser at 266nm (Karas et a/., 1985) however most older 
commercial instruments use N2 lasers at 337nm. This is most likely due to N2 
lasers being smaller and cheaper than other lasers available at the time like the 
flash-lamp pumped lasers. N2 lasers although cheap have some significant 
limitations, the repetition rate for N2 lasers that are commercially available is 
limited to about 50Hz (Holle et al., 2006) and they have an average life span of 2- 
6x107 shots. A typical imaging experiment of a sagittal rat brain section 
approximately 10mm x 20mm area, imaged at a resolution of 150pm x 150pm 
results in approximately 8911 (67x133) spots per image. Commonly each spot 
has an acquisition time of 3 seconds. Using a 50Hz N2 laser, each spot has 150 
laser shots. Over the entire image the laser fires approximately 1,336,650 times. 
If the laser lasts for 6x107 shots before it reaches the end of its life span, at best 
this only allows ~45 sections of this size to be imaged before the laser requires 
replacing.
One of the most common alternatives to the N2 laser are frequency tripled 
Nd:YAG lasers which have a wave length of 355nm and a repetition rate up to 
approximately 5KHz, these lasers have an average life span of over 1x109 shots.
McLean et al., 2003 presented work using a 1KHz Nd:YAG laser compared to a 
30Hz N2 laser, they showed that the 1KHz laser was capable of obtaining good
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quality data within a 1 second acquisition time, they also found that in some cases 
the Nd:YAG 1KHz laser enhanced the signal for angiotensin II by up to a factor of 
80. Moskovets et al., 2006 have presented work using a 2KHz rep rate frequency 
tripled Nd.YAG laser for high throughput spot analysis of liquid chromatography 
mass spectrometric spot analysis, using the 2KHz laser and a rapid plate 
movement allowed Moskovets et al., 2006 to achieve acquisition times much 
faster than commercially available instruments allowing the analysis of 625 LC-MS 
spots within a total run time of just 12 mins.
There are several things that are important when considering a laser for MALDI, 
the significance of the wavelength of the laser is one of the most important. The 
term matrix assisted laser desorption was first coined by Karas et al., 1985, within 
this work the authors looked at the laser desorption ionisation mass spectra of 
amino acid using two laser wavelengths one generated by a frequency quadrupled 
Nd:YAG laser i.e. 266nm and the other generated by a frequency tripled Nd:YAG 
laser i.e. 355nm. Within this work the observation was noted that a mass 
spectrum of alanine could be obtain with the addition of tryptophan at an 
irradiance almost a tenth of that required to obtain a mass spectra of alanine on its 
own, hence the authors deduced that tryptophan must be acting as an absorbing 
matrix resulting in the desorption of the non absorbing alanine. Modern UV- 
MALDI lasers are selected such that their wavelength is in the absorbing region of 
common matrices that are used but are not at a wavelength that is commonly
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absorbed by analyte molecules because this can cause considerable analyte 
fragmentation.
Another important consideration is the laser pulse length used within MALDI 
experiments. This has been shown to affect the internal energy transfer between 
matrix and analyte molecules (Vertes e ta l,  2004).
There are three main factors affecting the internal energy (IE) content of analyte 
ions within MALDI these are, the laser fluence (J/m2), the nature of the matrix and 
the analyte molecular type.
Different types of matrix can have significant effects on the IE of analyte molecules, 
aCHCA as a matrix can lead to increased fragmentation of peptide ions and is 
referred to as a “hot” matrix where as DHB leads to much fewer peptide fragment 
ions and hence has been referred to as a “cold” matrix for MALDI (Medzihradszky 
et a l, 2000). Vertes et al., 2004 demonstrated that the opposite is true for 
preformed ions. Matrix with preformed analyte ions desorbed with ns pulse length 
laser irradiation has shown that aCHCA imparts the least amount of energy on the 
analyte ions followed by SA and then DHB each imparting 3.69 ± 0.21 eV, 4.04 ± 
0.27eV and 4.3 ±0.29eV respectively.
Survival Yield (SY) is a parameter that can be calculated to compare different data 
sets in order to obtain information about the amount of analyte fragmentation. SY 
is calculated from the following simple equation, where lm is the molecular ion 
abundance and If is the abundance of the fragment ion.
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Equation 6.3 Calculation of survival yield (SY), where lm is the ion count for the molecular ion 
and If is the ion count for the fragment ion.
It has been shown that using a picosecond (ps) pulse duration with a frequency 
tripled Nd:YAG laser gave an increase in the SY compared to the use of a nano 
second (ns) pulse duration N2 laser (Vertes et al., 2004). The N2 laser also 
showed increased matrix suppression effects. A higher laser fluence was required 
for the ps pulse Nd:YAG laser before desorption/ionisation occurred. With both 
lasers increased fluence resulted in a decrease in the ion count for the molecular 
ion (lm) most likely due to the increased deposition of IE to the analyte ions from 
the matrix. The Nd.YAG laser showed a slower rate of decrease in lm compared 
to the N2 laser as the fluence was increased. Within this case study it was 
observed that the IE of analytes depended on the matrix and followed the trend of 
aCHCA < SA < DHB for the IE of the analytes or put another way the SY for each 
matrix for the analysis of 3-methoxy-benzylpyridinium salt was aCHCA > SA > 
DHB. Previous findings (Medzihradszky et al., 2000) found aCHCA to be a hot 
matrix, Vertes et al., 2004 proposed that this difference was caused by the 
ionisation pathways for each analyte. The 3-methoxy-benzylpyridinium salt studied 
by Vertes et al., 2004 are thought to be preformed ions. In contrast to the 
previous study on the analysis of peptides where the ionisation process would be
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likely to occur via proton transfer. Vertes et al., 2004 stated that the different 
results were possibly due to the ns pulse length excitation resulting in “ladder 
switching” or energy pooling by excitons, whereas the ps pulse length promotes 
ladder climbing. This would result in an increase in the number of electronically 
excited states within the matrix. The late onset of phase transition may be an 
indication of reduced exciton-phonon (vibrational energy) coupling.
Dreisewerd 2003 states that longer laser pulse durations can have a negative 
effect in MALDI. UV lasers used for MALDI generally have a pulse duration of 0.5- 
10ns, within this work the Nd:YV0 4  laser used has a pulse duration of 1.5ns. 
Long pulse durations do have a negative effect on MALDI and this is thought to be 
due to excessive thermal excitation of the analytes. Rapid excitation is key in 
MALDI experiments so that the desorption/ablation event predominantly occurs 
before analyte decay due to thermal degradation. If this is not the case this is 
called in source decay (ISD). This ISD requires fragmentation channels to occur 
within the time scale of the initial phase transition. Post source uni molecular 
decay (PSD) occurs at longer time scales than ISD, both ISD and PSD are analyte 
and matrix dependent, as previously mentioned aCHCA is thought to be a hot 
matrix for certain analytes because this matrix causes a higher degree of 
fragmentation compared to DHB for certain analytes such as peptides, due to their 
physiochemical properties.
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Holle et al., 2006 have shown that the beam profile of the laser also has a marked 
effect on the efficiency of Nd:YAG lasers within MALDI experiments. Conventional 
N2 lasers have a beam profile with multiple maxima throughout the laser spot 
these maxima shift position randomly with every laser shot and this is depicted in 
figure 6.5 which has been reproduced from Holle et al., 2006.
I00 |jm
Figure 6.5 A typical N2 laser spot, showing multiple maxima throughout the laser spot a) in a 
2d plane showing laser spot b) showing a laser spot in 3D also showing the multiple maxima 
throughout the laser spot and c) showing the random nature of the maxima as they change 
over 8 consecutive shots (Holle et al., 2006)
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Typical frequency tripled Nd:YAG lasers have a typical Gaussian distribution 
within the laser spot as shown in figure 6.6.
100|jm
Figure 6.6 The Gaussian distribution of a typical Nd:YAG laser. (Flolle et al., 2006)
This typical Gaussian distribution is disrupted when an Nd:YAG laser is fired 
through a fibre-optic cable. When this is done the spot profile of the Nd:YAG laser 
loses its Gaussian distribution and forms a spot with multiple maxima, however 
these do not vary like the N2 laser distribution figure 6.7 shows the distribution of 
maxima of a Teem Nd:YAG laser fired through a 100pm diameter fibre optic.
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Figure 6.7 Teem (Teem Photonics, MA, USA) Nd.YAG laser spot profiles at (a) 25% and (b) 
100% laser power, showing multiple maxima throughout the laser spot after it has been 
passed through a 100pm fiberoptic.
Holle et al., 2006 present data on the Bruker Daltonik (Bremen, Germany) laser 
system that is employed on the Bruker Ultraflex III MALDI TOF/TOF. This laser 
system is a frequency tripled Nd:YAG laser at 355nm, but the important difference 
is the structured beam profile that is generated using a modulator. This results in 
the generation of a structured beam with multiple maxima this pattern as shown in 
figure 6.8. This pattern is then moved by a few micrometers after each laser shot.
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Figure 6.8 The structured beam profile of a single shot from the Nd:YAG “smart beam™” laser 
(Holle e ta i, 2006).
Holle et al., 2006 have shown that a structured beam profile that moves after 
every laser shot can markedly increase the performace of the Nd;YAG laser for 
MALDI.
The laser used for the work reported in this chapter is a frequency tripled Nd:YV04 
which is a Neodymium doped Yttrium ortho Vanadate laser at 355nm wavelength. 
This laser allows for the use of a much higher repetition rates than the 
conventional lasers employed for MALDI. The Nd:YV04 laser allows for repetition 
rates up to approximately 100KHz, but within this work the highest repetition rate 
used will be 20KHz this is a hundred fold increase on the 200Hz Nd:YAG lasers 
and an increase of nearly a thousand fold on the traditional N2 lasers. The 
Nd:YV04 laser suffers from the same matrix limitations as the Nd:YAG laser, and 
also has a Gaussian distribution the same as the Nd:YAG laser as can be seen in 
figure 6.9
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Figure 6.9 The Gaussian spot profile of an Nd:YV04 laser before entering the fiberoptic cable. 
6.1.3 Raster imaging V's Conventional imaging
Conventional MALDI imaging is achieved by firing the laser onto the target in a 
stationary position and acquiring data at a number of discrete spots. The distance 
between each spot is defined by the user as the spatial resolution of the acquired 
image. A slight variation with this method is the use of "Dynamic Pixel" (Applied 
Biosystems/MDS Sciex, Concord, Ontario, Canada). Dynamic pixel moves the 
target plate during each acquisition within the defined spatial resolution, this 
improves the sensitivity for this instrument because more material is desorbed and 
ionised per acquisition. This method still takes the same time per image to 
acquire because the laser is fired for the same duration per spot. A further 
advancement of this technique is the introduction of raster imaging (Simmon 2008). 
When imaging using continuous raster imaging is performed the laser is fired at 
the sample and the sample is moved in a straight line from one side of the 
designated sample area to the other. The laser is then turned off and the target
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moved to the start of the next row where the process is repeated. The distance 
between these rows is manually set as the vertical axis resolution, the horizontal 
resolution is also set manually. Within this method the software bins the data at 
calculated time points based on the distance travelled by the laser. Using this 
method the image acquisition time can be reduced by several fold.
Spot to Spot 
Imaging 
 \
0 G 0 0 0
0 0 1
Figure 6.10 The three imaging modes that can be used within the oMALDI Server 5.1 software 
(Applied Biosystems/MDS Sciex, Concord, Ontario, Canada).
Simmons (Simmons 2008) also demonstrate how this technique could also 
improve the sensitivity of the technique due to the increased surface area 
sampled by continuous raster imaging figure 6.11 shows a brain section after 
imaging with conventional spot to spot imaging and raster imaging, it can be 
clearly seen that there is still areas of matrix left on the sample that has not been 
used for imaging on the spot to spot method, however, the entire matrix coating 
has been used for the image acquisition using the continuous rastering.
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Figure 6.11 The differences between the matrix ablation using raster imaging compared to 
conventional spot to spot imaging. Reproduced from Simmons 2008
6.2 Methodology
6.2.1 Sample Preparation (Numbers)
A column of numbers 1-10 and 10-20 were printed onto plain paper using a HP 
LaserJet 4250n (Hewlett-Packard, Bracknell, UK). The columns were cut to size 
and mounted onto an Opti-Tof® LC MALDI target plate (Applied Biosystems/MDS 
Sciex, Concord, Ontario, Canada) using double sided carbon conductive tape 
(Figure 6.12).
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Figure 6.12, The printed numbers mounted on to an Opti TOF target plate, after being coated 
in aCHCA matrix, prior to imaging.
The numbers were then manually spray coated with 10ml of 25mgmr1 a-CHCA in 
ethanol with 0.1% TFA, spray coating was achieved using a gravity fed pneumatic 
air spray gun, Iwata studio series compressor fitted with an Iwata Eclipse gravity 
feed airgun (Iwata-Media Inc., Portland, OR, USA) set at 40psi. The samples 
were spray coated at a distance of 20cm, for 20 series of 2 passes of the air brush, 
with 20 second intervals, this was carried out to obtain an even matrix coating 
whilst avoiding sample over wetting which would result in analyte migration.
6.2.2 Sample Preparation (Brain tissue)
A brain was harvested from a male Wistar rat which was sacrificed by schedule 
one method according to Home Office (UK) regulations. The harvested tissue was
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immediately snap frozen for 15 seconds in liquid nitrogen cooled iso-pentane, the 
frozen tissue was then stored at -80°C until required.
When required the tissue was mounted onto cork in the desired orientation and 
held in place with a minimal amount of optimum cutting temperature (OCT) 
embedding medium, ensuring that no OCT embedding medium is near the region 
to be sampled. Tissue sections (12pm) were cut using a Leica CM1510 cryostat 
(Leica Microsystems, Wetzlar, Germany) set at -12°C, each section was thaw 
mounted onto glass slides.
6.2.3 Vinblastine Profile and fragmentation due to laser repetition rate.
aCHCA 50:50:0.1(v:v:v) ethanol : w a te r: TFA (20mg/ml) was made up and mixed 
10:1 ratio Matrix to vinblastine (1 mg/ml) to give a final concentration of 0.1 mg/ml 
vinblastine, this was then spotted onto an opti TOF target plate (Applied 
biosystems) and allowed to air dry before analysis at 1, 5, 10, 15 and 20KFIz laser 
repetition rates at a laser power of 50%.
6.2.4 Mass spectrometric profiling and imaging
The samples were analysed in positive ion mode using a Q-Star Pulsar-/ / 
quadropole time-of-flight mass spectrometer (Applied Biosystems/MDS Sciex, 
Concord, Ontario, Canada) fitted with an orthogonal MALDI ion source, using the
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oMALDI server 5.1 software. The laser was a Neodymium : Yttrium ortho 
Vanadate laser or Nd:YV04 (Elforlight Ltd, Daventry, Northants, UK) with a 
manually variable repetition rate between 1-20KHz, images were obtained by 
continues raster imaging with a spatial resolution of 150pm.
Profiles were obtained by firing the laser at a defined area for 1min and summing 
the obtained spectra together.
6.2.5 Image Processing
The imaging data sets were then converted into Analyze 7.5 file format using 
oMALDI server 5.1 software
All images were processed using 'BioMap' ion imaging software (http://www.ma Id i- 
msi.org) resulting in the production of a 2D ion density map.
6.3 Results and discussion.
Whilst the ability to perform MALDLI imaging experiments on whole tissue 
sections or even whole body sections (Stoeckli et al., 2007) has been shown to be 
hugely beneficial there are two major draw backs with trying to implement MALDI 
imaging as a high throughput methodology. The major issue is time, to obtain a 
high resolution whole body image requires acquisition times of tens of hours or 
even several days. One whole body image obtained on the Bruker Ultraflex III
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(Bruker Daltonik GmbH, Bremen, Germany) took over 72hours of continuous 
acquisition (data not shown) and to obtain a high resolution image of individual 
organ sections requires hours of instrument time conventionally.
Applied Biosystems have recently introduced a new update for their oMALDI 
server 5.1 software (Applied Biosystems/MDS Analytical Technologies, Concord, 
ON). One of the key additions to the software is the inclusion of continuous laser 
raster image acquisition capabilities.
Shown in figure 6.13 is a sagittal rat brain section imaged using raster imaging, 
the image was acquired with a spatial resolution of 150pm. The entire image 
acquisition took only approximately 37mins to complete, using conventional 
imaging a comparable image at 150pm resolution would have taken approximately 
4 hours, this is a massive improvement in the acquisition time.
m/z 772.4 m/z 718.4
Figure 6.13 Brain image, imaged using raster imaging. Total acquisition time for the image at 
150gm resolution took ~37mins.
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The brain image was acquired with a 10KHz laser repetition rate, as can be seen 
from the image white and grey matter associated ions have been shown at a 
spatial resolution of 150pm in a fraction of the conventional time this would have 
required to acquire. Although the laser spot size is above 100pm it is still possible 
to obtain higher resolution images with the use of over sampling (Jurchen et al., 
2005). Conventionally this would be achieved by firing the laser in one position 
until the matrix is fully ablated then the laser would be moved a fraction of its size 
and hence the matrix contributing to the next pixel will only be from an area 
smaller than the size of the laser beam. This has also been shown to be possible 
for raster imaging using the same principle, Simmons (Simmons 2008) showed 
that for the experimental conditions that they used the ion intensity for several ions 
reduced to less than 5% of the initial ion count after approximately 200 laser shots, 
and this could be recalculated using equation 6.4 to show the distance from the 
front edge of the spot at which the ion count reduces to less than 5% of the 
original ion count in raster imaging for these instrument settings, this meant that 
they could image down to a spatial resolution of 30pm.
Distance fro m  fro n t edge o f laser =  number o f laser shots x  ( Raster Rate (p™
\ L q,S6tt R cjj R cl£c  ( s  } /
Equation 6.4 Calculation for the minimum spatial resolution obtainable by raster imaging.
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To assess the effects of the laser repetition rate on MALDI imaging experiments a 
series of printed numbers spray coated with aCHCA matrix, were imaged using a 
variable rep rate Nd:VY0 4  laser (Elforlight ltd, Northants, UK) fitted to a Q-Star 
Pulsar-i (Applied Biosystems/MDS Sciex, Concord, Ontario, Canada).
Figure 6.14 shows images from ion signals commonly observed with aCHCA as a 
matrix these are, a) the distribution of the molecular ion of the matrix aCHCA  
(M+H)+ at m/z 190, b) the distribution of the ion of matrix minus water (M -H20)+ at 
m/z 172, c) the distribution of the sodiated matrix adduct (M+Na)+ at m/z 212 and 
d) the distribution of the potassiated matrix adduct (M+K)+ at m/z 228. There 
appears to be a distinct difference as the repetition rate increases. The 2D ion 
map for the molecular ion shows a distinct area of high signal from 2KHz upto and 
including approximately 8KHz. The other matrix related ions show a area of high 
intensity around 2-4KHz laser rep rate. These results may be caused by 
unhomogeneity in the matrix coating, but as can be seen in figure 6.12 the matrix 
appears to be a relatively uniform covering on the paper. Therefore it is 
reasonable to assume that the differences observed are due to the laser repetition 
rate and not solely due to matrix coating.
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Figure 6.14 The distribution of matrix related ions over 1-20KHz laser repetition rate, a) the 
distribution of the molecular ion of the matrix aCHCA (M+H)+ at m/z 190, b) the distribution of 
the ion of matrix minus water (M-H2O f at m/z 172, c) the distribution of the sodiated matrix 
adduct (M+Naf at m/z 212 and d) the distribution of the potassiated matrix adduct (M+K)+ at 
m/z 228.
Figure 6.15 shows two ions with almost opposite distributions a) shows the 
distribution of m/z 134. The identity of this ion is not known. This ion is either an 
ion related to the paper, which has been used, or it is matrix related showing 
possible suppression effects from ink. The ion has a range of high intensity
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covering 3-9KHz laser repetition rates. The ink related ion m/z 325, is shown in 
figure 6.15, also shows a maximum intensity in the 2-10KHz laser repetition rates, 
and as for nearly all the images, the ion intensity seams to reduce when the laser 
repetition rate is increased above 15KHz.
Figure 6.15 The distribution of two different ions over 1-20KHz laser repetition rates, a) The 
distribution of m/z 134 this ion demonstrates the effect of matrix suppression, b) The 
distribution of the ink related ion m/z 325.
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Figure 6.16 shows ion map images of the two ions shown in figure 6.15 
normalised to the matrix ion m/z 190. This is common practice within many 
laboratories and is performed to try and compensate for possible matrix 
suppression effects caused by certain analytes and tissues. In this experiment it 
does not appear that the normalisation of the data against the matrix aids in 
decision making. This is due to the fact that we are looking for the difference 
within the ionisation of the matrix and possible analytes with the variation of laser 
repetition rate, and hence to normalise the data against the matrix only serves to 
remove the effect of reduced ionisation as can be seen by the intensity within 
these images being fairly constant
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Figure 6.16 The distribution of a) m/z 134 normalised against the matrix ion m/z 190 at laser 
repetition rates 1-10KHz, b) m/z 134 normalised against the matrix ion m/z 190 at laser 
repetition rates 10-20KHz, c) m/z 325 normalised against the matrix ion m/z 190 at laser 
repetition rates 1-10KHz and d) m/z 325 normalised against the matrix ion m/z 190 at laser 
repetition rates 10-20KHz.
The results obtained within this work can be predominantly explained by the graph 
shown in figure 6.17. This graph shows the effect laser repetition rate has on the 
average power and energy output of the laser. It can be seen that as the 
repetition rate of the laser is increased the power also increases until it reaches its
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maxima at 81 mW at a repetition rate of 13-15KHz. After this repetition rate the 
power starts to decrease as repetition rate increases. The graph also shows the 
effect of the repetition rate on the energy it can be seen that as the repetition rate 
increases the energy decreases after approximately 6KHz and the energy peaks 
at 8.3pJ at a laser repetition rate of 3KHz. The images shown in figure 6.14 and 
figure 6.15 follow this trend of the energy graph peaking at a similar repetition rate, 
at high repetition rates around 15-20KHz the energy is not enough to achieve a 
good ionisation of the matrix or analyte hence the markedly reduced signal at 
these repetition rates.
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Figure 6.17. The relationship between the laser repetition rate, average power and energy for 
the Elforlight spot series laser (Elforlight Ltd. Daventry, UK. Private communication).
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These results indicate that ionisation in this experiment is related to energy and 
possibly independent of laser repetition rates, to test this theory the percentage 
laser power was changed by an attenuator, to try and obtain similar intensity 
results for the base peak from the profile analysis of a matrix spot of aCHCA on a 
target plate, the results of this work are shown below (figure 6.18).
1000 
o
1 5 10 15 20
Rep Rate KHz
Figure 6.18 Chart showing the laser power selected for the conventional MALDI analysis of 
aCHCA. An attempt was made to maintain a similar signal for ion m/z 414, also shown are 
the ion counts fora series o f matrix related ions at m/z 172, 190 and 212.
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Laser Rep 
Rate (KHz)
Power 
level (%)
Counts 12 Seconds_ _ _
i
m/z 172 | m/z 190
4 Scans 3Sec/Scan), . (
■ I
m/z 212 m/z 414
900 j 400 310 6397
295 | 135 160 4160
1950 | 600 590 7338
740 | 230 285 6314
1 32 1600 | 450 475 7810
1 Mean 1097 i 363 364 6403.8
1500 | 750 1050 6832
1090 | 470 450 8600
1200 [ 445 590 7325
1640 | 610 570 5600
5 25 2735 j 675 650 8480
5 Mean 1633 | 590 662 7367.4
2130 | 700 750 6199
1460 | 420 250 5210
5450 j 1910 1800 7450
2910 | 870 800 7500
10 40 4200 | 1100 800 7785
10 Mean 3230 | 1000 880 6828.8
7832 | 2600 2400 6700
4400 | 1400 1200 4250
2200 | 800 700 5600
6000 | 1950 1900 7070
15 60 4700 | 1450 1300 6125
15 Mean 5026.4 | 1640 1500 5949
1770 | 430 380 6003
2150 j 640 750 6100
4950 j 1600 1450 7240
4150 | 1000 700 7930
20 75 1230 | 420 375 4315
20 Mean 2850 | 818 731 6317.6
Table 6.1 The values for each of the 5 acquisitions for each laser repetition rate used and the 
laser power selected.
It can be seen from figure 6.18 and table 6.1 that a lower laser power of 25%  was 
required for the generation of similar ion signals of m/z 414 at 5KHz repetition rate 
compared to the laser power required for other repetition rates, to the point that at 
20KHz it required 75% laser power to produce a similar ion count. The results
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show that in this case for MALDI analysis using a high repetition rate N d:V Y 04 
laser the best repetition rate at lower laser powers is approximately between 3- 
8KHz. The effect of laser repetition rate on fragmentation was also investigated. 
To investigate this conventional MALDI-MS analysis of vinblastine was carried out 
at five repetition rates; 1, 5, 10, 15 and 20 KHz using the same laser power. The 
aCHCA matrix ions at m/z 190 and m/z 172 which are the molecular ion of the 
matrix [M+H]+ and the dehydrated molecular ion [M+H -H20]+ respectively, and 
several known fragment ions of vinblastine were recorded.
Ion Counts for each m/z
Rep Rate Laser Power 172 190; 811.4! 809.4 793.4! 751.41 733.4 719.4! 691.4; 649.4 542.3 524.3 355.2 337.2
1
50
1900 415 7162 4193 1835 540 167 49 26 272 52 7 135 22
1710 373 5957 3600 1687 470 145 42 24 210 40 4 135 26
1236 278 7513 4346 2100 545 210 54 37 266 74 10 270 45
1500 340 7226 4140 1825 525 190 45 27 277 52 8 187 25
1046 248 6971 4125 2200 558 239 58 32 269 50 9 154 21
Mean 1478.4 r 330.8 r 6965.8 r 4080.8 r 1929.4 r 527.6 r 190.2 r 49.6 r 29.2 r 258.8 r 53.6 r 7.6 r 176.2 r 27.8
5
50
4162 950 13000 8414 5527 1410 650 180 83 605 210 44 624 120
4010 899 15000 9929 6505 1761 855 200 105 800 266 52 792 140
3536 860 12700 8369 5346 1400 645 155 90 650 190 47 682 125
3840 936 17000 11500 7863 1910 1030 197 128 943 217 51 598 99
6354 1743 21000 14000 9844 3200 1538 376 218 1450 645 149 1400 260
Mean 4380.4 1077.6 15740 10442 7017 1936.2 943.6 221.6 124.8 889.6 305.6 68.6 819.2 148.8
10
50
2050 600 8225 4770 2425 610 240 45 21 250 45 8 245 32
1180 280 5825 3210 1860 420 177 54 19 177 45 10 260 40
2059 500 8303 4925 2700 690 287 74 35 280 65 13 278 39
2010 480 7640 4200 2555 646 270 71 47 270 66 16 260 94
1744 412 8813 5200 3072 800 380 75 55 335 70 15 238 42
Mean 1808.6 454.4 7761.2 4461 2522.4 633.2 270.8 63.8 35.4 262.4 58.2 12.4 256.2 49.4
15
50
792 230 4640 2999 1963 351 230 55 21 211 32 8.5 76 23
1547 420 5731 3519 2600 460 315 85 36 270 42 12 134 37
1883 520 6294 4050 2671 560 391 79 41 349 40 19 180 46
2970 787 4788 2800 2053 420 256 239 34 239 45 11 160 120
3702 972 7961 4800 3520 750 499 105 67 382 78 23 375 220
Mean 2178.8 585.8 5882.8 3633.6 2561.4 508.2 338.2 112.6 39.8 290.2 47.4 14.7 185 89.2
20
50
209 67 906 599 400 56 45 10 4 46 4 2 13 8
310 88 1186 689 480 73 67 13 7 52 7 3 21 25
92 44 871 560 380 64 54 13 4 37 4 4 12 2
192 89 722 458 309 61 42 6 3 31 2 2 10 6
255 87 885 599 357 56 44 7 4 38 2 2 22 10
Mean 211.6 75 914 581 385.2 62 50.4 9.8 4.4 40.8 3.8 2.6 15.6 10.2
Table 6.2 The intensity values of some matrix ions and vinblastine associated ions over 5
replicate measurements over 5 different laser repetition rates.
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Figure 6.19 graph showing the mean ion count of 5 replicate measurements showing matrix 
ions and vinblastine associated ions.
As can be seen from figure 6.19 the ion intensity is consecutively higher for a laser 
repetition rate of 5KHz. To determine if the laser repetition rate affected the 
fragmentation of vinblastine the ratios of the parent ion m/z 811.4 and all the 
fragment ions m/z 809.4, 793.4, 751.4, 733.4, 719.4, 691.4, 649.4, 542.3, 524.3,
355.2 and 337.2 have been plotted in figure 6.20.
Page | 248
i nm r.j. O l l c J p i f c M  o
rocc
0.14
0.12
0.1
0.08
0.06
0.04
0.02 n
355
751.4
733.4
719.4
691.4
649.4
542.3
524.3 
337.2
10 15 20
Laser Rep Rate KHz
Figure 6.20 The ratio of m/z 811.4 the protonated molecule of vinblastine compared to 
possible fragment ions. Little difference between different laser repetition rates, is observed. 
Note: m/z 809 has not been shown due to the possibility that this ion is not a fragment o f the 
parent but a vinblastine related ion.
Survival yields of vinblastine at different laser repetition rates using the parent ion 
m/z 8 1 1 . 4  as the lm and the fragment ion m/z 3 5 5  as If,  have been calculated 
using equation 6 . 3 .
IHW MIINM IHIM IM tNM HNMRIRMIM MM MM M MIMM M i
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An example of this is shown below for the 1 KHz data.
I ttl
( l l m  +  Z I f )
6965.8SY = ------ ----------------(6965.8 +176.2)
SY =  0.975329
The SY for each repetition rate is given in Table 6.3.
R ep Rate S Y
1 0.975329
5 0.950529
10 0.968045
15 0.969511
20 0.983219
Table 6.3 The survival yields of vinblastine using different laser repetition rates using the 
parent ion m/z 811.4 as the lm and the fragment ion m/z 355 as lf.
As can be seen from the survival yields for each of the repetition rates, the 5KHz  
laser repetition rate causes the most fragmentation. This is most likely due to this 
being around the repetition rate where the laser energy peaks, and hence at this 
repetition rate more energy is transferred to the matrix and hence to the analyte. 
This causes a slight increase in the analyte fragmentation and hence decreases 
the survival yield. This result needs to be considered in relation to the total 
observed ions for the analyte of interest at this laser repetition rate.
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6.4 Conclusion
A High repetition rate MALDI Q -TO F instrument has been demonstrated with the 
capability of imaging samples at laser repetition rates up to and including 20KHz. 
This is a nearly a thousand fold increase on the traditional N2 laser and a hundred 
fold increase on the 200Hz Nd:YAG lasers widely commercially employed. The  
introduction of raster imaging allows this laser to be utilised for high throughput 
MALDI imaging experiments. This results in faster turnaround times for imaging 
experiments, and opens the possibility of routine whole body imaging at 
reasonable acquisition times. This has great potential within pharma because 
currently during the drug development process the distribution of drugs throughout 
the body is studied by whole body autoradiography, a technique that does not 
have the specificity of MALDI imaging. MALDI Imaging could be employed to 
track the distribution of drugs and their metabolites as well as endogenous 
markers of efficacy or toxicity. This would reduce the cost for pharma because the 
expensive development of active radiolabelled compounds could be avoided.
The high repetition rate laser demonstrated here could also further increase the 
speed of MALDI profiling. This will require enhanced instrumentation and build on 
the work of Moskovets et al., 2006, who used a 2KHz laser for high throughput 
LC-MALDI showing they could profile 625 MALDI spots in 12mins using 800 laser 
spots per spot.
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Further evaluation of this laser compared to the commercially available N2 and 
Nd:YAG lasers is required in order to assess the LOD of analytes with each laser 
and to assess the extent to which imaging speed could be increased whilst 
maintaining sensitivity, specificity and spatial resolution.
Theoretically from equation 6.4 an increase in the repetition rate of the laser 
makes it possible to achieve high spatial resolutions with raster imaging. In 
practice this is unlikely to any significant extent. Due to the beam profile of the 
lasers and the instrumental limitations this would also cause a reduction in the 
sensitivity of the instrument due to the limited amount of sample per pixel. 
However the increase of the rastering speed is a much more likely possibility 
based on this equation.
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CHAPTER 7
Conclusions & Future Work
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7.1 Conclusions
MALDI-MSI has a wide range of applications within both the biological and 
chemical fields. The specificity, sensitivity and spatial information obtainable from 
MALDI-MSI experiments are unique. The increasing interest in MALDI mass 
spectrometry has allowed the expansion of this technique into several fields. The 
further development of the technique, will allow increases in the spatial resolution 
most likely eventually allowing the imaging of analyte distributions within single 
cells, whilst maintaining some level of realistic acquisition time. Increased 
sensitivity for a wider range of analytes will allow the further expansion of this 
technique into a wider range of analytes, and also by removing some of the 
current limitations in ionisation efficiencies with the use of new matrices and 
improved sample preparation.
The added separation step obtained by the inclusion of ion mobility within MALDI- 
MSI has been shown in Chapter 3 to be beneficial within several applications for 
various analytes. With the continued improvement of this technology the possible 
information now obtainable within a single experiment is huge due to the 
possibility of separating previously overlooked isobaric ions. This new dimension 
of imaging data acquisition may redefine the way MALDI-MSI data is interpreted. 
The benefit of MALDI-IMS-MSI for the study of xenobiotic distribution has been
'i
demonstrated in Chapter 4 and 5 of this thesis. IMS allowed for the removal of 
interfering ions from the mass spectrum allowing clearly enhanced image quality 
of the distribution of vinblastine within tissues.
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Lipidomics has gained a huge amount of interest over recent years. Despite 
electrospray ionisation mass spectrometry still being the method of choice for 
many application, this technique does not have spatial information. With the 
recognition of the involvement of lipids within a wide range of cellular and disease 
processes, the use of MALDI-MSI within the field of lipidomics will serve to assist 
other techniques in the understanding of the diverse rolls lipids have within 
biological systems. Shown within chapters 2, 3 and 5 of this thesis are some of 
the applications of MALDLMSI within lipidomics. Shown in chapter 2 MALDI-MSI 
data processing using PCA statistical analysis has been able to identify ions 
accounting for some of the differences between tissue types. This has also been 
demonstrated within chapter 5 where PCA was applied to MALDI-MSI data from 
tumour xenographs, using this technique. Ions associated with the viable tumour 
and surrounding tissues were identified and some ions which altered with 
administration of vinblastine were observed.
MALDI imaging has been shown to be a very powerful technique for the 
identification and localisation of many different analytes. There is a large scope 
for MALDI-MSI within the drug development process, allowing the spatial 
distribution and characterisation of analytes within a single experiment. The 
current standard is QW BA for drug distribution studies. MALDI-MSI has several 
advantages over QWBA including the ability to identify the compound of interest,
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and MALDI-MSI does not require expensive radiolabelled compounds to be 
developed, which is a large expense within the development process.
The advancement of technology within this field is constantly improving, within 
chapter 6 of this thesis an Nd:YVC> 4  laser has been evaluated for MALDI-MSI. 
One of the benefits of this laser is the high repetition rates it is capable of 
operating at. Within this work up to 20KHz has been employed, the increase laser 
repetition rate and the use of raster imaging has allowed the massive reduction in 
sample acquisition time whilst maintaining a suitable number of laser shots per 
pixel.
7.2 Future work
In order to further develop the applications of MALDI-MSI and the technology itself 
within small molecule analysis, it is required to:
•  Increase the use of M ALDI-IMS-MSI for a wide variety of applications and 
improve the data processing and interpretations, with further software 
development via collaborations with instrument manufacturers.
•  Expand the separation of compounds especially lipids using M ALDI-IM S- 
MS to allow species identification without the need for ms/ms identification, 
but by using the drift time information for each compound class within the 
ion mobility cell, and accurate mass information. Using the increased ion 
mobility resolution of the new Synapt G2 (Waters Corporation, Manchester)
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this is a realistic possibility. This would allow for the tentative identification 
of compounds within a single experiment, and could reduce the time 
required for compound identification when trying to analyse a wide range of 
compounds within a single experiment. This would be especially relevant 
for the identification of new drug compound distributions and their 
metabolites, streamlining drug discovery and development and by reducing 
the cost and the number of animal experiments.
o Improved M S3 information using TAP (Time Aligned Parallel) fragmentation 
within the Tri-W ave of a Synapt HDMS system, TAP fragmentation allows 
for the initial fragmentation of an ion in the trap region of the Tri-W ave 
followed by fragment ion mobility separation, and further fragmentation 
within the transfer region. Using this, the technique the initial fragments are 
drift time separated so form a diagonal line within the DriftScope plot and 
the MS3 Fragment align vertically under their precursor ions.
•  Optimisation of high repetition rate lasers allowing the improvement in 
sample acquisition time whist maintaining sensitivity and spatial resolution.
•  Further identification of the peaks which are associated within the different 
regions of the tumour xenographs and identification of any endogenous 
induced changes caused by chemotheraputic drugs to aid in the discovery 
of possible new drug targets or help in the reduction of drug resistance.
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